Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study

Conclusions: Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not associated with increased risk of severe gastrointestinal complications is supplied from this study. Further research is required to clarify the role BPs and other drugs of co-medication in inducing UGIC. (Source: BMC Gastroenterology)

Challenge test to bisphosphonates in patients with hypersensitivity reactions to drugs.

CONCLUSIONS: In our experience drug challenge tests for bisphosphonates are safe and reliable. PMID: 24411095 [PubMed - as supplied by publisher] (Source: Allergologia et Immunopathologia)

Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.

This study was designed to evaluate the effect of deoxycholic acid derivatives on the permeability and oral bioavailability of risedronate by increasing its lipophilicity and affinity to bile transporters. We synthesized two bile acid derivatives, N (α)-deoxycholyl-L-lysyl-methylester (DCK) and N (α)-deoxycholyl-L-lysyl-hydroxide (HDCK) as oral absorption enhancers. After ionic complex formation with the bile acid derivatives, the complexes were characterized by powder X-ray diffraction. Their artificial membrane permeabilities and bioavailabilities in rats were investigated in comparison with pure risedronate. Complex formation with DCK or HDCK demonstrated that risedronate existed in an amorphous form in the complex. A physical complex of risedronate with DCK enhanced the apparent memb...

Calcium and vitamin D improve bone density in patients taking antiepileptic drugs

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs (AEDs). The results published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggest that risedronate, a bisphosphonate, may help to prevent new vertebral fractures when taken with calcium and vitamin D supplementation... (Source: Health News from Medical News Today)

Adding Actonel Ups Bone Density in Epilepsy (CME/CE)

(MedPage Today) -- Adding risedronate (Actonel) to vitamin D and calcium supplements in patients taking anti-epileptic drugs increased bone mineral density, both from baseline and relative to a control group. (Source: MedPage Today Neurology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Calcium and vitamin D improve bone density in patients taking antiepileptic drugs

(Wiley) A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs. The results published in Epilepsia, a journal of the International League Against Epilepsy, suggest that risedronate, a bisphosphonate, may help to prevent new vertebral fractures when taken with calcium and vitamin D supplementation. (Source: EurekAlert! - Medicine and Health)

Big Pharma??s plan to poison your bones

Would you use a drug that poisons a part of your body? That??s what the medical community is doing to your bones when you take bone drugs. Fosamax, Actonel, Boniva, Reclast, Zometa, Didronel, Aredia, Skelid? they??re all the same. Taking them is like feeding poison to the cells your body uses to remodel bone. Why [...]Related Posts:This mineral mends your DNABetter Than Aspirin (Source: Al Sears, MD Natural Remedies)

[Articles] Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. (Source: LANCET)

Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event.

CONCLUSION: Failure to suppress bone turnover while receiving ADT, even when otherwise responding to therapy, may identify patients with hormone-sensitive metastatic prostate cancer who are destined for a shorter time to SREs and progression. PMID: 24126237 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)

Risedronate for Bone Loss With Breast-Cancer TreatmentRisedronate for Bone Loss With Breast-Cancer Treatment

The oral bisphosphonate shows efficacy in preventing bone loss related to aromatase-inhibitor treatment for breast cancer. Medscape Medical News (Source: Medscape Today Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Osteoporosis

Abstract: Fractures resulting from osteoporosis are a major public health problem. Physicians should be aware of the chief risk factors for osteoporosis and refer appropriately for bone densitometry. Risk factors include previous fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is ??2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients at the highest risk for fracture benefit from many licensed treatments. These may be given orally (alendronic acid, disodium etidronate, risedronate sodium, ibandronic acid, strontium...

Anti-resorptive agents reduce the size of resorption cavities: A three-dimensional dynamic bone histomorphometry study

Abstract: Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator (raloxifene) or a bisphosphonate (risedronate). Adult female rats (6months of age) were submitted to ovariectomy (n=17) or sham surgery (SHAM, n=5). One month after surgery, the ovariectomized animals were separated into three groups: untreated (OVX, n=5), raloxifene treated (OVX+Ral, n=6) and risedronate treated (OVX+Ris, n=6). At 10months of age, the lumbar vertebrae were submitted to three-dimensional dynamic bone histomorphometry to examine the size (depth, breadth and volume) of individ...

Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors

This study may help to provide more insights into bone-site-specific responses to bisphosphonates.Highlights: (Source: Bone)

Osteoporosis drugs in real-world clinical practice: an analysis of persistence.

Authors: Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E Abstract The aim of our retrospective cohort study is to analyze the persistence rates in relation to antiosteoporotic drugs using administrative databases in the Campania Region. Patients, aged ?40 years, were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1 %) were classified as switchers. Switching rates were highest for patients taking Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or Risedronate 10.8. In the overall ...

Retraction: analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.

This article published in Anal. Sci., 2010, 26(3), 325 was withdrawn by the Editor on June 7, 2013, because it was concluded that the author has copied significant parts of an earlier paper (Y. Jiang and Z. Xie, Determination of Ibandronate and its Degradation Products by Ion-Pair RP LC with Evaporative Light-Scattering Detection, Chromatographia, 2005, 62, 257, doi: 10.1365/s10337-005-0618-4). We regret that this was not detected during the reviewing process. PMID: 24025580 [PubMed - in process] (Source: Analytical Sciences : the international journal of the Japan Society for Analytical Chemistry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Rebuilding old bones

Boniva, Fosamax, Actonel, and those other drugs for thinning bones have become really big business for big pharma. Now it appears that whole system has provided more profit for the drug companies than benefit for the patients. A German research team recently dug a little deeper with a disturbing discovery. The first thing researchers saw [...]Related Posts:Biological Age Genius&#8220;Dr. Sears, What Should I Take?&#8221; (Source: Al Sears, MD Natural Remedies)

Traditional and novel bone remodeling markers in premenopausal and postmenopausal women.

Conclusions:Our data suggest that measurement of β-CTX and P1NP show adequate analytical performance and potentially could be included in algorithms for the screening of osteoporosis. Furthermore, these two markers along with osteocalcin and TRACP-5b are useful to monitor the response to risedronate. PMID: 24001743 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Prevention of bone loss and vertebral fractures in patients with chronic epilepsy??Antiepileptic drug and osteoporosis prevention trial

Summary PurposeTo evaluate whether use of a bisphosphonate (risedronate) in addition to calcium and vitamin D in male veterans with epilepsy who were taking antiepileptic drugs (AEDs) long term can prevent the loss of bone mass (BMD, bone mineral density) associated with AED use compared to patients who were treated with a placebo plus calcium and vitamin D. As a secondary end point we studied the incidence of new morphometric vertebral and nonvertebral fractures. MethodsAntiepileptic drug and osteoporosis prevention trial (ADOPT) was designed as a prospective 2?year double?blind, randomized placebo controlled study involving 80 male veterans with epilepsy who were being treated with AEDs such as phenytoin, phenobarbital, sodium valproate, or carbamazepine for a minimum of 2 years. Al...

Oral Risedronate in Children With Mild Osteogenesis ImperfectaOral Risedronate in Children With Mild Osteogenesis Imperfecta

Children with mild osteogenesis imperfecta (OI) may benefit from treatment with oral risedronate, a new study suggests. Reuters Health Information (Source: Medscape Medical News Headlines)

Bisphosphonate-related Osteonecrosis of Jaw (BRONJ) in Japanese Population: A Case Series of 13 Patients at Our Clinic.

Authors: Nomura T, Shibahara T, Uchiyama T, Yamamoto N, Shibui T, Yakushiji T, Watanabe A, Muramatsu K, Ogane S, Murayama M, Sekine R, Nakata E, Fujimoto Y Abstract Bisphosphonate-related osteonecrosis of the jaw (BRONJ) affects quality of life and is an important problem for dentists. A Japanese position paper on BRONJ was published in 2010. The purpose of this study was to review clinical data on the treatment of BRONJ obtained at the Clinic of Oral and Maxillofacial Surgery, Tokyo Dental College, Chiba Hospital to further our understanding of this disease. A total of 13 patients (6 men and 7 women) were included. All the patients included in this study had received Bisphosphonate (BP) therapy and had BRONJ. Five of them (38.5%) had received oral BP therapy for osteoporosis, whil...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate Positively Affects Osteogenic Differentiation of Human Mesenchymal Stromal Cells

Conclusions: Risedronate concentrations used favor the osteogenic differentiation and the MSC commitment towards osteoblasts. This suggests the possibility of using this bisphosphonate in cyclic bone treatments with anabolic drugs, enhancing the effect of the latter via a previous MSC commitment to preosteoblasts. (Source: Archives of Medical Research)

Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series

Abstract: Bisphosphonates have been associated with a serious adverse reaction known as bisphosphonate-related osteonecrosis of the jaws (BRONJ). The aim of this study was to describe its clinical characteristics in patients with dental implants who were taking bisphosphonates orally. We made a retrospective multicentre study in 3 hospitals in Galicia, Spain. The medical records and clinical and radiological follow-up of the oral cavity were reviewed for those patients given bisphosphonates and diagnosed with BRONJ after the placement of dental implants within the previous 3 years. The series comprised 9 white patients (mean age 66 years). The bisphosphonates were alendronate (n=6), ibandronate (n=2), and risedronate (n=1), and the most common indication was osteoporosis (n=7). The mean in...

Duration of treatment for osteoporosis.

Authors: Idolazzi L, Fassio A, Gatti D, Tamanini S, Viapiana O, Rossini M, Adami S Abstract Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness. PMID: 23550257 [PubMed - in process] (Source: Reumatismo)

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Conclusions. Once-yearly i.v. infusion of ZOL 5 mg was well tolerated in different subgroups of GIO patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00100620. (Source: Rheumatology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Late onset psychosis and risedronate treatment for osteoporosis.

We report the case of M age 59, who was treated with risedronate for osteoporosis, and subsequently diagnosed with atypical psychosis after other organic causes were excluded. Though is conceivable that age-related psychosocial and physical factors triggered late-onset schizophrenia, the temporal relationship between the termination of treatment with risedronate and the improvement in her mental state, suggests that the risedronate might have triggered a psychotic reaction that resolved following cessation of treatment. PMID: 23644167 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)

Established and forthcoming drugs for the treatment of osteoporosis.

Authors: Lems WF, den Heijer M Abstract Nowadays, effective drugs are available to prevent fractures in patients at high risk for osteoporotic fractures. The generic bisphosphonates alendronate and risedronate are first choice, because of their effectiveness and tolerability in the majority of patients, while they also have a low cost price. However, the use of bisphosphonates can be associated with side effects: not only the well-known (upper) gastrointestinal side effects, but also (spontaneous) atypical fractures of the femur and aseptic necrosis of the jaw. Denosumab and zoledronic acid are both potent antiresorptive drugs that could be an attractive alternative for those patients who do not tolerate oral bisphosphonates. Strontium ranelate has both antiresorptive and anabolic ...

No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.

Conclusions: Risedronate did not influence the OARSI score and subchondral plate stiffness, but decreased serum CTX-II in Dunkin Hartley guinea pigs. PMID: 23527881 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Rheumatology)

Spontaneous Femoral Fracture Secondary to Risedronate UseSpontaneous Femoral Fracture Secondary to Risedronate Use

Was long-term bisphosphonate use a precipitating factor in this elderly woman's non-traumatic hip fracture? Journal of Medical Case Reports (Source: Medscape Today Headlines)

Sphingosine-1-phosphate protects against bisphosphonate??induced HUVEC cell death via regulation of c-Jun??N??terminal kinase signaling.

Authors: Lee YJ, Jeong JK, Lee JH, Park YG, Moon JH, Seol JW, Jackson CJ, Park SY Abstract Bisphosphonates (BPs) remain the most widely used and effective antiresorptive agents in the treatment of postmenopausal osteoporosis. In particular, nitrogen-containing BPs (N-BPs) are more potent at inhibiting bone resorption in vivo than simple BPs, but they are associated with a number of side-effects including increased endothelial cell apoptosis in patients with multiple myeloma. Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, plays important roles in the regulation of cell growth, differentiation and programmed cell death as a multifunctional bioactive lipid mediator. The aim of this study was to elucidate the protective effect and the possible mechanism of S1P against BP-in...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate increases osteoblastic differentiation and function through connexin43.

In this study, we investigated the effect of risedronate, one amino-bisphosphonate, on osteoblast differentiation and Cx43 expression using the mesenchymal cell line C2C12. Risedronate dose-dependently increased the activity of osterix (OSE)-luciferase containing Runx2 response element with highest activity at 50 μM. The activity of osteocalcin (OC)- and bone sialoprotein (BSP)-luciferase reporters, markers of osteoblast differentiation, were also increased by risedronate. When risedronate and BMP2 were used in combination, alkaline phosphatase (ALP) activity increased to a larger extent than when BMP2 was used alone. Risedronate as well as the pro-osteogenic transcription factors, Runx2, Osterix or Dlx5, increased transcriptional activity of the Cx43 promoter in a dose-dependent manner. ...

Improvement in Bone Properties by Using Risedronate Adsorbed Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of Osteoporosis

(Source: Journal of Biomedical Nanotechnology)

Model to Minimize Inappropriate Medications in the Elderly

Scott et al have designed an elegant and precise model to examine and rationalize drug use in older people. I have a few comments on step 1 (ascertain current drug use). I suggest the following actions: (1) Examine the dates on each medication container. If the current date is June 12, 2012, and the patient claims to be using spironolactone, why does the patient have a 30-day supply of spironolactone dispensed on December 23, 2011? (2) Examine the patient name on each medication container. Is the patient taking a medication prescribed for her husband? (3) Examine medication containers for double-dipping, for example, one container for Antenex 5 mg 30 tablets (diazepam 5 mg) and another for Apo-diazepam 5 mg 30 tablets (diazepam 5 mg) both dispensed on the same day. (4) Question the prescri...

Osteoprotegerin-Deficient Male Mice as a Model for Severe Alveolar Bone Loss: Comparison With RANKL-Overexpressing Transgenic Male Mice.

Authors: Koide M, Kobayashi Y, Ninomiya T, Nakamura M, Yasuda H, Arai Y, Okahashi N, Yoshinari N, Takahashi N, Udagawa N Abstract Periodontitis, an inflammatory disease of periodontal tissues, is characterized by excessive alveolar bone resorption. An increase in the receptor activator of nuclear factor-κB ligand (RANKL) to osteoprotegerin (OPG) ratio is thought to reflect the severity of periodontitis. Here, we examined alveolar bone loss in OPG-deficient (OPG(-/-)) mice and RANKL-overexpressing transgenic (RANKL-Tg) mice. Alveolar bone loss in OPG(-/-) mice at 12 weeks was significantly higher than that in RANKL-Tg mice. OPG(-/-) but not RANKL-Tg mice exhibited severe bone resorption especially in cortical areas of the alveolar bone. An increased number of osteoclasts was observ...

Molecular characterization of farnesyl pyrophosphate synthase from Bacopa monniera by comparative modeling and docking studies.

Authors: Vishwakarma RK, Patel KA, Sonawane P, Singh S, Ruby, Kumari U, Agrawal DC, Khan BM Abstract Farnesyl pyrophosphate synthase (FPS; EC 2.5.1.10) is a key enzyme in isoprenoid biosynthetic pathway and provides precursors for the biosynthesis of various pharmaceutically important metabolites. It catalyzes head to tail condensation of two isopentenyl pyrophosphate molecules with dimethylallyl pyrophosphate to form C15 compound farnesyl pyrophosphate. Recent studies have confirmed FPS as a molecular target of bisphosphonates for drug development against bone diseases as well as pathogens. Although large numbers of FPSs from different sources are known, very few protein structures have been reported till date. In the present study, FPS gene from medicinal plant Bacopa monniera (B...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Identification and management of osteoporosis in older adults

Abstract: Fractures resulting from osteoporosis are a major public health problem. Physicians should be aware of the major risk factors for osteoporosis and refer appropriately for bone densitometry. Risk factors include prior fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is ??2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients at the highest risk for fracture benefit from many licensed treatments. These may be given orally (alendronic acid, disodium etidronate, risedronate sodium, ibandronic acid, strontium ra...

[Ocular myasthenia revealed by risedronate].

Authors: Sanchez-Ayaso PA, Garcia-Munozguren S, Salmeron MP PMID: 23143965 [PubMed - in process] (Source: Revista de Neurologia)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

Abstract&nbsp;&nbsp;This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75&nbsp;mg on 2 consecutive days each month (2CDM) or 5&nbsp;mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12&nbsp;months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24&nbsp;months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage ch...

Fourier Transform Infrared Imaging as a Tool to Chemically and Spatially Characterize Matrix-Mineral Deposition in Osteoblasts

This study demonstrates that FTIRI is a complementary tool to histochemistry for spatially correlating the collagen matrix distribution and the nature of the resultant mineral during the process of osteoblast mineralization. It can further be used to detect small perturbations in the osteoid and mineral deposition process. Content Type Journal ArticleCategory Original ResearchPages 1-9DOI 10.1007/s00223-012-9667-5Authors Meghan E. Faillace, Department of Biomedical Engineering, Stony Brook University, Stony Brook, N Y 11790, USARoger J. Phipps, Husson University School of Pharmacy, Bangor, ME, USALisa M. Miller, Department of Biomedical Engineering, Stony Brook University, Stony Brook, N Y 11790, USA Journal Calcified Tissue InternationalOnline ISSN 1432-0827Print ISSN 0171...

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis

This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP&nbsp;+&nbsp;PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3&nbsp;months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2? Health Survey. Statistical compar...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Midterm outcome of risedronate therapy for patients with Paget??s disease of bone in the central part of Japan

Abstract&nbsp;&nbsp;Although Paget??s disease of bone (PDB) is common in western countries, it is extremely rare in Asian ones including Japan. Recently, oral risedronate (17.5&nbsp;mg once daily) was approved in Japan as a treatment of PDB besides calcitonin and etidronate. However, there are few data regarding the efficacy of this agent, dose for patients with PDB in Japan, or the durability of its effect. The purpose of this study was to evaluate the midterm outcome of oral risedronate (17.5&nbsp;mg once daily) for patients with PDB in Japan. Seventeen patients with PDB were treated with risedronate (17.5&nbsp;mg once daily) for 8&nbsp;weeks. Efficacy and its durability were accessed based on serum total alkaline phosphatase (ALP) and symptoms. Risedronate effectively suppressed ...

Combination therapy with risedronate and teriparatide in male osteoporosis

Abstract&nbsp;&nbsp;Most studies of combination therapy with teriparatide and a bisphosphonate have not shown greater efficacy over monotherapy. The bisphosphonate risedronate, has not been studied in this context. The purpose of this proof-of-concept study was to assess whether combination risedronate and teriparatide increases bone mineral density (BMD) more than monotherapy with either drug alone. This was a randomized, double-blinded study of risedronate (35&nbsp;mg weekly plus placebo injection), teriparatide (20&nbsp;μg subcutaneously daily plus placebo tablet), or both risedronate plus teriparatide (combination) for 18&nbsp;months in 29 men with low BMD. The primary endpoint was percentage change in lumbar spine (LS) BMD at 18&nbsp;months. Secondary outcomes included changes ...

A meta-analysis characterizing the dose??response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women

Conclusions&nbsp;&nbsp;All three NCBPs are approximately equipotent and exhibit a log??linear relationship between dose and the increase in spine BMD. Differences in efficacy between the available oral bisphosphonate regimens appear to be a function of dose rather than inherent differences in therapeutic potential. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-012-2179-3Authors J. Yates, 2590 Sumac Avenue, Boulder, CO 80304, USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

Updated Date: Oct 24, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Conclusions&nbsp;&nbsp;Risedronate 35&nbsp;mg DR weekly is as effective and as well tolerated as risedronate 5&nbsp;mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-012-2175-7Authors M. R. McClung, Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USAA. Balske, Abbott Laboratories, Abbott Park, IL, USAD. E. Burgio, The Procter and Gamble Company, Mason, OH, USAD. Wenderoth, Warner Chilcott Deutschland GmbH, Weiterstadt, GermanyR. R. Recker, Osteoporosis Research Center, Creighton University, Omaha, NE, USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis Internation...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008

Conclusion: This study reports a marked change in osteoporosis treatment in Spain, which includes an important increase in anti-osteoporosis medication use, particularly of bisphosphonates and a decrease in menopausal hormone therapy use secondary to the new information about their safety. (Source: Maturitas)

Prolia Helps Bone Density More Than Older Drugs (CME/CE)

MINNEAPOLIS (MedPage Today) -- Switching to denosumab (Prolia) from alendronate (Fosamax) in women with low bone mineral density was more effective than switching to risedronate (Actonel), a researcher said here. (Source: MedPage Today Endocrinology)

Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates

Conclusion: Our findings suggest that both bone resorption and bone formation were inhibited by long-term administrating of Bis alone, whereas combination therapy with Bis+statin may be associated with a less marked inhibition of bone metabolism. Cardiovascular disease is highly prevalent in RA patients and some patients are prescribed statins and bisphosphonate. Bis+statin may confer more benefit to the bone metabolism of these patients compared to Bis alone. (Source: Arthritis Research and Therapy)

Effect of bisphosphonates on gene expression of fibroblasts cultured in the presence of homocysteine

Abstract: Elevated plasma homocysteine (Hcys) levels are proposed as a bone fracture risk factor. Hcys blocks lysyl oxidase, an important enzyme in collagen post-translation modifications in all tissues. We have recently shown that Hcys affects fibroblast gene expression, including genes that are expressed in osteoblasts as well. In the present study the effect of 4mM Hcys on fibroblasts (NIH-3T3) in the presence or absence of any of the 3 most widely used bisphosphonates (alendronate, ibandronate, risedronate) in osteoporosis management was investigated. Cells were cultured for 6days, mRNA extracted, and subjected to gene array analysis. The results showed that bisphosphonates modulate homocysteine (Hcys) induced expression of genes implicated in organic matrix organization and quality. F...

In-Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-Cell Antitumor Cytotoxicity through ICAM-1 Engagement.

CONCLUSION: These findings suggest that N-BPs can have an adjuvant role in cancer therapy by activating Vγ9Vδ2T-cell cytotoxicity in patients with breast cancer that produces high IPP/ApppI levels after N-BP treatment. PMID: 23032740 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Spontaneous incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report

Conclusions: Previous case series have reported that long-term bisphosphonate use is associated with atypical fractures of the femur, and certain criteria have been established to help identify such rare fractures. Delayed union or non-union is expected in such fractures following definitive orthopedic treatment because of the long half life of bisphosphonates. In this case report, we try to raise questions related to this important subject, like the duration and safety of bisphosphonate use and the alternative medications used in osteoporosis in this rare condition. We consider this case report not only interesting but also important and unusual because it is about a patient who developed a potentially rare and serious side effect of long-term bisphosphonate use, estimated to affect 2.3 i...

Subsequent hip fracture in osteoporotic hip fracture patients.

Conclusion: Although primary surgical treatments are important for an excellent outcome in osteoporotic hip fractures, treatment of osteoporosis itself is just as important for preventing SHFs. PMID: 22869485 [PubMed - in process] (Source: Yonsei Medical Journal)

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

Os glicocorticoides (GC) são prescritos por praticamente todas as especialidades médicas, e cerca de 0,5% da população geral do Reino Unido utiliza esses medicamentos. Com o aumento da sobrevida dos pacientes com doenças reumatológicas, a morbidade secundária ao uso dessa medicação representa um aspecto importante que deve ser considerado no manejo de nossos pacientes. As incidências de fraturas vertebrais e não vertebrais são elevadas, variando de 30%-50% em pessoas que usam GC por mais de três meses. Assim, a osteoporose e as fraturas por fragilidade devem ser prevenidas e tratadas em todos os pacientes que iniciarão ou que já estejam em uso desses esteroides. Diversas recomendações elaboradas por várias sociedades internacionais têm sido descritas na literatura, poré...

Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice

Conclusions&nbsp;&nbsp;Treatment monitoring using U-NTX/Cr has a place in clinical practice for the early identification of non-compliance or presence of secondary osteoporosis. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00198-012-2097-4Authors I. Baxter, NIHR Musculoskeletal Biomedical Research Unit, Department of Human Metabolism, University of Sheffield, Sheffield, UKA. Rogers, NIHR Musculoskeletal Biomedical Research Unit, Department of Human Metabolism, University of Sheffield, Sheffield, UKR. Eastell, NIHR Musculoskeletal Biomedical Research Unit, Department of Human Metabolism, University of Sheffield, Sheffield, UKN. Peel, NIHR Musculoskeletal Biomedical Research Unit, Directorate of Specialised Medicine, Sheffield Teaching Hospitals NHS ...

Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.

Authors: Takakuwa M, Iwamoto J Abstract Intramuscularly administered elcatonin (ECT) reduces pain via the central nervous system. A prospective study was performed to determine whether ECT has a beneficial effect on back pain and function in postmenopausal women with osteoporosis during bisphosphonate therapy. Sixty-one postmenopausal osteoporotic women with back pain (mean age: 73.7 years, range: 54-96 years) were divided into two groups: the control group (n=30) and the ECT (intramuscular, 20 units a week) group (n=31). All patients received treatment with risedronate (17.5??mg weekly). The duration of the study was 8 weeks. Urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX), visual analogue scale (VAS) for back pain at rest and movement, and Roland-...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study

Abstract&nbsp;&nbsp;A prospective observational study to test the effects of risedronate 17.5&nbsp;mg/week treatment on quality of life (QOL) of 1,363 Japanese female patients with osteoporosis showed QOL improvement after 12&nbsp;weeks of administration. Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment. Few studies have investigated the effect of osteoporosis treatment on QOL in relationship to comorbid factors other than osteoporosis and fracture. Efficacy was determined by changes over time in EQ-5D at baseline, at 12 and 24&nbsp;weeks, and at the final assessment. Factors affecting changes in EQ-5D were evaluated with a multivariate analysis. Safety was determined by assessing the incident r...

Risedronate-associated scleritis: a case report and review of the literature

We report the first case of risedronate-induced scleritis. The case involves a 73-year-old woman who developed scleritis following exposure to risedronate in 2007 with recurrence of scleritis upon risedronate exposure again in 2009. Discontinuation of risedronate and treatment with intravenous and topical corticosteroids resulted in both clinical and radiological improvements within 24&nbsp;h. Applying Naranjo's adverse drug reaction probability scale, a causality assessment was made which categorized this reaction as definite with a score of 9. In our case, there was a strong causal relationship between the use of risedronate and scleritis. Although rare, ocular adverse effects of bisphosphonates may be serious and should be made known to prescribing physicians. This is important i...

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

This study was extended to include a 2-year, open-label extension to continue to assess the safety and efficacy of risedronate in men with osteoporosis. In the open-label extension, all patients received risedronate 35mg once a week, and 1000mg elemental calcium and 400 to 500IU vitamin D daily for up to 2years. The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results. BMD, BTMs, and the incidence of new vertebral fractures were also assessed. A total of 218 (of 284) patients enrolled in the open-label extension. Risedronate continued to produce significant increases in lumbar spine BMD from baseline (7.87%) in the group of patients who took it for 4years. Risedronate produced significant increases in lumbar spine BMD f...

Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice

Abstract: The gap junction protein, connexin43 (Cx43) controls both bone formation and osteoclastogenesis via osteoblasts and/or osteocytes. Cx43 has also been proposed to mediate an anti-apoptotic effect of bisphosphonates, potent inhibitors of bone resorption. We studied whether bisphosphonates are effective in protecting mice with a conditional Cx43 gene deletion in osteoblasts and osteocytes (cKO) from the consequences of ovariectomy on bone mass and strength. Ovariectomy resulted in rapid loss of trabecular bone followed by a slight recovery in wild type (WT) mice, and a similar degree of trabecular bone loss, albeit slightly delayed, occurred in cKO mice. Treatment with either risedronate (20μg/kg) or alendronate (40μg/kg) prevented ovariectomy-induced bone loss in both genotypes. ...

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis

Conclusions&nbsp;&nbsp;The conditional estimates of relative treatment efficacy indicate that there are important differences in fracture risk reduction profiles for marketed pharmacological therapies for postmenopausal osteoporosis. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00198-012-2068-9Authors N. Freemantle, Department of Primary Care and Population Health, University College London, London, NW3 2PF UKC. Cooper, University of Southampton, Southampton, UKA. Diez-Perez, Autonomous University of Barcelona, Barcelona, SpainM. Gitlin, Amgen Inc., Thousand Oaks, CA, USAH. Radcliffe, Amgen Ltd., Cambridge, UKS. Shepherd, Amgen Ltd., Uxbridge, UKC. Roux, Paris Descartes University, Paris, France Journal Osteoporosis InternationalOnline ISSN ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Lipid profiles within the SABRE trial of anastrozole with and without risedronate

In this study of postmenopausal women with early breast cancer receiving adjuvant anastrozole with or without risedronate, there was no adverse effect on LDL-cholesterol, HDL-cholesterol, TC or TG values over the 12&nbsp;months monitoring period. Content Type Journal ArticleCategory Clinical TrialPages 1-7DOI 10.1007/s10549-012-2147-9Authors Catherine Van Poznak, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, C346 Med Inn Building, Ann Arbor, MI 48109-5848, USAAndreas Makris, Mount Vernon Hospital, Northwood, Middlesex, UKGlen Clack, AstraZeneca, Macclesfield, Cheshire, UKDavid H. Barlow, The University of Glasgow, Glasgow, UKRichard Eastell, Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, ...

Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?

This study demonstrates that the timing of the post-operative administration of bisphosphonates does not appear to affect the rate of healing of an intertrochanteric fracture or the incidence of complications. PMID: 22733953 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. British volume)

Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis.

CONCLUSIONS: Denosumab has demonstrated efficacy and safety as a first-line treatment for postmenopausal osteoporosis in multiple clinical trials over at least 6 years. It may be most cost-effective for women who are unable or refuse to take bisphosphonate drugs. PMID: 22837347 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

Conclusions&nbsp;&nbsp;After 2&nbsp;years, treatment with risedronate 150-mg once a month provided similar efficacy and tolerability to daily dosing and provides an alternative for patients who prefer once-a-month oral dosing. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00198-012-2056-0Authors M. R. McClung, Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USAJ. R. Zanchetta, Instituto de Investigaciones (IDIM), Buenos Aires, ArgentinaA. Racewicz, Centrum Medyczne Specjalistyczny Gabinet Lekarski, Bialystok, PolandC. Roux, Paris Descartes University, Cochin Hospital, Paris, FranceC.-L. Benhamou, INSERM Research Unit U658, Orléans, FranceZ. Man, Centro TIEMPO, Buenos Aires, ArgentinaR. A. Eusebio, Procter and Gamble Company...

Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren??s syndrome

Abstract&nbsp;&nbsp;A 62-year-old woman was diagnosed with severe osteomalacia caused by renal tubular acidosis associated with Sjögren??s syndrome. She was treated with sodium bicarbonate, risedronate, alfacalcidol, and prednisolone (1&nbsp;mg/kg). By 24&nbsp;months, renal tubular acidosis was improved and the bone density had normalized. Here we report the successful amelioration of bone lesions through a multidisciplinary approach that improved renal tubular acidosis, with a special focus on treatment of the underlying inflammatory disorder with glucocorticoids. Content Type Journal ArticleCategory Case ReportPages 1-5DOI 10.1007/s10165-012-0667-0Authors Sunao Yamamoto, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environment...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice

Conclusion&nbsp;&nbsp;From this observational study not designed to compare drugs, both alendronate and risedronate decreased clinical vertebral and nonvertebral fractures over time. The reductions observed in fracture incidence, within each cohort, suggest that the effectiveness of each bisphosphonate in clinical practice is consistent with their efficacies demonstrated on surrogate markers in randomized controlled trials. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00198-012-2060-4Authors T. Thomas, INSERM U1059, Rheumatology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, FranceS. Horlait, Warner Chilcott, Paris, FranceJ. D. Ringe, Medizinische Klinik IV (Osteology, Rheumatology), Klinikum Leverkusen, University...

Randomised Phase II/III Study of Docetaxel With or Without Risedronate in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

This randomized study failed to show benefit to adding oral bisphosphonates to chemotherapy in patients with advanced prostate cancer. Endpoints included quality of life in addition to efficacy, and results... (Source: OncologySTAT Journal Scans)

Actonel (Risedronate Sodium) - Treatment for Osteoporosis

Actonel is targeted for the treatment of osteoporosis in postmenopausal women. It is also indicated for the treatment of osteoporosis in men, to improve BMD and Paget's disease. (Source: Drug Development Technology)

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

Conclusion: The addition of the third generation bisphosphonate, risedronate, in the setting of effective first line docetaxel based chemotherapy did not increase efficacy, as indicated by the lack of improvement in TTP, OS, PSA- and pain response. (Source: European Journal of Cancer)

25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis

Abstract: It remains unclear whether vitamin D sufficiency optimizes response to bisphosphonate (BP) treatment in postmenopausal osteoporosis. We evaluated the role and possible mechanisms of vitamin D in adequate response to standard BP treatment for postmenopausal osteoporosis.Methods: We included 120 postmenopausal osteoporotic women (aged 68±8years) receiving BP (alendronate or risedronate) at their annual follow-up, performing complete anamnesis, including treatment adherence, use of vitamin D supplements, and previous falls and fractures during the last year. We analyzed the evolution of bone mineral density (BMD) during this period and serum PTH and 25 hydroxyvitamin D (25(OH)D) and urinary NTx levels. Patients were classified as inadequate responders to antiosteoporotic treatment ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals

Conclusions&nbsp;&nbsp;Drug-induced life-threatening potassium disturbances remain a relevant problem. Potential strategies for prevention are to avoid polypharmacy, early discontinuation of treatment of drugs causing hyperkalemia or nephrotoxicity in cases of various clinical situations (cardiac descompensation, infection, hypovolemia) or obstructive causes, and insistence on albumin control during hospitalization. Content Type Journal ArticleCategory Pharmacoepidemiology and PrescriptionPages 1-14DOI 10.1007/s00228-012-1303-9Authors Elena Ramírez, Clinical Pharmacology Deparment, Hospital Universitario La Paz (IdiPaz), School of Medicine, Universidad Autónoma de Madrid, Arzobispo Morcillo s/n, 28029 Madrid, SpainTomás Rossignoli, Clinical Pharmacology Deparment, Hospital...

Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments

Abstract&nbsp;&nbsp;Early prevention of future fracture is an important goal in those at risk. A similar 3-year fracture efficacy is reported for most osteoporosis agents. Onset of fracture efficacy may be useful to help tailor treatment based on risk. We reviewed the peer-reviewed literature for onset of fracture efficacy data on the commonly prescribed osteoporosis treatments. All papers were reviewed independently by at least two reviewers for onset of efficacy for morphometric vertebral fracture (MVF), clinical vertebral fracture (CVF), nonvertebral fracture (NVF), hip fracture, and any clinical fracture (ACF). Alendronate is reported to reduce multiple CVF by 6&nbsp;months; all CVF, NVF, and multiple ACF by 12&nbsp;months; and all ACF and hip fracture by 18&nbsp;months. Ibandron...

Osteoporosis Drugs Linked to Fractures

Widely used osteoporosis drugs such as Fosamax and Actonel significantly raise the risk of a rare but serious thigh fracture, a new study found. (Source: WSJ.com: Health)

Osteoporosis Drugs Linked to Rare Fractures

Widely used osteoporosis drugs such as Fosamax and Actonel significantly raise the risk of a rare but serious thigh fracture, a new study found. (Source: WSJ.com: Health)

Pharmacovigilance of Oral Bisphosphonates: Adverse Effects Manifesting in the Soft Tissue of the Oral Cavity

Conclusions: Adverse effects of oral bisphosphonates with manifestations in the soft tissue of the oral cavity seem to be more common than the small number of published cases indicates. However, considering that oral bisphosphonates are widely used drugs, the incidence is still low. These adverse drug reactions are not limited to alendronate and may also be induced by etidronate and risedronate. Still, a significant proportion of the cases are associated with alendronate. Regardless of the substance used, discontinuing the drug is an effective treatment for the mucosal lesions. (Source: Journal of Oral and Maxillofacial Surgery)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Modulation of Bone Turnover in Orchidectomized Rats Treated with Raloxifene and Risedronate

AbstractOsteoporosis is a reduction in bone mineral density (BMD). It develops less often in men than in women. The present study aimed to evaluate the bone protective effects of Raloxifene (RAL), Risedronate (RIS), and their combination on osteoporotic male rats. Forty male Wister rats (12 weeks) were randomly divided into 5 groups; Sham? operated group (n=8), orchidectomized (ORX) group (n=7), RAL group (n=9), RIS group (n=7) and RAL+RIS group (n=7). RAL was orally administered at 3 mg/kg three times/week and RIS was given subcutaneously at 5μg/kg, twice weekly. After 6 weeks of treatment, serum cathepsin?K, alkaline (ALP) and acid phosphatase (ACP) activities, serum osteocalcin, serum Ca+2 and Pi were determined. Urinary Ca+2 and deoxypyridinoline levels, BMD and Ca+2 content of fe...

Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates

Abstract&nbsp;&nbsp;We investigated rates of insufficient and over-responsiveness to orally administered bisphosphonates in postmenopausal women, and tested the efficacy of intravenous ibandronate in patients with insufficient response to orally administered bisphosphonates. Postmenopausal women were treated with either alendronate (70&nbsp;mg/week; n&nbsp;=&nbsp;88) or risedronate (35&nbsp;mg/week; n&nbsp;=&nbsp;84) for 1&nbsp;year, and their response to orally administered bisphosphonates was assessed using serum C-telopeptide (CTX) levels. Insufficient responders were changed to once-quarterly intravenous ibandronate 3&nbsp;mg injection (n&nbsp;=&nbsp;13) or maintained on orally administered bisphosphonates (n&nbsp;=&nbsp;19), according to patients?? preference, for an additional 1&...

Prevention and treatment of osteoporosis in women: an update

Abstract: Osteoporosis is a growing health problem in the ageing population. A postmenopausal woman has an approximately 50% lifetime risk of suffering an osteoporotic fracture with hip fractures carrying the highest morbidity and mortality. Non-pharmacological prevention strategies focus on attainment and maintenance of a high peak bone mass and include a healthy lifestyle, nutritious and balanced diet, maintenance of optimal vitamin D level and physical exercise with skeletal mechanical loading. Pharmacological interventions include hormone replacement therapy in women with early menopause and postmenopausal women until the age of 60 in the absence of contraindications. Bisphosphonates (e.g. alendronate, risedronate and zoledronate) remain the mainstay of antiresorptive treatment and th...

Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial

Conclusions&nbsp;&nbsp;Our study suggests that younger postmenopausal women with normal BMD or mild osteopenia receiving A-only face an increased risk of bone loss in LS. Among patients with mild or severe osteopenia or osteoporosis treated with A&nbsp;+&nbsp;R, 12&nbsp;months LS or HP BMD variations were configured regardless of age group. Content Type Journal ArticleCategory Original PaperPages 1-9DOI 10.1007/s00432-012-1233-zAuthors Christos Markopoulos, Hellenic Society of Breast Surgeons, 6 Eslin Street, 11523 Athens, GreeceEvagelos Tzoracoleftherakis, Hellenic Society of Breast Surgeons, 6 Eslin Street, 11523 Athens, GreeceDimitrios Koukouras, Hellenic Society of Breast Surgeons, 6 Eslin Street, 11523 Athens, GreeceBasileios Venizelos, Hellenic Society of Breast Surgeons...

Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs

Source: PLoS ONE Area: Evidence &#62; Medicines Management &#62; References Background: We aimed to determine the representation of elderly people in published reports of randomised controlled trials (RCTs). &#160;We focused on trials of&#160;four medications - pioglitazone, rosuvastatin, risedronate and valsartan - frequently used by elderly patients with chronic medical conditions. Methods and Findings: We selected all reports of RCTs indexed in PubMed from 1966 to Apl 2008 evaluating one of the&#160;four medications of interest. &#160;Estimates of the community-based 'on-treatment' population were from a national health insurance database (SNIIR-AM) covering approximately 86% of the population in France. &#160;From this database, we evaluated data claims from Jan 2006 to Dec 2007 for...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients

Abstract&nbsp;&nbsp;Due to pleiotropic-synergistic actions on bone, muscle, gut, brain and different other non-skeletal tissues, alfacalcidol is an interesting drug for treating osteoporosis. In studies on glucocorticoid-induced osteoporosis, men have always been treated with calcitriol or this active D-hormone prodrug, but there is no study of male patients only in the literature. The AIM-Trial (Alfacalcidol In Men) is an extension of the control group (n&nbsp;=&nbsp;158) of our former risedronate study in male osteoporosis (Ringe et al. in Rheumatol Int 29:311??315, 2009). In that study, we treated daily those controls with prevalent vertebral fractures with 1&nbsp;μg alfacalcidol&nbsp;+&nbsp;500&nbsp;mg calcium (group A) and those without prevalent vertebral fractures with 1,000&n...

Risedronate improves bone mineral density in Crohn's disease: A complementary mechanism

I read with great interest the paper by Soo and colleagues entitled ??Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial.? This work addressed that Risedronate can increase bone density in Crohn's disease. I would like to complete the discussion of Soo et al. by introducing a major complementary route which Risedronate could improve bone volume. (Source: Journal of Critical Care)

Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation

Conclusion: Our findings that risedronate influences the crosstalk between bone marrow adipocyte??osteoclast represent a novel mechanism for the anti-osteoporotic effects of risedronate. (Source: Journal of Surgical Research)

risedronate, Actonel, Atelvia

Title: risedronate, Actonel, AtelviaCategory: MedicationsCreated: 3/12/2000 4:15:00 PMLast Editorial Review: 3/28/2012 12:00:00 AM (Source: MedicineNet Womens Health General)

Bisphosphonates May Have Protective Effect On Endometrial Cancer

Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital. Endometrial cancer affects more than 45,000 women a year in the U.S., usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known preventive medication for women at high risk of developing it... (Source: Health News from Medical News Today)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

Conclusion&nbsp;&nbsp;Our study showed persistence of overall hip fracture protection with long-term use of alendronate or risedronate. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00198-012-1952-7Authors M. Pazianas, The Botnar Research Centre, Oxford University, Oxford, UKB. Abrahamsen, Department of Medicine F, Gentofte Hospital, Copenhagen, DenmarkY. Wang, P&G Pharmaceuticals, Epidemiology & Health Outcomes, Mason, OH, USAR. G. G. Russell, The Botnar Research Centre, Oxford University, Oxford, UK Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Heel Ultrasound Can Assess Maintenance of Bone Mass in Women With Breast Cancer

In conclusion, risedronate helps to maintain skeletal integrity as assessed by heel QUS for women with early stage breast cancer. Heel QUS is associated with DXA-derived BMD at other major axial sites and may be used to follow skeletal health and bone mass changes in these women. (Source: Journal of Clinical Densitometry)

Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity [Chemistry]

We report the results of an in vitro screening assay targeting the intraerythrocytic form of the malaria parasite Plasmodium falciparum using a library of 560 prenyl-synthase inhibitors. Based on ??growth-rescue? and enzyme-inhibition experiments, geranylgeranyl diphosphate synthase (GGPPS) is shown to be a major target for the most potent leads, BPH-703 and BPH-811, lipophilic analogs of the bone-resorption drugs zoledronate and risedronate. We determined the crystal structures of these inhibitors bound to a Plasmodium GGPPS finding that their head groups bind to the [Mg2+]3 cluster in the active site in a similar manner to that found with their more hydrophilic parents, whereas their hydrophobic tails occupy a long-hydrophobic tunnel spanning both molecules in the dimer. The results o...

Pharmaceutical care issues encountered by post?menopausal osteoporotic women prescribed bisphosphonates

Conclusion:?? The main PCIs identified were related to the use of bisphosphonates and its adverse effects. The study showed that the presence of a clinical pharmacist has enabled patients to voice their medication?related issues and to allow appropriate recommendations and actions to be taken to resolve these issues. (Source: Journal of Clinical Pharmacy and Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Paget disease of bone - an update.

This article outlines the clinical features, diagnosis and management options for Paget disease of bone. Discussion The disease may be asymptomatic, found incidentally on radiography or biochemistry, or present with bone pain, deformity, fracture or other complications. Bisphosphonate therapy is indicated for patients with symptomatic disease and should also be considered in patients whose sites of disease suggest a risk of complications, such as long bones, vertebrae or base of the skull. The treatment of choice is a single infusion of zoledronic acid; courses of oral alendronate (3-6 months) or risedronate (2 months) are also effective. PMID: 22396921 [PubMed - in process] (Source: Australian Family Physician)

Modified osteoporosis drugs display strong anti-malarial activity

Researchers have discovered that modification of two drugs used to treat osteoporosis ?? zoledronate and risedronate ?? results in strong anti-malarial activity. (Source: MedWire News - Infectious Diseases)

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

Updated Date: Feb 22, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

An Evaluation of the Use of Oral Bisphosphonates and Risk of Esophageal Cancer (March).

CONCLUSIONS:Evidence on the use of bisphosphonates and risk of esophageal cancer is weak and conflicting. Additional studies are needed to further evaluate this issue and formulate stronger conclusions. In the meantime, health care professionals should ensure that patients take oral bisphosphonates properly to minimize esophageal irritation, are prescribed regimens that minimize exposure if adherence is difficult, and are evaluated for discontinuation of the drugs if appropriate. For patients at increased risk of esophageal cancer for other health reasons, nonoral bisphosphonates may be considered. PMID: 22333262 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial

Abstract: Background: Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis. This randomized, controlled, double-blind study assessed the efficacy of risedronate versus placebo in treating low bone mineral density (BMD) in patients with Crohn's disease.Methods: 88 Crohn's disease outpatients with BMD T-score (Source: Journal of Critical Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Pharmaceutical care issues encountered by post?menopausal osteoporotic women prescribed bisphosphonates

Conclusion:?? The main PCIs identified were related to the use of bisphosphonates and its adverse effects. The study showed that the presence of a clinical pharmacist has enabled patients to voice their medication?related issues and to allow appropriate recommendations and actions to be taken to resolve these issues. (Source: Journal of Clinical Pharmacy and Therapeutics)

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

Abstract: The association between bisphosphonate adherence in the first 12months after therapy initiation and subsequent fracture risk was examined. Patients were identified from a large, commercially-insured population with integrated pharmacy and medical claims. Eligible patients were aged ?45years, were new to osteoporosis therapy (no osteoporosis medication claims in prior year) with first (index) bisphosphonate claim between 1/1/2005 and 4/30/2008, and had continuous insurance coverage for ?12months pre- and post-index. Patients with fracture claims?12-months post-index were excluded. Adherence was assessed using the medication possession ratio (MPR) over 12-months post-index (i.e., sum of days' supply dispensed divided by 365days). Patients with a MPR>0.8 were considered adhere...

Three-Year Experience with Risedronate Therapy for Patients with an Increased Fracture Risk: Assessment of Proximal Femoral Bone Density and Geometry by DXA

(Source: Clinical Drug Investigation)

A study of changes in bone metabolism in cases of gender identity disorder

Abstract&nbsp;&nbsp;The aim of this study was to determine the effect of increasing estrogen and decreasing androgen in males and increasing androgen and decreasing estrogen in females on bone metabolism in patients with gender identity disorder (GID). We measured and examined bone mineral density (BMD) and bone metabolism markers retrospectively in GID patients who were treated in our hospital. In addition, we studied the effects of treatment on those who had osteoporosis. Patients who underwent a change from male to female (MtF) showed inhibition of bone resorption and increased L2??4 BMD whereas those who underwent a change from female to male (FtM) had increased bone resorption and decreased L2??4 BMD. Six months after administration of risedronate to FtM patients with osteopor...

A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?

Conclusion&nbsp;&nbsp;The CTX test was not predictive for the development of BRONJ following oral surgery. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s11845-011-0790-5Authors J. E. O??Connell, Department of Oral and Maxillofacial Surgery, St James??s Hospital, Dublin 8, IrelandO. Ikeagwani, Oral Surgeon, Cahercalla, Ennis, Clare, IrelandG. J. Kearns, Department of Oral and Maxillofacial Surgery, St James??s Hospital, Dublin 8, Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Abstract: Background: We studied 265 men (mean age 56.4years; range 18??83years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).Methods: Patients received either a single ZOL 5mg infusion or RIS 5mg oral daily at randomization, along with calcium (1000mg) and vitamin D (400??1200IU). Primary endpoint: difference in percentage change from baseline in bone mineral density (BMD) at the lumbar spine (LS) at 12months. Secondary endpoints: percentage changes in BMD at total hip (TH) and femoral neck (FN), relative changes in bone turnover markers (β-CTx...

Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

We examined the changes of femoral and trabecular bone morphologies after treatment. ? All mice showed powerful anti-osteoporosis effects in all parameters. ? No skin irritation was occurred in all groups of ovariectomized mouse after administration of risedronate. (Source: Bone)

Actonel and Dental Implants: What is the proper protocol?

How long should I wait after she stops the Actonel before I place the dental implants? (Source: Dental Implants Discussed by Experts)

Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): Small but increased risk of unusual thigh bone fractures

Health Canada is updating Canadians with respect to its review of bisphosphonate drugs, used to treat osteoporosis, and the risk of a rare but serious type of thigh bone fracture known as an "atypical femur fracture." (Source: Government of Canada News - Health Canada)

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer

In conclusion, anastrozole treatment for EBC in elderly women seems to have only mild negative effects on the femoral bone. Risedronate makes the use of anastrozole safer, even for osteopenic or osteoporotic elderly patients. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00774-011-0341-1Authors Giuseppe Sergi, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyGiulia Pintore, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyCristina Falci, Istituto Oncologico Veneto (IOV), IRCCS, Padua, ItalyNicola Veronese, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyLinda Berton, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyEgle Perissinotto,...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

Conclusions&nbsp;&nbsp;Although there were no differences in back pain-related endpoints, patients receiving teriparatide had greater skeletal benefit than those receiving risedronate. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1856-yAuthors P. Hadji, Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Philipps-University of Marburg, Marburg, GermanyJ. R. Zanchetta, IDIM, Buenos Aires, ArgentinaL. Russo, CCBR Brazil Clinical Research Center, Rio de Janeiro, BrazilC. P. Recknor, United Osteoporosis Centers, Gainesville, GA, USAK. G. Saag, University of Alabama, Birmingham, AL, USAF. E. McKiernan, Center for Bone Disease, Marshfield Clinic, Marshfield, WI, USAS. L. Silverman, Cedars-Sinai/UCLA and OMC Clinical Research ...

Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: Role of the akt pathway and the ERK/Bim axis

ConclusionOur findings indicate that the antiresorptive effect of risedronate in vivo is mainly mediated by the suppression of the bone?resorbing activity of osteoclasts and not by the induction of osteoclast apoptosis. (Source: Arthritis and Rheumatism)

The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

Authors: PMID: 22147217 [PubMed - in process] (Source: Orthopedics)

The association between automatic generic substitution and treatment persistence with oral bisphosphonates

Conclusion&nbsp;&nbsp;AGS causes increased product substitution which appears to be associated with reduced treatment persistence. Poor health outcomes and associated costs due to forgone drug exposure should be taken into account in the design and evaluation of policies implemented to encourage utilisation of generic medicines. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00198-011-1850-4Authors O. Ström, Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Berzelius väg 3, 171 77 Stockholm, SwedenE. Landfeldt, OptumInsight, Stockholm, Sweden Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Impact of Medication Adherence on Health Care Utilization and Productivity: Self-Reported Data From a Cohort of Postmenopausal Women on Osteoporosis Therapy.

CONCLUSIONS: Use of diagnostic testing differed significantly by osteoporosis treatment status. Compared with women who persisted with treatment, primary care provider visits were less common among those who discontinued treatment. Treatment persistence was not associated with significant differences in productivity measures. PMID: 22099387 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw

In conclusion, at the moment insufficient data are available to prove a greater risk of ONJ in children with OI than in children affected by other forms of bone fragility. However, cases may emerge in future because the risk of ONJ seems to be related to the cumulative dose and the duration of therapy. Content Type Journal ArticleCategory Original ArticlePages 1-5DOI 10.1007/s00774-011-0331-3Authors Evelina Maines, Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital ??Giambattista Rossi?, Piazzale Ludovico Antonio Scuro 10, 37134 Verona, ItalyElena Monti, Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital ??Giambattista Rossi?, Piazzale Ludovico Antonio Sc...

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial

Conclusions Treatment with once-weekly risedronate and ergocalciferol prevents hip fractures in older women with PD. (Source: Journal of Neurology, Neurosurgery and Psychiatry)

Treatment of osteoporosis in women intolerant of oral bisphosphonates

Abstract: In the past 15 years, oral bisphosphonate therapy has become the mainstay of pharmacological management in patients with osteoporosis. In the UK, alendronate is the drug of first choice, based on clinical efficacy data and cost. However, some patients are unable to take oral bisphosphonates for a number of reasons. In this article, we review the practical management of such cases, including strategies for monitoring adherence and switching to alternative oral agents (e.g. risedronate, strontium ranelate, raloxifene). In some cases, alternative parenteral agents may be considered, including intravenous bisphosphonates, parathyroid hormone therapies and denosumab. Specific concerns about safe prescribing are considered, when prescribing potent anti-resorptive medications, particula...

The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

Conclusions:Risedronate taken once weekly for six months following total hip arthroplasty was effective in reducing periprosthetic bone resorption around an uncemented femoral stem up to one year after surgery but had no discernible effect on implant migration or clinical outcome. Future studies of bisphosphonate treatment following total hip arthroplasty should focus on clinically relevant end points such as the risks of fracture and revision arthroplasty.Level of Evidence:Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence. PMID: 22012522 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)

Risedronate Decreases Bone Loss Around Hip Implants, But How Useful Is Its Effect?: Commentary on an article by Olof Gustaf Sköldenberg, MD, PhD, et al.: "The Effect of Weekly Risedronate on Periprosthetic Bone Resorption Following Total Hip Arthroplasty. A Randomized, Double-Blind, Placebo-Controlled Trial".

Risedronate Decreases Bone Loss Around Hip Implants, But How Useful Is Its Effect?: Commentary on an article by Olof Gustaf Sköldenberg, MD, PhD, et al.: "The Effect of Weekly Risedronate on Periprosthetic Bone Resorption Following Total Hip Arthroplasty. A Randomized, Double-Blind, Placebo-Controlled Trial". J Bone Joint Surg Am. 2011 Oct 19;93(20):e1201-2 Authors: Hamilton WG PMID: 22012537 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women

Conclusions&nbsp;&nbsp;Bone metabolism at the spine remained suppressed following treatment discontinuation. A significant increase in SUV at the femoral shaft and total hip after 12&nbsp;months was observed but for the ALN group only. This study was small, and further clinical studies are required to fully evaluate the persistence of BP treatment. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1805-9Authors M. L. Frost, Osteoporosis Research Unit, King??s College London, Guy??s Hospital Campus, Great Maze Pond, London, SE1 9RT UKM. Siddique, Osteoporosis Research Unit, King??s College London, Guy??s Hospital Campus, Great Maze Pond, London, SE1 9RT UKG. M. Blake, Osteoporosis Research Unit, King??s College London, Guy??s Hospital C...

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

Conclusions&nbsp;&nbsp;This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00198-011-1800-1Authors C. Roux, Rheumatology Department, Paris Descartes University, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75679 Paris cedex 14, FranceD. M. Reid, University of Aberdeen, Aberdeen, UKJ.-P. Devogelaer, Universite Catholique de Louvain, Brussels, BelgiumK. Saag, University of Alabama at Birmingham, Birmingham, AL, USAC. S. Lau, University of Hong Kong, Hong Kong, People??s Republic of ChinaJ.-Y. Reginster, University of Liege, Liege, Be...

Use of bisphosphonates in pregnancy

Source: UK Teratology Information Service Area: Evidence > Drugs in Pregnancy SUMMARY: The bisphosphonates are a class of drugs prescribed to prevent the loss of bone mass.&nbsp; They are used to treat osteoporosis (both idiopathic and glucocorticoid-induced), Paget's disease of the bone, and skeletal pain associated with metastatic breast cancer.&nbsp; There are currently eight bisphosphonates available in the UK: alendronic acid, disodium etidronate, disodium pamidronate, ibandronic acid, risedronate sodium, sodium clodronate, tiludronic acid and zoledronic acid. &nbsp; In rats, bisphosphonates are incorporated into fetal bones, affecting bone growth. &nbsp;This may also be a concern in human pregnancy, particularly as bisphosphonates are incorporated into the maternal bone and may ...

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Conclusions&nbsp;&nbsp;Risedronate 35&nbsp;mg DR weekly is similar in efficacy and safety to risedronate 5&nbsp;mg IR daily, and will allow patients to take their weekly risedronate dose immediately after breakfast. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1791-yAuthors M. R. McClung, Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USAP. D. Miller, Colorado Center for Bone Research, Lakewood, CO, USAJ. P. Brown, Groupe de recherche en rhumatologie et maladies osseuses, Québec, QC, CanadaJ. Zanchetta, University of El Salvador, Metabolic Research Institute, Buenos Aires, ArgentinaM. A. Bolognese, Bethesda Health Research, Bethesda, MD, USAC. L. Benhamou, Institut de Prévention et de Recherche sur l??Ostéop...

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

Conclusion: Teriparatide, zoledronic acid and denosumab have the highest probabilities of being most efficacious for non-vertebral and vertebral fractures, and having the greatest effect sizes. The estimates from indirect comparisons were robust to differences in methodology. (Source: BMC Musculoskeletal Disorders)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

Abstract: In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a dire...

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Conclusions?? Osteoporosis treatment change occurred in approximately 12% of members, while a greater proportion of members discontinued treatment completely within 12 months. Member characteristics may be used to predict therapy change for evaluation and quality initiatives within a health plan. (Source: Journal of Evaluation in Clinical Practice)

F.D.A. Panels Back Sterner Language on Bone Drugs

The F.D.A. is expected to issue a revised label in November for bone-building drugs like Fosamax, Actonel and Boniva. (Source: NYT Health)

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage

Conclusions&nbsp;&nbsp;Oral bisphosphonates are the primary drugs used to treat osteoporosis in Canada. Prescribing practices changed over time as newer medications came to market, yet access to second-generation bisphosphonates through BC PharmaCare was limited. Implications of differential access to oral bisphosphonates warrants further study. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00198-011-1771-2Authors S. M. Cadarette, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, M5S 3M2 ON, CanadaG. Carney, Therapeutics Initiative, University of British Columbia, Victoria, BC, CanadaD. Baek, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, M5S 3M2 ON, CanadaN. Gunraj, Institute f...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Distinguishing the pro?apoptotic and anti?resorptive functions of risedronate in osteoclasts: Role of the Akt pathway and the Erk/Bim axis

Conclusion.Our findings indicate that the anti?resorptive effect of RIS in vivo is mainly mediated by the suppression of the bone?resorbing activity of OCs, not the induction of OC apoptosis. (Source: Arthritis and Rheumatism)

Actonel (risedronate) May Be Tied to Lower Colon Cancer RiskActonel (risedronate) May Be Tied to Lower Colon Cancer Risk

A new study adds to evidence that bisphosphonates may play a role in suppressing cancer development, although there is still no firm proof. Reuters Health Information (Source: Medscape Gastroenterology Headlines)

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover.

Conclusions: One year of discontinuation of risedronate treatment in patients who had received 2 or 7 yr of risedronate therapy led to increases in NTX/Cr levels toward baseline and decreases in femoral trochanter and total hip BMD. PMID: 21865359 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo. (Source: Journal of Cystic Fibrosis)

Elevated International Normalized Ratio Associated with Use of Dronedarone and Warfarin (September).

CONCLUSIONS: Clinicians should monitor patients who are taking warfarin and dronedarone for INR changes and bleeding episodes about 1 week after initiation of dronedarone. If a significant interaction is noted, the warfarin dosage should be decreased and the patient should be monitored within 2 weeks to assess the need for further adjustments. PMID: 21811004 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Conclusions?? Osteoporosis treatment change occurred in approximately 12% of members, while a greater proportion of members discontinued treatment completely within 12 months. Member characteristics may be used to predict therapy change for evaluation and quality initiatives within a health plan. (Source: Journal of Evaluation in Clinical Practice)

[Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios].

Authors: Di Munno O, Delle Sedie A Osteoporosis (OP) and increased risk of fracture (Fx) associated with chronic glucocorticoid treatment pushed panels of experts and scientific societies to produce recommendations for both prevention and treatment of glucocorticoid-induced OP (GIO). Recently the American College of Rheumatology developed and/or endorsed their updated guidelines and recommendations for the prevention and treatment of GIO. In these recommendations the use of FRAX tool, for the 10-year probability of a major osteoporotic Fx, was integrated with other clinical risk factors to define low-, medium-, and high-risk patients. Updated approaches are delineated for post-menopausal women and men &gt;50 years, pre-menopausal women not of childbearing potential, men &lt;50 years an...

Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover

This study evaluated the urinary excretion of alendronate and risedronate in patients treated with these drugs for osteoporosis and analysed its relationship with bone turnover, time of previous drug exposure and time of treatment discontinuation. We included 43 women (aged 65±9.4years) previously treated with alendronate (36) or risedronate (7) during a mean of 51±3 and 53±3months, respectively, who had not been treated with other antiosteoporotic treatment and with a median time of discontinuation of 13.5 and 14months, respectively. Both BP were detected in 24-hour urine by HPLC. In addition, bone formation (PINP) and resorption (NTx) markers were analysed. Both BP were also determined in a control group of women during treatment. Alendronate was detected in 41% of women previously tr...

FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer

Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) AUDIENCE: Geriatrics, Family Practice, Internal Medicine ISSUE: FDA notified... (Source: Drugs.com - Pharma News)

Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer

Audience: Geriatrics, Family Practice, Internal Medicine Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified... (Source: Drugs.com - FDA MedWatch Alerts)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

Conclusions&nbsp;&nbsp;Risedronate in adults with OI type I results in modest but significant increases in BMD at LS, and decreased bone turnover. However, this may be insufficient to make a clinically significant difference to fracture incidence. Content Type Journal ArticlePages 1-10DOI 10.1007/s00198-011-1658-2Authors L. A. Bradbury, University of Queensland Diamantina Institute, University of Queensland, Brisbane, AustraliaS. Barlow, Nuffield Orthopaedic Centre NHS Trust, Oxford, UKF. Geoghegan, Ealing Hospital NHS Trust, Oxford, UKR. A. Hannon, Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UKS. L. Stuckey, Monash University, Melbourne, AustraliaJ. A. H. Wass, Nuffield Orthopaedic Centre NHS Trust, Oxford, UKR. G. G. Russell, Nuffield Department of O...

Bisphosphonates do not alter the rate of secondary mineralization

Abstract: Bisphosphonates function to reduce bone turnover, which consequently increases the mean degree of tissue mineralization at an organ level. However, it is not clear if bisphosphonates alter the length of time required for an individual bone-modeling unit (BMU) to fully mineralize. We have recently demonstrated that it takes ~350days (d) for normal, untreated cortical bone to fully mineralize. The aim of this study was to determine the rate at which newly formed trabecular BMUs become fully mineralized in rabbits treated for up to 414d with clinical doses of either risedronate (RIS) or alendronate (ALN). Thirty-six, 4-month old virgin female New Zealand white rabbits were allocated to RIS (n=12; 2.4μg/kg body weight), ALN (n=12; 2.4μg/kg body weight), or volume-matched saline con...

Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (SARA)

In conclusion, no significant difference in the incidence of GIAEs was found between patients prescribed alendronate, risedronate, and strontium ranelate. Individuals prescribed raloxifene had a significantly lower risk of GIAEs compared with patients prescribed alendronate. No significant difference was found in the frequency of hospitalization for GIAEs. Switching between osteoporosis medications and drug classes was uncommon. Prescribers should consider the real-world gastrointestinal safety of osteoporosis drugs when choosing between treatment options to potentially improve medication adherence and consequently effectiveness. Content Type Journal ArticlePages 1-12DOI 10.1007/s00223-011-9511-3Authors Erik Landfeldt, Innovus, Stockholm, SwedenAndrea Lang, Innovus, Stockholm, ...

Physiology of the aging bone and mechanisms of action of bisphosphonates.

Authors: Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M Fragility fractures, a major public health concern, are expected to further increase due to aging of the world populations because age remains a cardinal, independent determinant of fracture risk. With aging the balance between bone formation and resorption during the remodeling process becomes negative, with increased resorption and reduced formation. Bisphosphonates (BPs) are widely prescribed anti-resorptive agents that inhibit osteoclasts attachment to bone matrix and enhance osteoclast apoptosis. BPs can be divided into nitrogen-containing (N-BPs) and non-nitrogen-containing BPs (non-N-BPs). Both classes induce apoptosis but they evoke it differently. Several studies have examined the molecular mechanisms underlying BPs'...

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

Updated Date: Jun 9, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months

The objective of this 18-month prospective study was to investigate the effect of teriparatide [rhPTH(1??34)] in 25 female osteoporotics who were inadequate responders to oral bisphosphonates and to correlate microarchitectural changes in three consecutive iliac crest biopsies measured by micro-computed tomography (μCT) with bone mineral density (BMD) and bone serum markers. Scanned biopsies at baseline (M0), 6&nbsp;months (M6), and 18&nbsp;months (M18) demonstrated early significant (P&nbsp;&lt;&nbsp;0.01) increases in bone volume per tissue volume (+34%) and trabecular number (+14%) at M6 with only moderate changes in most μCT structural parameters between M6 and M18. μCT-measured bone tissue density was significantly decreased at M18, expressing an overall lower degree of tissu...

Resolved Recurrent Bilateral Anterior Uveitis With Discontinuation of Bisphosphonate

Bisphosphonates such as ibandronate, alendronate, and risedronate are commonly used in postmenopausal women to treat osteoporosis. There are ocular complications associated with the use of bisphosphonates including uveitis, iritis, scleritis, and conjunctivitis. Ocular incidence range from 0.046% to 1%. The symptoms usually improve and are reversible with discontinuation of the medication, but recurrent ocular inflammation and affected and contralateral eye involvement often lasts up to 1 year. (Source: Optometry - Journal of the American Optometric Association)

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott (US), LLC]

Updated Date: May 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Assessment of Regional Skeletal Metabolism: Studies of Osteoporosis Treatments Using Quantitative Radionuclide Imaging

Abstract: Studies of bone remodeling using bone biopsy and biochemical markers of bone turnover play an important role in research studies to investigate the effect of new osteoporosis treatments on bone quality. Quantitative radionuclide imaging using either positron emission tomography with fluorine-18 sodium fluoride or gamma camera studies with technetium-99m methylene diphosphonate provides a novel tool for studying bone metabolism that complements conventional methods, such as bone turnover markers (BTMs). Unlike BTMs, which measure the integrated response to treatment across the whole skeleton, radionuclide imaging can distinguish the changes occurring at sites of particular clinical interest, such as the spine or proximal femur. Radionuclide imaging can be used to measure either bo...

Bisphosphonate treatment delays stress fracture remodeling in the rat ulna

In conclusion, high dose bisphosphonate treatment impaired healing of a large stress fracture line by reducing the volume of bone resorbed and replaced during remodeling. We also confirmed that periosteal callus formation was not adversely affected by risedronate treatment. © 2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res (Source: Journal of Orthopaedic Research)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bisphosphonates: The first 40years

This article is part of a Special Issue entitled Bisphosphonates.Research highlights: ? The biological effects of bisphosphonates (BPs) were first published in 1969. ? The potency of BPs on bone resorption depends on binding to bone mineral and osteoclast inhibition. ? Nitrogen-BPs inhibit farnesyl pyrophosphate synthase(FPPS) and protein prenylation. ? BPs are the major drugs for treating Paget??s disease, bone metastases, and osteoporosis. ? Knowledge of structure-activity enables rational design of new BP drugs. (Source: Bone)

Risedronate and low-dose testosterone help BMI in anorexia nervosa

NEW YORK (Reuters Health) - For women with anorexia nervosa, weekly risedronate increases spinal bone mineral density. Adding low-dose testosterone does not improve BMD further but does increase lean body mass, a Boston team reports. (Source: Modern Medicine)

The relationship between the chemistry and biological activity of the bisphosphonates

This article is part of a Special Issue entitled Bisphosphonates.Research Highlights: ? Understanding how bisphosphonates (BPs) work has progressed to a more rational basis. ? Bisphosphonate-farnesyl pyrophosphate synthase(FPPS) complexes can be co-crystallized. ? Antiresorptive activity of N-BPs depends on mineral binding and FPPS inhibition. ? Fluorescent probes are providing new information on bisphosphonate localization. ? New knowledge of structure-activity enables rational design of bisphosphonate drugs. (Source: Bone)

Review: Vertebral Fractures

Source: N Engl J Med Area: News This review in the New England Journal of Medicine on vertebral fractures begins with a case vignette followed by a discussion of the following topics, ending with the author's clinical recommendations on the management of the case in hand: &nbsp; .&nbsp;Evaluation .&nbsp;Bone mineral density .&nbsp;Diagnosis .&nbsp;Treatment - pain management, rehabilitation, vertebroplasty and kyphoplasty, calcium and vitamin D, pharmacotherapy (alendronate, ibandronate, risedronate, zoledronic acid, bazedoxifene, lasofoxifene, raloxifene, parathyroid hormone, denosumab, strontium ranelate, calcitonin, teriparatide) .&nbsp;Areas of uncertainty .&nbsp;Guidelines from professional societies (Source: NeLM - News)

Effects of Risedronate and Low-Dose Transdermal Testosterone on Bone Mineral Density in Women with Anorexia Nervosa: A Randomized, Placebo-Controlled Study.

Conclusions: Risedronate administration for 1 yr increased spinal BMD, the primary site of bone loss in women with anorexia nervosa. Low-dose testosterone did not change BMD but increased lean body mass. PMID: 21525157 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice

In conclusion, the response to mechanical loading in both trabecular and cortical bone in mice is therefore not impaired by short-term treatment with risedronate, even over a 1000-fold dose range. In considering the optimization of treatments for osteoporosis, it is reassuring that anti-resorptive therapy and mechanical loading can exert independent beneficial effects.This article is part of a Special Issue entitled Bisphosphonates.Research highlights: ? We assessed the combined effect of a bisphosphonate and loading on bone structure. ? Non-invasive tibia loading and a 1000-fold dose range of risedronate were used. ? Loading significantly increased both cortical and trabecular bone mass. ? Risedronate does not reduce the osteogenic effect of loading. (Source: Bone)

Adherence to osteoporosis medications amongst Singaporean patients

Conclusion&nbsp;&nbsp;In contrast to studies conducted in the US and Europe that show poor adherence, our study suggests higher adherence rates to bisphosphonate therapy amongst Singaporean patients. Content Type Journal ArticlePages 1-8DOI 10.1007/s00198-011-1635-9Authors M. H. H. Cheen, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeM. C. Kong, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeR. F. Zhang, Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, 1 Hospital Drive, 169608 Singapore, SingaporeF. M. H. Tee, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeM. Chandran, Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hos...

Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes.

In conclusion, these findings unveil novel functions targeted by N-BPs in osteocytes and could be useful to design novel pharmaceutical compounds. PMID: 21504803 [PubMed - as supplied by publisher] (Source: Journal of Proteomics)

Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single?center study

SummaryThe aim of this study was to investigate the effect of risedronate (RIS) on bone loss and bone turnover markers after liver transplantation (LT). Patients with osteopenia or osteoporosis within the first month after LT were randomized to receive RIS 35??mg/week plus calcium 1000??mg/day and vitamin D3 800??IU/day (n??=??45) or calcium and vitamin D3 at same dosages (n??=??44). Primary endpoint was change in bone mineral density (BMD) 6 and 12??months after LT. Secondary endpoints included changes in serum β?CrossLaps (β?CTX) and procollagen type 1 amino?terminal peptide (P1NP) and fracture rate. Spine X?rays were obtained at baseline and after 12??months. There was no significant difference in BMD changes between both treatment groups at any sites; either at 6 or ...

Prevention of Bone Loss in Patients Taking Anti-Epileptic Drugs (AEDs)- Results of the Antiepileptic Drugs and Osteoporosis Prevention Trial (ADOPT).

Patients with epilepsy have a nearly twofold increase risk of vertebral or non-vertebral fractures as compared to the general population. It is known that long term use of AEDs is associated with an increased rate of bone loss. The primary objective of this trial was to evaluate whether the use of an oral bisphosphonate can help in preventing bone loss and osteoporosis in an epileptic population treated with phenytoin, phenobarbital, sodium valproate or carbamazepine. This investigator initiated study design is a phase IV, prospective, randomized, placebo controlled, double-blind study involving 80 male veterans with epilepsy who were being treated with the above AEDs for at least 2 years. Patients who were found to be osteoporotic according to WHO criteria (BMD T-score < -2.5 at spine or ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of Risedronate in Runx2 Overexpressing Mice, an Animal Model for Evaluation of Treatment Effects on Bone Quality and Fractures

In conclusion, young mice overexpressing Runx2 have high bone turnover-induced osteopenia and spontaneous fractures. Ris at 20&nbsp;μg/kg weekly induced an increase in bone mass, changes in bone microarchitecture, and decreased vertebral fractures. Content Type Journal ArticlePages 1-12DOI 10.1007/s00223-011-9480-6Authors Valerie Geoffroy, INSERM U606, University Paris Diderot, Hôpital Lariboisière, Centre Viggo Petersen, 2 rue Ambroise Paré, 75010 Paris, FranceEleftherios P. Paschalis, Ludwig Boltzman Institute of Osteology at the Hanusch Hospital of WGKK, Heinrich Collin-Str. 30, 1140 Vienna, AustriaHelene Libouban, INSERM U922, LHEA Faculté de Médecine, 1 rue Haute de Reculée, 49045 Angers Cedex, FranceStephane Blouin, Ludwig Boltzman Institute of Osteology at the Hanusc...

Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36

Abstract&nbsp;&nbsp;Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis. In order to compare the effects of elcatonin and risedronate on such pain, 20 units of elcatonin was intramuscularly injected to 18 patients, and 5&nbsp;mg of risedronate was orally administered daily to 20 others with similar backgrounds. Exercise-induced pain was analyzed by measuring the fall of skin impedance by electroalgometry (EAM), and subjective pain was recorded by a visual rating system (VRS) on a scale of 0 (no pain) to 100 (unbearable pain). In patients treated with elcatonin, the mean EAM-estimated pain was significantly reduced after 4, 5 and 6&nbsp;months o...

Simultaneous bilateral subtrochanteric fractures following risedronate therapy

Content Type Journal ArticlePages 1-4DOI 10.1007/s00776-011-0058-yAuthors Mikko T. Ovaska, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, FinlandTatu J. Mäkinen, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, FinlandRami Madanat, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, Finland Journal Journal of Orthopaedic ScienceOnline ISSN 1436-2023Print ISSN 0949-2658 (Source: Journal of Orthopaedic Science)

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Authors: K Izumi, A Mizokami, K Sugimoto, K Narimoto, Y Kitagawa, E Koh & M Namiki (Source: Prostate Cancer and Prostatic Diseases)

Actonel with Calcium (Risedronate Sodium with Calcium Carbonate) - updated on RxList

Actonel with Calcium (Risedronate Sodium with Calcium Carbonate) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.

Authors: Räikkönen J, Taskinen M, Dunford JE, Mönkkönen H, Auriola S, Mönkkönen J A class of drugs successfully used for treatment of metabolic bone diseases is the nitrogen-containing bisphosphonates (N-BPs), which act by inhibiting the vital enzyme, farnesyl pyrophosphate synthase (FPPS), of the mevalonate pathway. Inhibition of FPPS by N-BPs results in the intracellular accumulation of isopentenyl pyrophosphate (IPP) and consequently induces the biosynthesis of a cytotoxic ATP analog (ApppI). Previous cell-free data has reported that N-BPs inhibit FPPS by time-dependent manner as a result of the conformational change. This associated conformational change can be measured as an isomerization constant (K(isom)) and reflects the binding differences of the N-BPs to FPPS. In the pr...

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

The primary goal of treatment for post-menopausal osteoporosis (PMO) is reduction in fracture risk. Therefore, clinicians must recommend therapies that are safe and have proven anti-fracture efficacy. Bisphosphonates have long been established as first-line therapy for osteoporosis and several of these drugs significantly reduce osteoporotic fracture risk. However, choosing among different bisphosphonates can represent a difficult clinical decision. This review outlines the pharmacology of various bisphosphonates, discusses how their pharmacological characteristics affect their efficacy, and summarizes clinical safety and efficacy data. Clinical trial data and the opinions of expert bodies suggest that alendronate, risedronate, ibandronate and zoledronic acid all provide fracture protectio...

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women

Conclusions&nbsp;&nbsp;No significant differences were observed between the two groups. The incidence of unaffected side hip fracture was significantly lower in the risedronate group. Accordingly, risedronate may have a preventive effect on hip fracture in high-risk Japanese female osteoporosis patients for fracture with a history of unilateral hip fracture. Content Type Journal ArticlePages 1-9DOI 10.1007/s00198-011-1556-7Authors M. Osaki, Department of Orthopaedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501 JapanK. Tatsuki, Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka, 540-8645 JapanT. Hashikawa, Department of Orthopaedic Surgery, Nagasaki University Graduate School of Biomedical Sc...

Bisphosphonates for postmenopausal osteoporosis

This article is part of a Special Issue entitled Bisphosphonates.Research Highlights: ? Bisphosphonates reverse the key pathophysiological changes of postmenopausal osteoporosis. ? The bisphosphonates that have been licensed in many countries for postmenopausal osteoporosis include alendronate, ibandronate, risedronate and zoledronic acid. ? These bisphosphonates all reduce the level of bone turnover and increase the bone mineral density in postmenopausal osteoporosis. ? The bisphosphonates differ in their potency in their effects on bone turnover and bone density. ? The licensed bisphosphonates have all been shown to reduce the risk of vertebral fractures; some of them have also been shown to reduce the risk of non-vertebral and hip fractures. (Source: Bone)

Efficacy of risedronate with cholecalciferol on 25?hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis

Conclusion?? In patients with osteoporosis, a once?weekly pill of risedronate and cholecalciferol provided equivalent anti?resorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D level over a 16?week treatment period without significant adverse events. (Source: Clinical Endocrinology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

Conclusions&nbsp;&nbsp;Risedronate significantly reduced the risk of new vertebral fractures compared with placebo, regardless of PPI concomitant use. Content Type Journal ArticlePages 1-8DOI 10.1007/s00198-011-1574-5Authors C. Roux, Department of Rheumatology, AP-HP Cochin Hospital, Paris Descartes University, 27 rue Faubourg Saint Jacques, Paris, 75014 FranceJ. L. Goldstein, Department of Medicine, University of Illinois at Chicago, Chicago, IL USAX. Zhou, Procter & Gamble, Mason, OH USAA. Klemes, Procter & Gamble, Mason, OH USAR. Lindsay, Helen Hayes Hospital, West Havershaw, NY USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats

Conclusions: Risedronate improved prednisolone-induced retardation of trabecular and cortical bone growth, but the bone turnover in these 2 sites was regulated differently in the growing rat mandibles. (Source: American Journal of Orthodontics and Dentofacial Orthopedics)

In vitro and in vivo antiplasmodial activity of risedronate and its interference with protein prenylation in P. falciparum.

Authors: Jordão FM, Saito AY, Miguel DC, Peres VD, Kimura EA, Katzin AM The increasing resistance of malarial parasites to almost all available drugs calls for the identification of new compounds and the detection of novel targets. Herein, we establish the antimalarial activity of risedronate, one of the most potent bisphosphonates clinically used to treat bone resorption diseases, against blood stages of Plasmodium falciparum (IC50 20.3 ± 1.0 μM). We also suggest a mechanism of action for risedronate against the intraerythrocytic stage of P. falciparum, and show that protein prenylation seems to be directly modulated by this drug. Risedronate inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins, an effect not observed for the transfer of geranylgeranyl pyr...

Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF?κB Ligand and Apoptosis in Mesenchymal Stem Cells

In this study, we investigated the effects of risedronate (RIS), a nitrogen?containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC?derived osteoblasts. The RANKL expression induced by 1,25?(OH)2 vitamin D3 was not affected by RIS in human MSC?derived osteoblasts. In addition, treatment with high concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS?induced chromatin condensation was suppressed by a pan?caspase inhibitor zVAD?FMK and a cell permeable isoplenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiat...

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

Updated Date: Feb 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Good long-term adherence to osteoporosis prophylaxis decreases fracture risk but may be uncommon

Source: Osteoporosis Int Area: News A large observational study from Sweden found that only a quarter of patients started on drugs for prophylaxis of osteoporosis were still taking them after 3 years, dropping to 14% after 4 years; however long-term use did reduce risk of fractures significantly. &nbsp; There is much evidence that persistence (long-term adherence) is poor with drugs for prophylaxis of osteoporosis, but reported values vary widely. The authors of this paper report experience from Sweden, using data from a historical cohort derived from Swedish prescribing registers. They extracted data on all patients aged 50 and over newly prescribed (no eligible prescription in previous five months) any one of alendronate, risedronate, strontium ranelate, and raloxifene between June ...

[Bisphosphonate treatment of osteoporosis and other skeletal diseases.]

Authors: Syversen U, Halse JI Background. Bisphosphonates are antiresorptive drugs widely used to treat osteoporosis. They are also used to treat hereditary skeletal diseases with systemic or local defects, and as a supplement in treatment of cancer. This paper provides an overview of pharmacokinetics, mode of action, and clinical effects. Material and methods. Literature was retrieved through a non-systematic search in Pubmed/Medline. Results. Bisphosphonates are derivates of pyrophosphate which bind to hydroxyapatite with high affinity. Aminobisphosphonates inhibit an enzyme in the mevalonate pathway, thereby inducing apoptosis and inhibiting osteoclast activity. A reduced incidence of vertebral and hip fractures has been shown for alendronate, risedronate and zoledronate, while iban...

Dose-dependent Differential Effects of Risedronate on Gene Expression in Osteoblasts.

Authors: Wang J, Stern PH Bisphosphonates have multiple effects on bone. Their actions on osteoclasts lead to inhibition of bone resorption, at least partially through apoptosis. Effects on osteoblasts vary, with modifications in the molecule and concentration both resulting in qualitatively different responses. To understand the mechanism of the differential effects of high and low bisphosphonate concentrations on osteoblast activity, we compared the effects of 10(-8)M and 10(-4)M risedronate on gene expression in UMR-106 rat osteoblastic cells. Two targeted arrays, an 84-gene signaling array and an 84-gene osteogeneic array were used. Gene expression was measured at 1 and 24 hr. Although some genes were regulated similarly by low and high concentrations of the drug, there was also di...

Adherence to treatment of primary osteoporosis and its association to fractures??the Swedish Adherence Register Analysis (SARA)

Conclusions&nbsp;&nbsp;Persistence to treatment of osteoporosis in Sweden is poor and approximately 50% of all treatment-naïve patients discontinue therapy within 1&nbsp;year. Average refill compliance, estimated only while the patients were persistent, was found to be close to perfect. A strong association was identified between treatment persistence and fracture incidence, which calls for action to improve the current situation. Content Type Journal ArticlePages 1-11DOI 10.1007/s00198-011-1549-6Authors E. Landfeldt, i3 Innovus, Stockholm, SwedenO. Ström, i3 Innovus, Stockholm, SwedenS. Robbins, Amgen (Europe) GmbH, Zug, SwitzerlandF. Borgström, i3 Innovus, Stockholm, Sweden Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteop...

These Drugs Poison Your Bones

Dear Health Conscious Reader, Would you use a drug that gives you the problem it??s supposed to prevent? Well, that??s exactly what??s going on with the new osteoporosis drugs. Fosomax, Boniva, Reclast, Actonel &#8230; these medications are supposed to help stop you from getting bone fractures as you get older. But we now have evidence that they cause bone breaks. Researchers studied women taking these medications ?? called bisphosphonates ?? who experienced some sort of fracture. Over 65 percent had the same rare fracture in the same area of their thigh bones. And these were the women who had been on the drugs for the longest periods.1 Plus they??ve also found that if you??re on the drugs for a long time and you do get a bone break, you??ll heal very slowly. Sometimes it can take...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study

This study examined patients?? risk profiles and adherence to treatment in relation to the effect of risedronate and raloxifene on hip fracture incidence. Administrative billing data were used to follow two cohorts of women aged 65 and older after starting therapy with either risedronate (n&nbsp;=&nbsp;86,735) or raloxifene (n&nbsp;=&nbsp;37,726). The fracture risk profile was described using a 6-month history period before starting therapy. Effectiveness of each therapy was evaluated by comparing the incidence of hip fractures during the first 3&nbsp;months with the subsequent 12&nbsp;months among women adherent (medication possession ratio &gt;80%) compared with those non-adherent to treatment. At the start of therapy, the raloxifene cohort was younger than the risedronate cohort (...

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women??the six-month effect of risedronate and teriparatide

Conclusions&nbsp;&nbsp;Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6&nbsp;months treatment with RIS, whereas remained essentially unchanged after 6&nbsp;months TPTD treatment. Content Type Journal ArticlePages 1-6DOI 10.1007/s00198-010-1525-6Authors S. A. Polyzos, Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34 Thessaloniki, GreeceA. D. Anastasilakis, Department of Endocrinology, 424 General Military Hospital, Thessaloniki, GreeceC. Bratengeier, Biomarker Design Forschungs GmbH, Vienna, AustriaW. Woloszczuk, ...

Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis

Abstract&nbsp;&nbsp;In addition to the well-described implications of estrogen deficiency in postmenopausal osteoporosis (PMO), free radicals are also effective on bone metabolism. The antioxidant vitamins C and E play an important role in the production of collagen, mesenchymal cell differentiation into osteoblasts, and bone mineralization. Therefore, the incidence of osteoporosis and the risk of fractures were decreased with vitamin C and E. It was proposed that free oxygen radicals are responsible for biological aging, atherosclerosis, carcinogenesis, and osteoclastic activity via their negative effects on the cell and DNA. In this study, we aimed to investigate and compare the levels of free radicals and serum antioxidant activity in patients with PMO and healthy subjects before ...

Recalls and Safety Alerts: Update on Femur Fracture Risk with Bisphosphonates

The FDA has issued updated information on atypical fractures of the femur associated with the use of bisphosphonates to treat osteoporosis. These drugs include Fosamax (alendronate sodium), Actonel (risedronate sodium), Boniva (ibandronate sodium), ... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Spontaneous Supracondylar Femoral Fracture in an HIV Patient in Lotus Position

Abstract: Bone disorders have been described in patients chronically infected with human immunodeficiency virus (HIV). A case of spontaneous supracondylar femoral fracture that occurred in a 58-year-old monk during meditation is reported. His AIDS disease was controlled with combination antiretroviral therapy. Vitamin D and calcium had been added 3yr before since osteoporosis was detected by dual-energy X-ray absorptiometry (DXA). At the time of the fracture, the patient was on treatment with 35mg every week of sodium risedronate, 1000mg of calcium, and 400IU of Vitamin D every day. Clinical use of DXA for HIV patients should be considered as a routine measure to help reducing risk for fractures. (Source: Journal of Clinical Densitometry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Authors: Reginster JY Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad for consideration in osteoporosis is morbidity, mortality and cost. Vertebral fracture is an important source of morbidity in terms of pain and spinal deformity. On the other hand, hip fracture is associated with the worst outcomes and is widely regarded as a life-threatening event in the elderly; it is the source of the bulk of the cost of the disease in contemporary healthcare. The prevention of osteoporosis-associated fracture should include fall ...

Transformation of hemipenta hydrate to mono hydrate of risedronate monosodium by seed crystallization in solution

AbstractThe transformation from a hemipenta to a mono hydrate of risedronate monosodium(RS) was studied by seed crystallization in solution. By using the in?line measurement based on ultrasonic measuring technique and the off?line measurements such as optical microscopic and crystallography, transformation of hydrate forms and crystallization of monohydrate were observed. The effect of concentration of solution and solid fraction of suspension on the ultrasonic velocity was found. The hydrate composition, concentration of solution and supersaturation during the transformation were estimated with elapsed time. The effect of mono hydrate seed, agitation rate and temperature on the induction time, transformation and crystallization was also investigated. Eventually transformation from hem...

Transformation of hemipentahydrate to monohydrate of risedronate monosodium by seed crystallization in solution

AbstractThe transformation from a hemipentahydrate to a monohydrate of risedronate monosodium was studied by seed crystallization in solution. By using the in?line measurement based on ultrasonic measuring technique and the off?line measurements such as optical microscopic and crystallography, transformation of hydrate forms and crystallization of monohydrate were observed. The effect of concentration of solution and solid fraction of suspension on the ultrasonic velocity was found. The hydrate composition, concentration of solution, and supersaturation during the transformation were estimated with elapsed time. The effect of monohydrate seed, agitation rate and temperature on the induction time, transformation, and crystallization was also investigated. Eventually, transformation from...

One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study

Introduction: Bone loss is a well known complication of aromatase inhibitor therapy in breast cancer patients. The bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) is a randomized, placebo-controlled, double-blind trial to study the effect of anastrozole (1mg/day) on bone mineral density (BMD) and to evaluate the impact of oral risedronate on bone loss in healthy postmenopausal women at a high risk of breast cancer. Materials and Methods: Lumbar spine (LS) and total hip (TH) BMD at baseline and 1year were available for 657 women at the time of analysis. Of these, 384 with normal BMD (stratum-I) received only monitoring with DXA scans, 194 osteopenic women (stratum-II) were randomised to receive either risedronate 35mg/week or placebo and 79 osteoporotic women en...

Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates

Authors: J M Olmos, M T Zarrabeitia, J L Hern&#225;ndez, C Sa&#241;udo, J Gonz&#225;lez-Mac&#237;as & J A Riancho (Source: The Pharmacogenomics Journal)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: Dec 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Proposed new approach for treating Paget??s disease of bone

Conclusions&nbsp;&nbsp;Newly diagnosed patients with PDB should be treated for 6&nbsp;months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist. Content Type Journal ArticleDOI 10.1007/s11845-010-0652-6Authors W. Mahmood, St. Michaels Hospital, Lower George??s Street, Dún Laoghaire, Co. Dublin IrelandM. J. McKenna, St. Michaels Hospital, Lower George??s Street, Dún Laoghaire, Co. Dublin Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

Updated Date: Dec 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis

In conclusion, Japanese osteoporotic women treated by either alendronate or risedronate showed significant improvements of geometry in proximal femur within 1&nbsp;year. Content Type Journal ArticleDOI 10.1007/s00774-010-0242-8Authors Junichi Takada, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, JapanGenichiro Katahira, Sapporo Kiyota Orthopaedic Hospital, Sapporo, JapanKousuke Iba, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, JapanTakashi Yoshizaki, Kitago Orthopedic Clinic, Kitago, 3jyo-8, 5-33, Shiroishi-ku, Sapporo, 003-0833 JapanToshihiko Yamashita, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, Japan Journal Journal of Bone and Mineral MetabolismOnline ISSN 1435-5604Print ISSN 0914-8779 (Source:...

Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase.

Authors: Ohno K, Mori K, Orita M, Takeuchi M Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Paget's disease. Non-nitrogen containing BPs (non-N-BPs), namely etidronate, clodronate, tiludronate, as well as nitrogencontaining BPs (N-BPs), namely pamidronate, alendronate, ibandronate, risedronate, zoledronate and minodronate have been launched on the market to date. N-BPs act by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS), and several crystal structures of complexes between FPPS and N-BPs have been revealed. Understanding the physical basis of the binding between protein and small molecules is an important goal in both medicinal chemistry and structural biology. In this review, we analyze in detail the energetic basis of molecu...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Osteoporosis in Men: What has Changed?

Abstract&nbsp;&nbsp;Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture. Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram. Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors. Alendronate, risedronate, zoledronic acid, and teriparatide are US Food and Drug Administration (FDA)??approved therapy for men. Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density. The new antiresorptive drug, denosumab, although FDA-approved onl...

Bisphosphonates in phenytoin-induced bone disorder

Abstract: Chronic administration of phenytoin (PHT) has been associated with bone loss. Bisphosphonates [alendronate (ALD), ibandronate (IBD) and risedronate (RSD)] are potential candidates to prevent PHT-induced bone disorders, and the present study evaluated their effect on the antiepileptic efficacy of PHT. The PHT-induced depletion in folic acid (FA), vitamin B6 and vitamin B12 results in hyperhomocysteinemia. The elevated circulating homocysteine (hcy) could be a risk indicator for micronutrient-deficiency-related osteoporosis via generation of free radicals. Thus, an attempt was also made to unravel the PHT's and bisphosphonates' effect on hcy. Male mice received PHT (35mg/kg, p.o.) for 90days to induce bone loss. ALD, RSD and IBD were administered orally at doses 0.65mg/kg, 0.33mg/k...

Atelvia (Risedronate Sodium Delayed-Release Tablets) - updated on RxList

Atelvia (Risedronate Sodium Delayed-Release Tablets) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35&nbsp;mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24&nbsp;months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P&nbsp;&lt;&nbsp;0.05). Women not on an AI gained total body fat compared to baseline and AI users (P&nbsp;&lt;&nbsp;0....

Erratum to: Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate

Content Type Journal ArticleDOI 10.1007/s00223-010-9430-8Authors Stuart H. Ralston, Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, EH4 2XU UKTzuyung D. Kou, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USABettina Wick-Urban, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USAMichael Steinbuch, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USATahir Masud, Nottingham University Hospitals NHS Trust, Nottingham, UK Journal Calcified Tissue InternationalOnline ISSN 1432-0827Print ISSN 0171-967X (Source: Calcified Tissue International)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

In conclusion, our results suggest that low concentrations of N-BPs inhibit angiogenesis in a FPPS-independent manner, whereas higher drug concentrations were required to inhibit FPPS activity in vivo. (Source: Bone)

FDA: Osteoporosis Drugs May Raise Thigh Fracture Risk

The bisphosphonate class of osteoporosis drugs -- including Actonel, Atelvia, Boniva, Fosamax, Reclast, and generics -- may riase the risk of thigh-bone fracture, the FDA warns. (Source: WebMD Health)

Bisphosphonates (Osteoporosis Drugs): Label Change - Atypical Fractures Update

Audience: Patient, Family Practice, Geriatric including Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast ISSUE: FDA is updating the public regarding information previously communicated describing the risk of... (Source: Drugs.com - FDA MedWatch Alerts)

Warner Chilcott Announces FDA Approval of Next Generation Actonel

ARDEE, Ireland, Oct. 11 (HSMN NewsFeed) -- Warner Chilcott plc (Nasdaq:WCRX ) today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL&reg; (risedronate sodium) product for the treatment of postme... Biopharmaceuticals, FDAWarner Chilcott, ACTONEL, risedronate, osteoporosis (Source: HSMN NewsFeed)

Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel

ARDEE, Ireland, October 11, 2010 /PRNewswire-FirstCall/ -- Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation Actonel (risedronate sodium) product for the treatment... (Source: Drugs.com - New Drug Approvals)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Conclusion&nbsp;&nbsp;Improving persistence with osteoporosis treatment impacts positively on cost-effectiveness with a larger number of fractures avoided in the population targeted for treatment. Denosumab is a cost-effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture and low expected adherence to oral treatments. Content Type Journal ArticleDOI 10.1007/s00198-010-1424-xAuthors B. Jönsson, Stockholm School of Economics, Box 6501, SE 11383 Stockholm, SwedenO. Ström, i3 Innovus, Stockholm, SwedenJ. A. Eisman, UNSW, Garvan Institute of Medical Research, St Vincent??s Hospital, Sydney, AustraliaA. Papaioannou, McMaster University, Hamilton, ON CanadaE. S. Siris, Columbia University, New York, NY USAA. Tosteson, Dartmouth Me...

Osteoporotic fracture prevention guidance

Postmenopausal women at increased risk of osteoporotic fractures should be treated with denosumab (Prolia), if treatment with the oral bisphosphonates alendronate, risedronate or etidronate is unsuitable, according to draft guidance from NICE. (Source: Nursing Times Breaking News)

Switching osteoporosis drugs 'increases GI risk'

Patients with osteoporosis who are switched from risedronate to alendronate have a much higher risk of developing an adverse gastrointestinal event, a UK study shows. (Source: Pulse)

Final Draft Guidance Recommends Osteoporosis Treatment As A New Option For Women At Increased Risk Of Fractures

Postmenopausal women who are at increased risk[1] of osteoporotic fractures should be treated with denosumab if treatment with the currently available oral bisphosphonates alendronate, and either risedronate or etidronate is unsuitable, according to draft guidance published today (Wednesday 15 September) by NICE. Denosumab (Prolia, Amgen) is licensed to treat postmenopausal women at increased risk of osteoporotic fractures. It is given by injection twice a year and works by reducing bone breakdown and increasing bone mass and strength... (Source: Health News from Medical News Today)

NICE issues Final Appraisal Determination (FAD) on denosumab for osteoporotic fractures

Source: NICE Area: News After considering the feedback from consultation, the Appraisal Consultation Committee has published a Final Appraisal Determination (FAD) on denosumab for the prevention of osteoporotic fractures in postmenopausal women and submitted it to the Institute. &nbsp; The FAD states the following: &nbsp; Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures: .&nbsp;who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and .&nbsp;who have a combination of T-score, age and number of independent clinical risk ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis

Conclusion: Of the available bisphosphonates for osteoporosis, zoledronic acid has the highest probability of offering the best overall fracture protection. (Source: Seminars in Arthritis and Rheumatism)

Bone drugs and cancer rates

Conclusion This was a large cohort study that looked at whether using oral bisphosphonates for osteoporosis increased the risk of oesophageal, stomach or colorectal cancer. The study was well conducted and accounted for other factors that could affect the risk of these types of cancer, most importantly smoking and alcohol consumption. Although the study found that people taking many prescriptions of these drugs over a long time had an increased risk compared to patients who had never taken these drugs, there are limitations to this study, some of which were raised by the researchers. Points for consideration include: The researchers had prescription data but no information on how the patients took the drugs. For example, this type of drug will contain safety information designed to mini...

Bone-building drugs double the risk of esophageal cancer, but the risk is still small

The family of bone-building drugs that includes Fosamax, Actonel and Boniva can double the risk of developing throat cancer, researchers reported Thursday in the latest development in what has become a confusing discussion. Other studies have reported... (Source: OrlandoSentinel: Medical Research)

Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women

In conclusion, risedronate 5&nbsp;mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone. Content Type Journal ArticleDOI 10.1007/s00223-010-9411-yAuthors S. Qiu, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USAR. J. Phipps, Husson University School of Pharmacy, 1 College Circle, Bangor, ME USAF. H. Ebetino, Warner Chilcott, Mason Business Center, Mason, OH USAS. Palnitkar, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USAD. Sudhaker Rao, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USA Journal Calcifi...

Osteoporosis Drugs May Be Linked to Cancer Risk

The long-term use of oral bisphosphonate osteoporosis drugs such as Actonel, Boniva, and Fosamax may be associated with a doubling in esophageal cancer risk, but the risk to individual users remains small, researchers say. (Source: WebMD Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

[Jaw osteonecrosis induced by oral biphosphonates: 12 cases.]

We report 12 cases of JONOBP observed from January 2007 to January 2009. MATERIAL AND METHODS: A pluridisciplinary committee including odontologists, stomatologists, and maxillofacial surgeons from two Paris hospitals was asked to manage patients treated by BP. Twelve patients presenting with JONOBP were included from January 2007 to January 2009. For each of these patients, age, sex, associated co-morbidities, any triggering factor, previous or current combination treatments, the type of BP used, its initial indication, dosage, delay before onset of JONOBP, and delay between first clinical signs and diagnosis were studied. JONOBP localization, stage (American Association of Oral and Maxillofacial Surgeons [AAOMS] classification), clinical and radiological signs, anatomopathological and ba...

Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate

Abstract&nbsp;&nbsp;Upper gastrointestinal (GI) side effects are a known complication of therapy with oral aminobisphosphonates, but it is currently unclear if bisphosphonate type or formulation influences the risk of developing side effects. Here, we performed a retrospective cohort study to determine if patients who switched from weekly risedronate to weekly alendronate had an increased risk of upper GI side events. The study utilized The Health Improvement Network (THIN) database, which contained anonymous medical records from 390 general practices in the United Kingdom. The study was performed following the introduction of generic alendronate preparations, by which point 94% of alendronate prescriptions were for the generic formulation. We identified 3,446 patients who had been s...

Community based intervention to optimize osteoporosis management: randomized controlled trial

Conclusions: A multi-faceted community-based intervention improved management of osteoporosis in high risk patients compared with usual care.Trial Registration: This trial has been registered with clinicaltrials.gov (ID: NCT00465387) (Source: BMC Geriatrics)

The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation

IntroductionThe purpose of this study was to evaluate the effects of risedronate (Ris) in the modulation of bone formation in rats with glucocorticoid (GC) - induced osteoporosis by histomorphometric, immunohistochemical and gene expression analyses. Methods: We analyzed structure, turnover and microarchitecture, cyclooxygenase 2 (COX-2) levels and osteocyte apoptosis in 40 female rats divided as follows: 1) vehicle of methylprednisolone (vGC) + vehicle of risedronate (vRis); 2) Ris 5[microg]/Kg + vGC; 3) methylprednisolone (GC) 7mg/Kg + vRis; 4) GC 7mg/Kg +Ris 5[microg]/Kg. In addition, we evaluated cell proliferation and expression of COX-2 and bone alkaline phosphatase (b-ALP) genes in bone marrow cells and MLO-y4 osteocytes treated with Ris alone or in co-treatment with the selective C...

Synthesis and biological evaluation of a series of aromatic bisphosphonates.

Authors: Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF Geminal bisphosphonates display varied biological activity depending on the nature of the substituents on the central carbon atom. For example, the nitrogenous bisphosphonates zoledronate and risedronate inhibit the enzyme farnesyl diphosphate synthase while digeranyl bisphosphonate has been shown to inhibit the enzyme geranylgeranyl diphosphate synthase. We now have synthesized isoprenoid bisphosphonates where an aromatic ring has been used to replace one of the isoprenoid olefins in an isoprenoid bisphosphonate and investigated the ability of these new compounds to impair protein geranylgeranylation within cells. Several of these new compounds are potent inhibitors of the enzyme geranylgeranyl diphosphate synthase. PMI...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Pharmaceuticals Inc.]

Updated Date: Aug 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate

This article is part of a Special Issue entitled Bisphosphonates. (Source: Bone)

Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.

CONCLUSION. Continuous local injection of risedronate into the lengthened segment can prevent osteopenia during distraction osteogenesis but fails to enhance mechanical strength of newly distracted segments. PMID: 20808018 [PubMed - in process] (Source: Journal of Orthopaedic Surgery)

Effects of risedronate on bone marrow adipocytes in postmenopausal women

Conclusions&nbsp;&nbsp;Risedronate reduces bone marrow fat in postmenopausal women. These findings are the first demonstration of an effect of bisphosphonates on marrow fat in humans in vivo. By regulating the amount of fat within the bone marrow, this effect may contribute to the beneficial effect of bisphosphonates on bone mass. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-010-1353-8Authors G. Duque, The University of Sydney Aging Bone Research Program, Sydney Medical School??Nepean Campus Penrith NSW AustraliaW. Li, The University of Sydney Aging Bone Research Program, Sydney Medical School??Nepean Campus Penrith NSW AustraliaM. Adams, The University of Sydney Aging Bone Research Program, Sydney Medical School??Nepean Campus Penrith NSW Austral...

Strategies for Strengthening Patent Protection of Pharmaceutical Inventions in Light of Federal Court Decisions.

Authors: Pillai X, Kinney WA In this article, a brief history of patent law is presented, along with recent changes in its interpretation that are relevant in securing patents in the current landscape. Specific patent examples are presented to illustrate key issues. For example, the case of KSR International Co. v. Teleflex, Inc. is an important recent decision by the United States Supreme Court, which developed a more flexible definition of the teaching-suggestion-motivation (TSM) test in determining obviousness, which negates patentability. Although KSR case involved a mechanical invention, the ruling in this case has had implications in other areas of patent law, particularly as it applied to pharmaceutical and chemical inventions. It has had a significant impact on the outcome of p...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.

Authors: Dissette V, Bozzi P, Bignozzi CA, Dalpiaz A, Ferraro L, Beggiato S, Leo E, Vighi E, Pasti L Adducts based on a bisphosphonate drug (sodium risedronate) and titanium dioxide (TiO(2)) particles have been developed and characterized in order to improve the bioavailability of orally administrated bisphosphonates. Nanocrystalline and colloidal TiO(2), both characterized by powder X-ray diffraction, were used to obtain the adducts 1 and 2, respectively. Adducts 1 and 2 appeared constituted by nanoparticles of about 50 and 90nm grouped in clusters of about 0.2 and 2.5mum, respectively. Higher amounts of drugs were adsorbed on adduct 2 (7.2+/-0.3%) with respect to adduct 1 (4.0+/-0.3%). In vitro studies demonstrate that the adducts were able to release the drug in the pH range 6-9, wh...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Pharmaceuticals Inc.]

Updated Date: Jul 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

How do bisphosphonates inhibit bone metastasis in vivo?

Authors: Fournier PG, Stresing V, Ebetino FH, Cl?©zardin P Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of bone resorption remains unclear. To address this question, we used here a structural analog of the bisphosphonate risedronate, NE-58051, which has a bone mineral affinity similar to that of risedronate, but a 3000-fold lower bone antiresorptive activity. In vitro, risedronate and NE...

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

The use of adjuvant aromatase inhibitors is associated with an increase risk of osteoporosis and fractures. The oral bisphosphonate, risedronate, dosed as FDA approved for the treatment or prevention of postmenopausal osteoporosis, appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early stage breast cancer (Source: Breast Cancer Research)

The pros and cons of Prolia, Amgen's new osteoporosis drug

Bone-weakened patients who cannot take Fosamax and its cousins may find it a good alternative. The U.S. Food and Drug Administration approved a new drug for osteoporosis this month. Amgen's Prolia (denosumab) prevents fractures in postmenopausal women at a rate similar to the most popular drugs on the market &#8212; bisphosphonates such as Fosamax, Actonel, Boniva and Reclast. (Source: L.A. Times - Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study

Abstract&nbsp;&nbsp;The purpose of this practice-based observational study was to clarify the acute effect of risedronate on proximal femur bone mineral density (BMD) and structural geometry in patients with an increased risk of fractures. One hundred sixty-four patients (7 men and 157 postmenopausal women; mean age, 69.2&nbsp;years) with osteoporosis or osteopenia and clinical risk factors of fractures were analyzed. All these patients were treated with risedronate for 1&nbsp;year. Urinary levels of cross-linked N-terminal telopeptide of type I collagen (NTX) were measured at baseline and 4&nbsp;months after the start of treatment. BMD of the lumbar spine and proximal femur and structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry w...

Management of Anastrozole-Induced Bone Loss in Breast Cancer Patients With Oral Risedronate: Results From the ARBI Prospective Clinical Trial

Preventive treatment for those at risk for bone loss may minimize adverse effects of anastrozole. Breast Cancer Research (Source: Medscape Today Headlines)

Long-Term Osteoporosis Drug Use May Harm Bone

Medications called bisphosphonates are standard tools for the treatment of osteoporosis. They include Fosamax, Boniva, Actonel and Reclast. But new data released raise some concern about whether the drugs are safe for long-term use. Although the... (Source: OrlandoSentinel: Medical Research)

Osteoporosis Drug Use May Harm Bone Over Long-Term

Medications called bisphosphonates are standard tools for the treatment of osteoporosis. They include Fosamax, Boniva, Actonel and Reclast. But new data released raise some concern about whether the drugs are safe for long-term use. Although the... (Source: OrlandoSentinel: Medical Research)

Management of osteoporosis in a pre-menopausal woman

There is no agreed definition of osteoporosis in pre-menopausal women. The International Society for Clinical Densitometry recommends using Z-score, and women with Z-scores of ??2.0 or lower should be defined as having a bone density that is ??below the expected range for age??. The diagnosis is more readily made in the presence of a low-trauma fracture. The relationship between low bone mineral density (BMD) in young pre-menopausal women and its associated fracture risk is not the same as in older women with a low BMD. Between 50% and 90% of pre-menopausal women will have an underlying secondary cause, the most common being eating disorders, anorexia nervosa and use of glucocorticoids. Management should focus on identifying the underlying cause and treating it where possible. The use o...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone?releasing hormone?agonist therapy for prostate cancer

(Source: BJU International)

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To determine whether increased bone loss and bone turnover during the first 6 months of therapy for prostate cancer with luteinizing hormone-releasing hormone (LHRH)-agonist therapy could be prevented by bisphosphonate therapy with risedronate 35 mg/week, as prostate cancer is commonly treated with LHRH agonists and this often leads to rapid bone loss within the first 6 months of therapy. A 6-month randomized, double-blind, placebo-controlled trial was conducted, including 40 men aged [ge]55 years receiving LHRH-agonist treatment for 6 months for locally advanced prostate cancer. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip was measured every 6 months. In addition, bone turnover markers including N-telopept...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Limited]

Updated Date: Apr 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget??s disease of bone

We describe hereby the case of a patient with Paget??s disease of bone accompanied by nonalcoholic fatty liver disease (NAFLD) who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. NAFLD had been diagnosed 1&nbsp;year before presentation, based on liver ultrasonography (US). One day after infusion, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 8.1, 6.7, and 6.7 times, respectively, compared with pretreatment values. Serum bilirubin remained normal. US revealed hepatic mild homogenous brightness without focal lesion of the liver or biliary ducts. Subsequent biochemical and serologic investigation did not reveal a specific liver or systematic disease. The patient remained asymptomat...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Apr 16, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

IntroductionThe aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). Methods: Pre-treatment BMD of 213 patients with hormone receptor-positive BC was evaluated at lumbar spine (LS) and hip (HP). Patients were categorized according to their baseline BMD T-score at low, moderate and high risk of osteoporosis. Low risk patients received anastrozole only (A), moderate risk were randomized to anastrozole +/- risedronate (A+/-R) administration and high risk patients received anastrozole + risedronate (A+R). Anastrozole was given at a dosage of 1mg/day while oral risedronate was given at 35mg/week. BMD was th...

Warner Chilcott Announces Amendment to Actonel Collaboration Agreement with sanofi-aventis

&nbsp; ARDEE, Ireland, April 5 /PRNewswire-FirstCall/ -- Warner Chilcott plc (NASDAQ:WCRX) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today an amendment to the Actonel&reg; global collaboration agreement with respect to the... (Source: Drugs.com - Pharma News)

Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies

To quantify the effect of age on the incidence of osteoporosis-related fractures and of risedronate treatment on fracture risk in different age groups in women with postmenopausal osteoporosis. Data from four randomized, double-blind, placebo-controlled, Phase III studies were pooled and analyzed. The analysis population (N=3,229) consisted of postmenopausal women with osteoporosis as determined on the basis of prevalent vertebral fractures, low bone mineral density (BMD), or both. Patients had received risedronate 5 mg daily or placebo for 1 to 3 years. The endpoints of interest were the incidence of osteoporosis-related fractures, clinical fractures, nonvertebral fractures, and morphometric vertebral fractures. The effect of age on fracture risk and treatment benefit was examined using C...

Long-term use of popular osteoporosis drugs may harm bone

Medications called bisphosphonates are standard tools for the treatment of osteoporosis. They include Fosamax, Boniva, Actonel and Reclast. But new data released this month raise some concern about whether the drugs are safe for long-term use. Although... (Source: OrlandoSentinel: Medical Research)

Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.

Authors: Zhang L A simple method has been developed for the analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography (RPLC) with evaporative light-scattering detection (ELSD). After optimization of the chromatographic conditions, satisfactory separation of the compounds was achieved on an Intersil C(8) column with an isocratic mobile phase: 8:4:88 (v/v) acetonitrile-methanol-12 mM ammonium acetate buffer containing 35 mM n-amylamine (pH 7.0). The mobile-phase flow rate was 1.0 mL min(-1). The calibration plot was linear in the range of 352 to 1760 mug mL(-1) for risedronate. The precision and reproducibility were 0.3 and 0.5%, respectively. The average recovery of risedronate was 100.4% and the RSD was 0.6%. The method was validat...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment

In conclusion, measurement of undercarboxylated osteocalcin may be useful for assessing fracture risk in patients receiving amino-BP treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-010-0167-2Authors Masataka Shiraki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanYasushi Yamazaki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanYumiko Shiraki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanTakayuki Hosoi, National Center for Geriatrics and Gerontology Department of Clinical Research and Development Aichi JapanNaoko Tsugawa, Kobe Pharmaceutical University Department ...

Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis?

Abstract&nbsp;&nbsp;Osteoporosis and fractures are under-recognized and undertreated, both in men and women worldwide. Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts. Until recently, alendronate, risedronate, and teriparatide were the only pharmacologic agents approved by the US Food and Drug Administration for treating male osteoporosis. In December 2008, zoledronic acid was approved for ??treatment to increase bone mass in men with osteoporosis.? In 2009, zoledronic acid was also a...

An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral.

Authors: Jahnke W, Henry C Targeted delivery of drugs to their site of action is a promising strategy to decrease adverse effects and enhance efficacy, but successful applications of this strategy have been scarce. Human bone is a tissue with unique properties due to its high hydroxyapatite mineral content. However, with the exception of bisphosphonates, bone mineral has not been targeted in a successful clinical application of drugs that act on bone, such as anti-resorptive or bone anabolic agents. Herein we present an NMR-based in vitro assay to measure binding affinities of small molecules to hydroxyapatite (HAP) or bone powder. Binding was shown to be specific and competitive, and the assay can be carried out in a direct binding format or in competition mode. A selection of clinica...

Effects of risedronate on osteoarthritis of the knee.

Authors: Iwamoto J, Takeda T, Sato Y, Matsumoto H The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cart...

Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget??s disease of bone

In conclusion, treatment with high-dose risedronate for 8&nbsp;weeks resulted in clinically significant and sustained improvement of biochemical markers of bone turnover for 48&nbsp;weeks in patients with PDB, and this improvement was associated with a decrease of RI uptake by Paget??s bone lesions and with reduced pain. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-009-0152-9Authors Kousei Yoh, Sasayama Hospital, Hyogo Medical College Department of Orthopedic Surgery 75 Yamauchi-cho Sasayama 669-2337 JapanShinjiro Takata, University of Tokushima Graduate School Department of Orthopedics, Institute of Health Biosciences Tokushima JapanNoriko Yoshimura, University of Tokyo Department of Joint Disease Research, 22nd Medical and Research Center Tokyo JapanJ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Long-Term Use of Bisphosphosphonates in Osteoporosis.

Conclusions: Bisphosphonates are popular and effective for treatment of osteoporosis. Because they accumulate in bone and provide some residual antifracture reduction when treatment is stopped, we recommend a drug holiday after 5-10 yr of bisphosphonate treatment. The duration of treatment and length of the holiday are based on fracture risk and pharmacokinetics of the bisphosphonate used. Patients at mild risk might stop treatment after 5 yr and remain off as long as bone mineral density is stable and no fractures occur. Higher risk patients should be treated for 10 yr, have a holiday of no more than a year or two, and perhaps be on a nonbisphosphonate treatment during that time. PMID: 20173017 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Meta...

Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial [Breast Cancer]

Conclusion In postmenopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable effects in BMD during 24 months. (Source: Journal of Clinical Oncology)

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: Feb 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Conclusions. This economic analysis showed that risedronate is a cost-effective treatment in a population of Italian women at high risk of PMO related fractures, aged 65 years and older. Risedronate becomes dominant over generic alendronate in patients of 75 years or older and its cost-effectiveness appears even improved in patients with BMD score &lt;/=-3 or &lt;/=-3.5, with/without maternal history of fractures. Risedronate should be considered as a cost-effective option versus generic alendronate, in the Italian NHS' perspective. PMID: 20145427 [PubMed - as supplied by publisher] (Source: Aging Clinical and Experimental Research)

Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy

Abstract: Purpose: In addition to bone mineral density (BMD), trabecular microstructure contributes to skeletal strength. Our goal was to examine changes in trabecular microstructure in women on therapy.Materials and methods: We followed 10 postmenopausal women receiving a bisphosphonate, risedronate (35 mg once weekly), over 12 months and examined trabecular microarchitecture with high resolution wrist MR images (hr-MRI). MRI parameters included bone volume/total volume (BV/TV), surface density (representing plates), curve density (representing rods), surface-to-curve ratio and erosion index (depicting deterioration). We assessed BMD of the spine, hip and radius and markers of bone turnover.Results: Women had been receiving bisphosphonate therapy for 43±9 months (mean±SD) prior to the f...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Treatment Options for Osteoporosis

I selected a few excerpts from a patient information review in the New York Times: What is osteoporosis Osteoporosis is defined as having a bone mineral density T score of minus 2.5 or lower. Lesser degrees of bone loss, known as osteopenia, may not benefit from drug therapy. Bisphosphonates The first drug licensed to counter osteoporosis, Fosamax, is now available generically as alendronate, which can be taken once a day or, at a higher dose, once a week. A reluctance on the part of many patients to adhere to a daily or weekly regimen led to the development of Boniva (ibandronate), administered by an intravenous injection every three months. To further simplify the frequency of administration, Reclast (zoledronic acid) was developed as a once-a-year intravenous treatment. Actonel, al...

Calcium and vitamin D supplements reduce the risk of bone fractures in everyone, young and old

(NaturalNews) In recent years, Big Pharma has produced a variety of widely hyped bisphosphonate drugs including alendronate (Fosamax), ibandronate (Boniva), risedronate (Actonel) and zoledronic acid (Reclast) that are aimed at preserving bone mass and reducing the risk of fractures. Unfortunately, as NaturalNews has reported, the more these medications are pushed on patients, the more serious side effects are being reported, from dangerous heart arrhythmias (http://www.naturalnews.com/026027_drugs_health_osteoporosis_drugs.html) to dental problems, esophageal ulcers, abdominal pain and severe damage to the jaw bone. But a new study involving almost 70,000 people from throughout the U.S. and Europe shows that nutrients -- calcium and vitamin D taken together -- offer a natural, side effect-...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Jan 26, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

SABRE: Adding risedronate to anastrozole improved BMD in postmenopausal women with early breast cancer

(Source: HemOncToday.com)

Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis.

Conclusions: Treatments for osteoporosis with established vertebral and nonvertebral fracture efficacy reduce mortality in older, frailer individuals with osteoporosis who are at high risk of fracture. PMID: 20080842 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE Trial

Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, in post-menopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for early breast cancer (EBC), the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favourable effects in bone mineral density (BMD) during 24 months. &nbsp; Researchers had sought to investigate the management of bone health in women with early breast cancer, who were scheduled to receive anastrazole. The study included post-menopausal women with hormone receptor-positive EBC who were assigned to one of three strata by risk of fragility fracture: &nbsp; .&nbsp;Patients with the highest risk (H) received anastrozole 1 mg/day plus risedr...

Osteonecrosis of the Jawbones in 2 Osteoporosis Patients Treated With Nitrogen-Containing Bisphosphonates: Osteonecrosis Reduction Replacing NBP With Non-NBP (Etidronate) and Rationale

Among the bisphosphonates (BPs), the nitrogen-containing BPs (NBPs), such as zoledronate, risedronate, and alendronate, have antibone-resorptive effects (ABREs) that are much more powerful than those of the non-NBPs, such as etidronate and clodronate (). In the past few years, 1,000 or so cases of osteonecrosis of the jaw (ONJ) have been suspected to be associated with the administration of NBPs. However, the mechanism underlying the osteonecrosis remains unclear, and no effective therapeutic methods have been developed. Because NBPs accumulate in the hydroxyapatite within bone, our concern has been that more cases will develop if NBPs continue to be used as they are now. The situation has been made more complex by 1) NBP-associated ONJ developing even after a pause in NBP treatment, and 2...

Update in male osteoporosis.

CONCLUSIONS: Despite significant advances, there remain a number of key unresolved issues regarding the pathogenesis and management of male osteoporosis, not the least of which is increasing public awareness of this important cause of morbidity and mortality in men. PMID: 20056806 [PubMed - in process] (Source: The Journal of Clinical Endocrinology and Metabolism)

Effect of Single Annual Infusion of Zoledronic Acid (5 Mg) on Lumbar Spine Bone Mineral Density versus Daily Oral Risedronate (5 Mg) in Subgroups of Patients Receiving Glucocorticoid Therapy

Background: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Prevention and treatment of glucocorticoid-induced osteoporosis is best established with bisphosphonates.1 This 1-year, randomized, double-blind, study evaluated the effect of a single annual i.v. infusion of zoledronic acid (ZOL 5 mg) compared to daily oral risedronate (RIS 5 mg) on lumbar spine bone mineral density (LS BMD) in different subgroups of patients receiving glucocorticoid therapy. (Source: Journal of Clinical Densitometry)

BMD Response to Delayed-Release Risedronate 35 Mg Once-A-Week Formulation Taken With or Without Breakfast

Since their introduction, bisphosphonates (BPs) have become the first line treatment for postmenopausal osteoporosis. BPs have to be taken on an empty stomach at least 30 to 60 minutes before first food or drink. Here we present one year efficacy and safety results of a novel delayed release (DR) formulation of risedronate 35 mg once-a-week (OaW) that can be taken with or without breakfast. (Source: Journal of Clinical Densitometry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ACTONEL WITH CALCIUM (Risedronate Sodium And Calcium Carbonate) Kit [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Dec 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice

In this study, we investigated whether administration of the third-generation bisphosphonate risedronate (RIS) is effective for treating osteopenia in OASIS??/?? mice. Histological and histomorphometric analyses revealed that the trabecular bones increased dramatically in OASIS??/?? mice treated with RIS, owing to the inhibition of bone resorption. Intriguingly, the abnormal expansion of the rough ER in OASIS??/?? osteoblasts was improved by the treatment with RIS. Taken together, we conclude that OASIS??/?? mice will be useful as new model mice for evaluating the medicinal effects of osteopenia treatments and developing new drugs for the osteopenia associated with diseases such as OI and osteoporosis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-00...

Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats

We report the results of a series of experiments designed to determine the effects of ibandronate (Ibn) and risedronate (Ris) on a number of bone quality parameters in aged osteopenic rats to explain how bone material and bone mass may be affected by the dose of bisphosphonates (BP) and contribute to their anti-fracture efficacy.Eighteen-month old female rats underwent either ovariectomy or sham surgery. The ovariectomized (OVX) groups were left untreated for 2 months to develop osteopenia. Treatments started at 20 months of age as follows: sham and OVX control (treated with saline), OVX + risedronate 30 and 90 (30 or 90 μg/kg/dose), and OVX + ibandronate 30 and 90 (30 or 90 μg/kg/dose). The treatments were given monthly for 4 months by subcutaneous injection. At sacrifice at 24 months...

Bone drugs may help prevent breast cancer: studies

New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. (Source: CTV Health)

Studies: Bone Drugs May Help Prevent Breast Cancer

From Associated Press (December 10, 2009) SAN ANTONIO--New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were... (Source: Drugs.com - Pharma News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Study: Bone Drugs May Prevent Breast Cancer

New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. (Source: WDSU.com - Health)

NATION: Bone drugs may prevent breast cancer

Bone drugs may prevent breast cancer -- New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were using these medicines when... (Source: OrlandoSentinel: Medical Research)

Osteoperosis Drugs Could Help Prevent Breast Cancer

There's new evidence that women on the bone drugs Fosamax and Actonel could be cutting their chances of getting breast cancer. Women involved in the large study who were already taking these medicines, were nearly on-third less likely to develop the... (Source: OrlandoSentinel: Medical Research)

Bone-building drugs like Fosamax and Actonel may help prevent breast cancer, studies suggest

SAN ANTONIO (AP) &#8212; New results from a large women's health study suggest that bone-building drugs such as Fosamax and Actonel might help prevent breast cancer. Women who already were taking these medicines when the study began were nearly one-third... (Source: OrlandoSentinel: Medical Research)

NICE issues second final appraisal determination on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporosis

Source: NICE Area: News After considering the feedback from consultation, the NICE Appraisal Committee has prepared a second Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The amendments made in this FAD (published originally as technology appraisal guidance 160 in October 2008) are the consequence of reconsideration by the Appraisal Committee following Her Majesty's High Court of Justice order of March 2009 (see link to NeLM report below for details of the judicial review). &nbsp; This guidance relates to treatments for the primary prevention of fragility fractures in postmenopausal women who have ost...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

NICE issues second final appraisal determination on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporosis

Source: NICE Area: News After considering the feedback from consultation, the NICE Appraisal Committee has prepared a second Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The amendments made in this FAD (published originally as technology appraisal guidance 161 in October 2008) are the consequence of reconsideration by the Appraisal Committee following Her Majesty's High Court of Justice order of March 2009 (see link to NeLM report below for details of the judicial review). &nbsp; This guidance relates to treatments for the secondary prevention of fragility fractures in postmenopausal ...

Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity

Abstract: Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized. Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed with bisphosphonate treatments. The aim of this work was to analyze the effect of a 1-year treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone material and compositional properties that could contribute to the fracture efficacy of these agents.Distal tibias from 30 normal beagles that had been treated daily for 1 year with oral doses of vehicle...

Morphological Assessment of Basic Multicellular Unit Resorption Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects on Bone

Abstract&nbsp;&nbsp;Bisphosphonates (BPs) slow bone loss by reducing initiation of new basic multicellular units (BMUs). Whether or not BPs simply prevent osteoclasts from initiating new BMUs that resorb bone or also reduce the amount of bone they resorb at the BMU level is not clear. The goal of this study was to determine the effects of BPs on three morphological parameters of individual BMUs, resorption depth (Rs.De), area (Rs.Ar), and width (Rs.Wi). After 1&nbsp;year of treatment with vehicle (VEH), alendronate (ALN; 0.10, 0.20, or 1.00&nbsp;mg/kg/day), or risedronate (RIS; 0.05, 0.10, or 0.50&nbsp;mg/kg/day), resorption cavity morphology was assessed in vertebral trabecular bone of beagle dogs by histology. Animals treated with ALN or RIS at the doses representing those used to ...

Review of osteoporosis pharmacotherapy for geriatric patients.

Conclusions: Evidence indicates that the osteoporosis treatments currently available in the United States are beneficial for treating osteoporosis in geriatric patients. However, data are limited for the oldest patients (&gt;/=80 years) and those with significant comorbidities. Because of the limited availability of data for geriatric patients with significant comorbidities, the properties of the various agents, including efficacy, tolerability, and potential contraindications, should be considered carefully for each geriatric patient. PMID: 20129253 [PubMed - as supplied by publisher] (Source: The American Journal of Geriatric Pharmacotherapy)

Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1Year Compared With Historical Placebo

Abstract: The use of historical controls may be a viable alternative for comparing antifracture efficacy in osteoporosis fracture endpoint trials that do not have a placebo control group. The risedronate 2 consecutive days a month (2CDM) study showed that risedronate 75mg on 2 consecutive days had similar increases in bone mineral density compared with risedronate 5mg/d. To assess the antifracture efficacy of this regimen, data collected in the 2CDM study were analyzed using historical control data matched for key clinical characteristics from 2 placebo-controlled trials. Fracture rates in historical groups were compared with those of the 2CDM study treatment groups. At 12mo, vertebral fractures occurred in 5.1% and 1.0% of the placebo and 5-mg risedronate historical patients, respectively...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

Conclusion: The use of AIs appears to lead to lower HSA-derived BMD and hip structural indices as compared to women on no or non-AI therapy in chemotherapy-induced postmenopausal breast cancer patients. Preventive therapy with once weekly oral risedronate maintains structural, skeletal integrity independently of the use of or type of adjuvant therapy. (Source: Bone)

Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws

Conclusions: BRONJ is relatively rare but has been increasingly recognized in our clinic. The usefulness of the serum CTX value as an index of risk prediction continues to be debated. Considering the staging of lesions and the number of lesions, we found a significant correlation between the disease severity and the risk assessment using serum CTX. (Source: Journal of Oral and Maxillofacial Surgery)

Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading

Abstract: The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague??Dawley OVX rats (n=60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. T...

Differences between bisphosphonates in binding affinities for hydroxyapatite.

Authors: Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RG Bisphosphonates (BPs) inhibit bone resorption and are widely used for the treatment of bone diseases, including osteoporosis. BPs are also being studied for their effects on hydroxyapatite (HAP)-containing biomaterials. There is a growing appreciation that there are hitherto unexpected differences among BPs in their mineral binding affinities that affect their pharmacological and biological properties. To study these differences, we have developed a method based on fast performance liquid chromatography using columns of HAP to which BPs and other phosphate-containing compounds can adsorb and be eluted by using phosphate buffer gradients at pH 6.8. The individual compounds emerg...

Prescription of anti-osteoporosis drugs during 2004??2007??a nationwide register study in Norway

Conclusion&nbsp;&nbsp;There was an increasing prevalence and a decreasing incidence of AOD use over this limited time period. There was substantial geographical variation in the prevalence of anti-osteoporosis drugs. We also observed a high minimum refill rate. Content Type Journal ArticleCategory Pharmacoepidemiology and PrescriptionDOI 10.1007/s00228-009-0746-0Authors Helene M. Devold, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayGia Man Doung, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayAage Tverdal, Norwegian Institute of Public Health Department of Pharmacoepidemiology Oslo NorwayKari Furu, Norwegian Institute of Public Health Department of Pharmacoepidemiology ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Nov 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

P&G: Actonel reduced fractures

Procter & Gamble Co. said a program to promote its Actonel osteoporosis drug, which is in the process of being sold, has resulted in a reduced reimbursement rate for broken bones. (PG) (Source: bizjournals.com Health Care:Hospitals headlines)

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis

Conclusions: Based on "real world" data the analysis supports the first line use of risedronate for the treatment of osteoporotic women in Germany. (Source: Value in Health)

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

Conclusion&nbsp;&nbsp;Bisphosphonates seem associated with an increased risk of DVT/PE. However, the association does not seem to be causal. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1091-yAuthors P. Vestergaard, Aarhus University Hospital Department of Endocrinology and Metabolism C Tage Hansens Gade 2 8000 Arhus C DenmarkK. Schwartz, University of Copenhagen Department of Oral and Maxillofacial Surgery, Institute of Odontology, Faculty of Health Sciences Norre alle 20 2200 Copenhagen N DenmarkE. M. Pinholt, University of Copenhagen Department of Oral and Maxillofacial Surgery, Institute of Odontology, Faculty of Health Sciences Norre alle 20 2200 Copenhagen N DenmarkL. Rejnmark, Aarhus University Hospital Department of Endocrinology and Metaboli...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body

The objective of this study was to use quantitative computed tomography (CT)-based nonlinear finite element modeling to evaluate how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the biomechanical effectiveness of teriparatide. Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study. These models were subjected to uniaxial compression. Total BMD-derived bone volume fraction (BV/TVd, i.e., bone volume [BV]/total volume [TV]), estimated from quantitative CT-based volumetric BMD, vertebral stiffness, and failure load (strength) were calculated for each time measurement point. The results of this study demonst...

Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases

Conclusions: Understanding of the benefits of bisphosphonate treatment can be maximised by evaluating complementary data from RCTs and observational database studies. Fracture risk reduction with bisphosphonates is shown in RCTs and in real-world clinical settings. (Source: International Journal of Clinical Practice)

Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women

This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens. Content Type Journal ArticleDOI 10.1007/s00223-009-9294-yAuthors Yoon-Sok Chung, Ajou University School of Medicine Department of Endocrinology and Metabolism Suwon KoreaSung-Kil Lim, Yonsei University College of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine 134 Shinchon-dong, Seodaemun-gu Seoul 120-752 South KoreaHo-Yeon Chung, KyungHee University Division of Endocrinology and Metabolism, Department of Internal Medicine Seoul KoreaIn-Kyu Lee, Kyungpook National University School of Medi...

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

Conclusion&nbsp;&nbsp;Strength/weight training exercises may prevent loss of BMD in postmenopausal BCS at risk for bone loss. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1083-yAuthors N. L. Waltman, University of Nebraska Medical Center College of Nursing Lincoln Division 1230 ??O? Street, Ste. 131 Lincoln NE 685880220 USAJ. J. Twiss, University of Nebraska Medical Center College of Nursing Omaha Division Omaha NE USAC. D. Ott, University of Nebraska Medical Center College of Nursing Kearney Division Kearney NE USAG. J. Gross, University of Nebraska Medical Center College of Nursing Omaha Division Omaha NE USAA. M. Lindsey, University of Nebraska Medical Center College of Nursing Omaha NE USAT. E. Moore, University of Nebraska College of Medicine...

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

Conclusion&nbsp;&nbsp;Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1079-7Authors C. Asche, University of Utah School of Medicine Salt Lake UT USAR. Nelson, University of Utah School of Medicine Salt Lake UT USAC. McAdam-Marx, University of Utah School of Medicine Salt Lake UT USAM. Jhaveri, Sanofi-Aventis Bridgewater NJ USAX. Ye, University of Utah School of Medicine Salt Lake UT USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations

Abstract: Introduction: Irradiation of normal, non-malignant bone during cancer therapy can lead to atrophy and increased risk of fracture at several skeletal sites, particularly the hip. This bone loss has been largely attributed to damaged osteoblasts. Little attention has been given to increased bone resorption as a contributor to radiation-induced osteoporosis. Our aims were to identify if radiation increases bone resorption resulting in acute bone loss and if bone loss could be prevented by administering risedronate.Methods: Twenty-week-old female C57BL/6 mice were either: not irradiated and treated with placebo (NR+PL); whole-body irradiated with 2 Gy x-rays and treated with placebo (IR+PL); or irradiated and treated with risedronate (IR+RIS; 30 μg/kg every other day). Calcein inj...

Genistein-like isoflavones suppress net bone resorption in postmenopausal women

Dietary supplements containing genistein-like isoflavones suppress net bone resorption in postmenopausal women, although effects are modest compared with estrogen or risedronate therapy, show US study findings. (Source: MedWire News - Ob/Gyn)

British doctor faces action over claims of 'ghost writing'

? Medics credited with work of firms' employees? US court documents reveal 'author' cultureDoctors have been agreeing to be named as authors on studies written by employees of the pharmaceutical industry, giving greater credibility to medical research, according to new evidence.The Guardian has learned that one of Britain's leading bone specialists is facing disciplinary action over accusations that he was involved in "ghost writing".The wider phenomenon has come to light through documents disclosed in the US courts which have revealed a culture in which doctors agree to "author" studies written by employees of drug firms. The doctors may have some input but do not have access to all the evidence from the drug trial on which the paper's conclusions are based, the documents showed.The G...

Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years

Conclusion: The results of this study suggest that strontium ranelate is a cost-effective strategy, in a Belgian setting, for the treatment of postmenopausal osteoporotic women aged over 75 years. (Source: Bone)

Confounder summary scores when comparing the effects of multiple drug exposures

Little information is available comparing methods to adjust for confounding when considering multiple drug exposures. We compared three analytic strategies to control for confounding based on measured variables: conventional multivariable, exposure propensity score (EPS), and disease risk score (DRS).Each method was applied to a dataset (2000-2006) recently used to examine the comparative effectiveness of four drugs. The relative effectiveness of risedronate, nasal calcitonin, and raloxifene in preventing non-vertebral fracture, were each compared to alendronate. EPSs were derived both by using multinomial logistic regression (single model EPS) and by three separate logistic regression models (separate model EPS). DRSs were derived and event rates compared using Cox proportional hazard mod...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection

Conclusions: The dataset obtained from the yeast screen was validated in a mammalian system, allowing the discovery of new biological processes involved in the cellular response to nitrogen-containing bisphosphonates and opening up opportunities for development of new anticancer drugs. (Source: Genome Biology)

FDA Safety Changes: Actonel, Gardasil, Myfortic

The FDA has approved safety labeling revisions for risedronate sodium tablets, human papillomavirus quadrivalent [recombinant] vaccine, and mycophenolic acid delayed-release tablets. Medscape Medical News (Source: Medscape Today Headlines)

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

Conclusions&nbsp;&nbsp;Differences in the baseline fracture incidence among the cohorts may reflect differences in the risk profile of patients prescribed each bisphosphonate. The reductions observed in fracture incidence over time within each cohort suggest that the effectiveness of each bisphosphonate in clinical practice has been consistent with their efficacies demonstrated in randomized controlled trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1046-3Authors A. Abelson, Cleveland Clinic Mail Code A50 9500 Euclid Avenue Cleveland OH 44195 USAJ. D. Ringe, University of Cologne Medizinische Klinik IV, Klinikum Leverkusen Cologne GermanyD. T. Gold, Duke University Medical Center Durham NC USAJ. L. Lange, Procter & Gamble Mason OH USAT. Thoma...

Osteoporosis

Abstract: The fractures that result from osteoporosis are a major public health problem. The physician needs to be aware of the major risk factors for osteoporosis and refer appropriately for bone densitometry. These risk factors include prior fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is ??2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients at the highest risk for fracture benefit from the many licensed treatments for this common disorder. These may be given orally (alendronate, etidronate, risedronate, iba...

Ireland's Warner Chilcott buys P&G drug business for $3.1B

Warner Chilcott said Monday it bought Procter & Gamble.'s prescription drug business, including Actonel for osteoporosis, in ... (Source: USATODAY.com Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

G.P.13.11 Oral bisphosphonates as prophylaxis of steroid-induced osteoporosis in Duchenne muscular dystrophy

Corticosteroids are the gold-standard treatment for muscle weakness in Duchenne muscular dystrophy (DMD). The commonest side effects of steroid treatment are weight gain, behavioural problems and, in the long term, reduction of bone mineral density, with vertebral fractures being reported in up to 75% of DMD boys on steroids. Vertebral fractures may be very debilitating, cause severe pain, and where ambulation is critical, precipitate loss of independent walking. Over a 2 year period in our clinic we observed at least 6 cases of symptomatic vertebral fracture. In adult patients on long-term steroid regimens, prevention of osteoporosis with concomitant oral bisphosphonates is standard practice. Use of i.v. bisphosphonates to treat symptomatic vertebral fracture in DMD has been advocated, bu...

Actonel (Risedronate Sodium) - updated on RxList

Actonel (Risedronate Sodium) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009]

Authors: Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, Klaushofer K, Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence...

Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial.

Page: 521DOI: 10.1097/01.ogx.0000356937.03800.0fAuthors: Reid, David M.; Devogelaer, Jean-Pierre; Saag, Kenneth; Roux, Christian; Lau, Chak-Sing; Reginster, Jean-Yves; Papanastasiou, Philemon; Ferreira, Alberto; Hartl, Florian; Fashola, Taiwo; Mesenbrink, Peter; Sambrook, Philip N.; for the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly (HORIZON) Trial (Source: Obstetrical & Gynecological Survey)

Risedronate inhibits human osteosarcoma cell invasion

Conclusions: Given that MMP-2 and MMP-9 are instrumental in tumor cell invasion, our results suggest the risedronate could reduce osteosarcoma cell invasion. (Source: Journal of Experimental and Clinical Cancer Research)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antiresorptive Effects of Phytoestrogen Supplements Compared to Estradiol or Risedronate in Postmenopausal Women Using 41Ca Methodology.

Conclusions: Dietary supplements containing genistein-like isoflavones demonstrated a significant but modest ability to suppress net bone resorption in post-menopausal women at the doses supplied in this study over a 50-d intervention period. PMID: 19584189 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Aclasta® (zoledronic acid 5mg) approved in EU to treat steroid induced osteoporosis in men and post-menopausal women

Source: Personal Communication Area: News Zoledronic acid 5mg, currently licensed for the treatment of osteoporosis, has received a new licence in the EU for the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. &nbsp; The new indication for glucocorticoid induced osteoporosis (GIO) is based on data from a study data published in The Lancet, which found that a single intravenous (IV) dose of zoledronate was at least as effective as daily oral risedronate in maintaining lumber spinal bone mineral density (BMD) in patients on long-term oral corticosteroid therapy (see previous NeLM report linked below). (Source: NeLM - Bone Diseases)

Treatment with Risendronate and its Effect on Postmenopausal Women

In conclusion, Risedronate therapy in postmenopausal women increases BMD at lumbar spine and femoral neck. Patients receiving Risedronate showed an improvement of BMD vs control untreated group. (Source: Journal of Clinical Densitometry)

The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis ?? 2 Year Study Results

Daily dosing with risedronate reduces the incidence of vertebral and nonvertebral fractures in patients with postmenopausal osteoporosis. To explore less frequent dosing options, this double-blind, randomized, active-controlled, parallel-group study evaluated the efficacy and safety of 75mg oral risedronate administered on 2 consecutive days a month (2CDM) compared to 5mg oral risedronate daily in women with postmenopausal osteoporosis.Subjects were postmenopausal, 50 years or older with a lumbar spine (LS) BMD T-score of (Source: Journal of Clinical Densitometry)

Risedronate 150mg Once a Month in the Treatment of Postmenopausal Osteoporosis: 2 Year Efficacy and Safety Data

This was a 2-year randomized, double-blind, multi-center study designed to assess the efficacy and safety of a single 150mg risedronate once-a-month oral dose compared with the 5mg daily regimen. Postmenopausal women, at least 50 years of age,=5 years since last menses and a lumbar spine T-score < ??2.5 or a T-score < 2.0 with at least one prevalent vertebral fracture (T4 to L4) were enrolled in the study. Patients were randomly assigned to receive risedronate 5mg daily (n=642) or 150mg once a month (n=650) in a double-blind fashion for 2 years. Study drug was taken on an empty stomach at least 30minutes before breakfast. Change in lumbar spine (LS) bone mineral density (BMD) was the primary endpoint. BMD of the proximal femur, bone turnover markers (urine NTX and serum CTX and BAP), new ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Osteoporosis-Related Nonvertebral Fracture Risk Reduction vs. Hitoric Control at Two Years with Risedronate 150mg Once-A-Month

New osteoporosis therapies are evaluated in randomized placebo-controlled trials. When evaluating alternate dosing regimens of proven therapies, it may be difficult to include a placebo group for ethical or practical reasons. Non-inferiority of the 150mg once-a-month (OAM) dose of risedronate was established in an active controlled trial (vs. risedronate 5mg daily). This analysis was done to assess the anti-fracture efficacy of OAM risedronate using historical controls.Fracture data collected as treatment emergent adverse events in the active controlled study of 150mg of risedronate was analyzed using matched historical controls (HC) from previous placebo-controlled risedronate trials. Women in the OAM study were matched with placebo subjects from the Vertebral Efficacy of Risedronate Ther...

Effectiveness of Bisphosphonates for the Reduction of Clinical Fractures ?? An Observational Study

In this study, women aged=65 years starting treatment with any of the three bisphosphonates were followed within two databases of healthcare utilization records inclusive of years 2000??2006. Fracture risk at the time of initiating a bisphosphonate was described by utilizing, up to a 5-year history period to obtain measures of co-morbidities, medication history and a FRAX® probability of fracture. To estimate the effectiveness of each bisphosphonate, a pre-post study design was used to assess if the clinical fracture incidence decreased with adherence to an individual bisphosphonate. ??Pre?? was defined by the fracture incidence during a wash-in phase of 3 months after starting therapy and ??post?? was defined by the fracture incidence in the subsequent 1-year follow-up on therapy. P...

Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

Authors: Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J Risedronate, a nitrogen-containing bisphosphonate, is widely used in the clinical field for the treatment of osteoporosis. Risedronate is known to exert its effects through binding to hydroxyapatite in bone tissue, inhibiting osteoclastic activity, and inducing apoptosis of osteoclasts. The purpose of this study was to determine the effects of risedronate on osteoclast differentiation in vitro and on an inflammatory bone loss model in vivo. Risedronate inhibited osteoclast differentiation in co-culture of bone marrow cells (BMCs) and osteoblasts, and suppressed receptor activator of nuclear factor (NF)-kappaB ligand (RANK...

Bisphosphonate therapy

Bisphosphonates inhibit bone resorption and bone deposition, effectively decreasing bone turnover. The most common oral bisphosphonates are alendronate (Foxamax), risedronate (Actonel), and ibandronate (Boniva). Patients who have metastatic bone disease, especially related to multiple myeloma or carcinoma of the breast or prostate, may be taking intravenous bisphosphonates to relieve bone pain. Oral forms are used to manage osteoporosis and Paget's disease. The use of these medications is generally considered lifelong. Since 2003, reports have linked widening of the periodontal ligament, tooth loss, and osteonecrosis of the jaw with the use of bisphosphonates. Most of these complications develop after dental treatment, but 25% of cases are spontaneous. Before these reports appeared, many o...

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

Conclusions&nbsp;&nbsp;Risedronate is a cost-effective agent for the treatment of established osteoporosis (osteoporosis and a prior fragility fracture) in women from the age of 50&nbsp;years and older and above 65&nbsp;years in women with osteoporosis alone. The results support the treatment recommendations in recent UK guidelines for osteoporosis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0989-8Authors F. Borgström, Karolinska Institute Medical Management Centre Stockholm SwedenO. Ström, Karolinska Institute Medical Management Centre Stockholm SwedenJ. Coelho, I3 Innovus Klarabergsviadukten 90, Hus D 111 60 Stockholm SwedenH. Johansson, Centre for Metabolic Bone Diseases (WHO Collaborating Centre) University of Sheffield Medical School Sheff...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

Conclusions: These results demonstrate that the combination treatment of ALF and RIS at their sub-therapeutic doses can improve the mechanical properties of the spine as well as the femur and ameliorate changes in Ca metabolism in an animal model of osteoporosis, suggesting that the combination treatment of ALF and RIS has a therapeutic advantage over each monotherapy for the treatment of osteoporosis. (Source: BMC Musculoskeletal Disorders)

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Abstract&nbsp;&nbsp;To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment. Osteonecrosis of the jaw was a rare event, occurring in 13 (0.24%) of the 5,312 patients receiving bisphosphonates, and in one of the 5,382 patients in the control group. All the 13 events of osteonecrosis of the jaw reported among bi...

Reply to Letter to the Editor Re ??Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors? by A. Luckish et al.

We agree with Yang Ye and Shen-jiang Hu that the evaluation of the effect of risedronate treatment on circulating lipoproteins would have added an interesting dimension to the present study and would have elucidated the pathophysiology for vascular action of bisphosphonates. However, our study question focused mostly on the effect of risedronate on arterial elasticity parameters, using arterial pulse-wave contour analysis . Metabolic parameters measured during the study included routine assessment of lipid profile, which didn't include the evaluation of circulating lipoproteins. Moreover, in a recently published study which assessed the effects of alendronate on lipids levels including circulating lipoproteins, no changes in apolipoprotein-A1 and apolipoprotein-B were found . In concurrenc...

Re ??Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors? by A. Luckish et al.

I read with great interest the work by A. Luckish et al. ??Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors? . Accumulating evidences suggest for a link between osteoporosis and cardiovascular disease. A population-based longitudinal study demonstrated that progression of atherosclerotic calcification is associated with bone loss in women during the menopause . Cardiovascular disease and osteoporotic fractures are major health problems and the primary causes of morbidity and mortality in postmenopausal women . (Source: Bone)

Risedronate on Two Consecutive Days per Month.

Page: 355DOI: 10.2165/00002512-200926040-00006Authors: Frampton, James E. (Source: Drugs & Aging)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

How Does Alendronate Compare With Risedronate for Osteoporosis Prevention?

Both agents are taken once weekly, but some differences have been found in clinical trials. Medscape Pharmacists (Source: Medscape Med Students Headlines)

Risedronate on Two Consecutive Days per Month

(Source: Drugs)

Prevention and treatment of osteoporosis in women: an update

Abstract: Approximately 45% of all women will suffer at least one osteoporotic fracture during their lifetime. Until recently, 25??50% of postmenopausal women were on hormone therapy often with prevention of osteoporosis as their main motivation. Following the Women??s Health Initiative, however, the use of hormone therapy has decreased by 30??40% in several countries. Fortunately, several other options for pharmacological intervention have been demonstrated to decrease the risk of fractures in randomised studies. Anti-catabolic drugs include calcium plus vitamin D, oestrogen, raloxifene, and bisphosphonates (e.g. alendronate, etidronate, ibandronate, pamidronate risedronate and zoledronate). Anabolic drugs include parathyroid hormone (1??34) and (1??84). Finally, strontium ranelate h...

Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease

Conclusion&nbsp;&nbsp;RCTs can be used to examine whether bisphosphonates prevent bone loss associated with intermittent GC therapy, providing metabolically active sites such as WT are employed as the primary outcome. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0960-8Authors M. H. Kriel, University of Bristol Department of Clinical Sciences at South Bristol Bristol UKJ. H. Tobias, Avon Orthopaedic Centre, Southmead Hospital Department of Academic Rheumatology Bristol BS10 5NB UKT. J. Creed, University Hospitals Bristol NHS Foundation Trust Bristol UKM. Lockett, Frenchay Hospital Department of Medicine North Bristol NHS Trust Bristol UKJ. Linehan, Royal United Hospital Department of Medicine Bath UKA. Bell, Weston-super-Mare General Hospital Weston-...

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Conclusions&nbsp;&nbsp;Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00520-009-0655-xAuthors Ann E. Kearns, Mayo Clinic Rochester 200 First Street, SW Rochester MN 55905 USADonald W. Northfelt, Mayo Clinic Arizona Scottsdale AZ 85259-5404 USAAmylou C. Dueck, Mayo Clinic Arizona Scottsdale AZ 85259-5404 USAPamela J. Atherton, Mayo Clinic Rochester 200 First Street, SW Rochester MN 55905 USAShaker R. Dakhil, Wichita Community Clinical Oncolo...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the Jaws

Conclusions: The CTX test is not predictive of the development of ONJ for an individual patient but does identify those in the ??risk zone,? which is a value of less than 150 pg/mL to 200 pg/mL. If medically appropriate, the bisphosphonate can be ceased so that the CTX value increases to bring the patient out of the ??risk zone.? (Source: Journal of Oral and Maxillofacial Surgery)

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly. In this retrospective patient chart analysis, we reviewed the 1-year observational treatment results for 186 women (ITT population) with postmenopausal osteoporosis. Patients from our outpatient department, who had started with once-weekly bisphosphonate therapy between 36 and at least 12&nbsp;months before this chart review, were included in this comparative three-arm study according to their treatment: A, Generic Alendonate 70&nbsp;mg products; B, Branded Alendronate (Fosamax®) 70&nbsp;mg once...

Implant failure with bisphosphonates

Bisphosphonates inhibit bone resorption and bone deposition, with the net effect of reducing bone turnover. These agents are given intravenously (IV) during chemotherapy to manage bone pain resulting from metastatic bone disease, especially that related to multiple myeloma and breast or prostate cancer. Oral bisphosphonates are used to manage osteoporosis and Paget's disease. Once patients begin taking bisphosphonates, their use is often lifelong. The most commonly prescribed oral bisphosphonates are alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Reports have linked widening of the periodontal ligament, tooth loss, and osteonecrosis with the use of bisphosphonates, usually the IV forms. Because these complications have the potential to compromise the survival of os...

Evaluating the antifracture efficacy of bisphosphonates.

This article presents a comprehensive review of the key efficacy data for currently available BPs, including their nondaily regimens, to assist clinicians in assessing treatment options for NVF prevention. PMID: 19463108 [PubMed - in process] (Source: Reviews on Recent Clinical Trials)

Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

CONCLUSION: The present study showed differential effect of vitamin K(2) and risedronate on trabecular bone in GC-treated rats. PMID: 19430549 [PubMed - in process] (Source: Yonsei Medical Journal)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Agreements Between Some Drugmakers, Insurers Link Prescription Drug Effectiveness to Price

Some drugmakers -- encouraged by health insurers -- have begun linking the prices of their medications to the drugs' efficacy, the New York Times reports. According to some experts, the strategy could be a positive shift toward pay-for-performance care rather than fee-for-service treatment. The practice "in theory" would unify the goal of insurers, drugmakers and employers that offer worker health coverage toward improving people's health, the Times reports. According to the Times, nationalized health systems in other countries in the past few years began using pay-for-performance contracts as a method of reducing costs and promoting cost-effective treatments.The Times profiled two examples of the agreements in the U.S. In one, Procter & Gamble and Sanofi-Aventis -- which jointly market th...

Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage

The objectives of the current study were to develop a mathematical model that simulates control and 1 year experimental results following bisphosphonate treatment (alendronate or risedronate) in the canine fourth lumbar vertebral body, validate the model by comparing simulation predictions to 3 year experimental results, and then use the model to predict potential long term effects of bisphosphonates on remodeling and microdamage accumulation. To investigate the effects of bisphosphonates on bone volume and microdamage, a mechanistic biological model was modified from previous versions to simulate remodeling in a representative volume of vertebral trabecular bone in dogs treated with various doses of alendronate or risedronate, including doses equivalent to those used for treatment of post...

Zoledronic acid 'better than risedronate for treating bone loss'

Zoledronic acid is more effective than risedronate in treating bone loss that has been caused by glucocorticoids, new research published in the Lancet has suggested. (Source: Arthritis Research Campaign)

Zoledronic Acid Infusion Effective for Bone Loss Linked With Glucocorticoid Use

In a randomized trial, a single 5-mg intravenous infusion of zoledronic acid was more acceptable to patients vs 5 mg of oral risedronate daily to prevent and treat glucocorticoid-related bone loss. Medscape Medical News (Source: Medscape Internal Medicine Headlines)

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

Abstract: The eValuation of IBandronate Efficacy (VIBE) head-to-head database fracture study compared fracture rates between patients treated with monthly ibandronate and weekly oral bisphosphonates (BPs).This large study included women ?45 years old, newly prescribed monthly oral ibandronate or weekly oral alendronate or risedronate, and without malignancy or Paget's disease of bone. The primary analysis included patients who were adherent to treatment during the first 90 days after the index date. The risks of hip, nonvertebral, vertebral and any clinical fracture were compared using Cox proportional hazards models and adjusted for potential confounding factors. A secondary, ??intent-to-treat? analysis included all patients who received at least one BP prescription. Sensitivity an...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence

Abstract: Introduction: Osteoporosis and fracture risk increase exponentially in postmenopausal females. This places a significant burden in terms of morbidity, mortality and costs that are likely to increase with an ageing population. Despite this there is very limited data on pharmacological management of osteoporosis in this high risk group.Objectives of this review: To review the published literature on the clinical efficacy and safety of specific anti osteoporosis treatments in the reduction in fracture risk in females ?75 years of age. The following major endpoints were used in this review:Search methods for identification of studies: We performed an electronic search of Medline (1970 to June 2007) and the Cochrane Library (1996 to June 2007). Our search strategy included MeSH ter...

Actonel Makers Paying Insurer to Fix Fractures

The makers of osteoporosis drug Actonel (risedronate) are testing a program to reimburse an insurer for the cost of treating non-spinal bone fractures among women who take the drug. Reuters Health Information (Source: Medscape Ob/Gyn & Women's Health Headlines)

Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy

Conclusions: The results of our study have shown that oral administration of risedronate is effective for the recovery of ADT-induced bone loss in patients with PCa. (Source: Urology)

P&G enters deal to cover fractures

Procter & Gamble Co., in a move to promote is Actonel osteoporosis drug, will begin paying an Illinois insurer for broken bones. (Source: bizjournals.com Health Care:Hospitals headlines)

Aclasta(R)/Reclast(R) Better Than Risedronate For Prevention And Treatment Of Bone Loss In Patients With Steroid-induced Osteoporosis

A study published in The Lancet1 shows that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)* is significantly more efficacious than risedronate in preventing and treating bone loss in men and women with osteoporosis caused by glucocorticoids, often referred to as corticosteroids or steroids1. (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats

Conclusions: While risedronate sodium prevented the decrease in bone mineral density in ovariectomized rats, atorvastatin maintained mechanical characteristics of bone and also prevented the decrease in bone mineral density as risedronate sodium. (Source: Maturitas)

Health News of the Day

is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day.Zoledronic acid 5 mg IV x 1 more effective than risedronate 5 mg po qd for prevention/tx of steroid-induced osteoporosis http://is.gd/rOYzAvotermin (recombinant, active, human TGFβ3, ID) can provide accelerated and permanent improvement in skin scarring http://is.gd/rP0AThe American Board of Allergy and Immunology is on Twitter @a_iboard and Facebook http://is.gd/rP40"Urinary potassium shows if a person is hitting the salad bar on lunch breaks-- or taking a trip to Mickey D's" http://is.gd/rPPhImage source: OpenClipArt.org, public domain. (Source: Clinical Cases and Images)

Bisphosphonate Once a Year Beats Daily Pill for Steroid-Induced Bone Loss

WHEELING, W.Va. (MedPage Today) -- A single, yearly infusion of zoledronic acid (Reclast) was more effective at preventing steroid-induced osteoporosis than daily oral risedronate (Actonel), researchers found in a randomized trial. (Source: MedPage Today Endocrinology)

Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.

CONCLUSIONS: Patients receiving monthly ibandronate therapy had a significantly reduced risk of severe GI events compared with those receiving weekly BP treatment. In addition, patients receiving a weekly BP were more likely to discontinue treatment after a severe GI event. PMID: 19318598 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres.

In conclusion, incorporation of hMSCs into CHA with controlled delivery of BMP showed prolonged bone formation in immunodeficient mice. Further research is required to optimize the growth factor delivery system and to understand the underlying cellular and molecular mechanisms involved. (c) 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2009. PMID: 19322875 [PubMed - as supplied by publisher] (Source: Biomed Res)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate taken before breakfast 'shows better results'

Taking risedronate before breakfast increases bone mineral density more compared to taking the drug later in the day, new research published in the journal Osteoporosis International has suggested. (Source: Arthritis Research Campaign)

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

Conclusion&nbsp;&nbsp;Results of these two studies demonstrate that overall flexible dosing of risedronate leads to smaller BMD gains compared to before-breakfast dosing. This result may be due to poorer adherence to the flexible dosing instructions that may be more pronounced in patients in certain geographic regions. If patients cannot abide by before-breakfast dosing and flexible dosing is an approved option, one can expect suboptimal BMD results with flexible dosing. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0893-2Authors D. L. Kendler, Osteoporosis Centre of British Columbia 600-1285 W Broadway Vancouver BC V6H 3X8 CanadaJ. D. Ringe, Klinikum Leverkusen Leverkusen GermanyL. -G. Ste-Marie, Université de Montréal Centre de Recherche du CH...

The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study

In conclusion risedronate could improve osteoporosis by increasing osteoprotegerin and reducing RANKL and IL-1β. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-009-0055-9Authors Umit Dundar, Afyon Kocatepe University Faculty of Medicine Department of Physical Medicine and Rehabilitation Mavi Hastane 03200 Afyonkarahisar TurkeyVural Kavuncu, Afyon Kocatepe University Faculty of Medicine Department of Physical Medicine and Rehabilitation Mavi Hastane 03200 Afyonkarahisar TurkeyIhsan H. Ciftci, Kocatepe University Faculty of Medicine Microbiology and Clinical Microbiology Afyonkarahisar TurkeyDeniz Evcik, Ufuk University Faculty of Medicine Physical Medicine and Rehabilitation Ankara TurkeyOzlem Solak, Afyon Kocatepe University Faculty of Medicine Department of...

Unusual mid-shaft fractures during long term bisphosphonate therapy.

Conclusion: Long-term bisphosphonate therapy may increase the risk of unusual long bone mid-shaft fractures. This is likely due to prolonged suppression of bone turnover, which could lead to accumulation of microdamage and development of hypermineralized bone. At present, the scope of this complication in the larger context of patients receiving bisphosphonate therapy is not known, but appears to be small. PMID: 19302584 [PubMed - as supplied by publisher] (Source: Clinical Endocrinology)

Prior treatment with vitamin K2 significantly improves the efficacy of risedronate

Conclusion&nbsp;&nbsp;Prior treatment with MK-4 followed by risedronate significantly increased femur strength in comparison to the OVX controls. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0888-zAuthors Y. Matsumoto, Kanagawa Dental College Division of Radiology, Department of Maxillofacial Diagnostic Science 82 Inaokacho Yokosuka Kanagawa 238-8580 JapanY. Mikuni-Takagaki, Kanagawa Dental College Department of Functional Biology 82 Inaokacho Yokosuka 238-8580 Kanagawa JapanY. Kozai, Kanagawa Dental College Division of Radiology, Department of Maxillofacial Diagnostic Science 82 Inaokacho Yokosuka Kanagawa 238-8580 JapanK. Miyagawa, Kanagawa Dental College Department of Functional Biology 82 Inaokacho Yokosuka 238-8580 Kanagawa JapanK. Naruse, Kitas...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Discussion&nbsp;&nbsp;Relative risk estimates from IPD analyses were the best choice for modelling fracture outcomes when applied in a specified high-risk population. In addition to superior statistical methodology, they utilized RCT cohorts that are more representative of higher risk patients requiring treatment (osteoporotic women ?65&nbsp;years with a prevalent vertebral fracture). Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0870-9Authors J. D. Adachi, St Joseph??s, Healthcare??McMaster University Department of Medicine 25 Charlton Avenue East, Suite 501 Hamilton Ontario L8N 1Y2 CanadaC. C. Kennedy, St Joseph??s, Healthcare??McMaster University Department of Medicine 25 Charlton Avenue East, Suite 501 Hamilton Ontario L8N 1Y2 CanadaA. Pap...

Comparative gastrointestinal safety of weekly oral bisphosphonates

Conclusions&nbsp;&nbsp;We found no important difference in gastrointestinal safety between weekly oral bisphosphonates. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0871-8Authors S. M. Cadarette, Brigham and Women??s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAJ. N. Katz, Brigham and Women??s Hospital, Harvard Medical School Division of Rheumatology, Immunology and Allergy Boston MA USAM. A. Brookhart, Brigham and Women??s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAT. Stürmer, Brigham and Women??s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAM. R. Stedman, Brigham and Women??s...

Generalized arterial calcification of infancy: treatment with bisphosphonates.

Authors: Ramjan KA, Roscioli T, Rutsch F, Sillence D, Munns CF Abstract BACKGROUND: A baby girl developed respiratory distress immediately after birth and required supplemental oxygen. She was born at term via lower-segment cesarean section. The parents were nonconsanguineous, and antenatal ultrasonography during the pregnancy at 18 and 32 weeks of gestation did not reveal any abnormalities. On examination at birth, no pulses were palpable; however, the baby's blood pressure was normal and no remarkable abnormalities were detected. Ultrasonography revealed widespread arterial calcification. INVESTIGATIONS: Chest and abdominal radiography at birth and serial abdominal, renal and cardiac ultrasonography at follow-up examinations; dual-energy X-ray absorptiometry during treatment ...

[Breast Cancer] Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. (Source: Journal of Clinical Oncology)

Generalized arterial calcification of infancy: treatment with bisphosphonates.

Authors: Ramjan KA, Roscioli T, Rutsch F, Sillence D, Munns CF, Background A baby girl developed respiratory distress immediately after birth and required supplemental oxygen. She was born at term via lower-segment cesarean section. The parents were nonconsanguineous, and antenatal ultrasonography during the pregnancy at 18 and 32 weeks of gestation did not reveal any abnormalities. On examination at birth, no pulses were palpable; however, the baby's blood pressure was normal and no remarkable abnormalities were detected. Ultrasonography revealed widespread arterial calcification.Investigations Chest and abdominal radiography at birth and serial abdominal, renal and cardiac ultrasonography at follow-up examinations; dual-energy X-ray absorptiometry during treatment with bisphosphonat...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).

Conclusions: In postmenopausal women at risk for fragility fracture receiving adjuvant anastrozole for BCA, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable affects in BMD over 24 months. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1137. (Source: Cancer Research)

Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance

Abstract&nbsp;&nbsp;Analgesic effects of etidronate, alendronate and risedronate were compared in patients with osteoporosis and/or osteoarthritis by measuring the fall of skin impedance along with conventional subjective pain-estimation by visual rating scale (VRS). One hundred ninety-nine postmenopausal women consulting the Osteoporosis and Osteoarthritis Clinic of Katsuragi Hospital complaining of back and/or knee pain were randomly divided into four groups; Group A (49 subjects) given 5&nbsp;mg/day alendronate, Group E (50 subjects) 200&nbsp;mg/day etidronate, Group R (50 subjects) 2.5&nbsp;mg/day risedronate and Group P no bisphosphonate. None of the four groups showed significant deviation from others as to age and parameters of bone metabolism. Proportions of subjects with ost...

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

Conclusions: Overall, in this study, the safety profiles of risedronate 100, 150, and 200 mg/mo were not different from that of risedronate 5 mg/d. Changes in efficacy measures in the monthly treatment groups were considered dose related and were not significantly different between the 5-mg/d group and the 150- and 200-mg/mo groups; similarity was greatest with 150 mg/mo. PMID: 19302900 [PubMed - in process] (Source: Clinical Therapeutics)

Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study

Abstract&nbsp;&nbsp;Although osteoporosis in men is already a major public health problem, there is still a dearth of data about the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. Therefore, the objective of our study was to investigate the effects of risedronate on bone mineral density (BMD), bone turnover, back pain, and fractures in these patients prospectively for two years (at baseline, three&nbsp;months, six months, twelve&nbsp;months, and twenty-four&nbsp;months) both longitudinally and compared with those of alfacalcidol. The subjects enrolled for this study were 66 Japanese male patients with untreated primary osteoporosis (mean age 63.52&nbsp;±&nbsp;8.7&nbsp;years), who were divided into two groups (44 with risedronate and 22 ...

LRP5 Polymorphisms and Response to Risedronate Treatment in Osteoporotic Men

In conclusion, the LRP5 A1330V polymorphism is associated with hip BMD in osteoporotic men, but allelic variations in LRP5 do not appear to be associated with response to bisphosphonate treatment. Content Type Journal ArticleDOI 10.1007/s00223-008-9207-5Authors Marcin Kruk, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UKStuart H. Ralston, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UKOmar M. E. Albagha, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UK Journal Calcified Tissue InternationalOnline IS...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

THe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib

Abstract&nbsp;&nbsp;We evaluated the effects of suppressed bone remodeling caused by bisphosphonate on microdamage accumulation and degree of mineralization of bone (DMB) for the dog rib in two independent studies. Study 1: 36 female beagles, 1-2 years old, were treated daily for 1 year with saline vehicle, risedronate at 0.5 mg/kg/day, or alendronate at 1.0 mg/kg/day. Study 2: 29 beagles, 1 year old, were given lactose, or incadronate at 0.3 mg/kg/day or 0.6 mg/kg/day for 3 years. In both studies, the ninth rib was harvested. Intracortical remodeling was significantly suppressed following either 1 year or 3 years of bisphosphonate treatment without impairment of primary mineralization, although the remodeling rate was obviously lower in study 2 than in study 1 because of the aging o...

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study.

Authors: Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL The eValuation of IBandronate Efficacy (VIBE) head-to-head database fracture study compared fracture rates between patients treated with monthly ibandronate and weekly oral bisphosphonates (BPs). This large study included women &gt;/=45 years old, newly prescribed monthly oral ibandronate or weekly oral alendronate or risedronate, and without malignancy or Paget's disease of bone. The primary analysis included patients who were adherent to treatment during the first 90 days after the index date. The risks of hip, nonvertebral, vertebral and any clinical fracture were compared using Cox proportional hazards models and adjusted for potential confounding factors. A secondary, "intent-to-treat" anal...

Small cancer risk reported with bone-strengthening drugs

The FDA mentions a few dozen cases of esophageal cancer in patients who took Fosamax, Actonel or Boniva. And a dentist sees a high incidence of osteonecrosis of the jaw. The family of bone-strengthening drugs called bisphosphonates -- best known by the brand names Fosamax, Actonel and Boniva -- pose a small risk of causing esophageal cancer, a Food and Drug Administration official reported Thursday in a letter to the New England Journal of Medicine. (Source: Los Angeles Times - Science)

Risedronate Doesn't Prevent Bone Loss During Chemotherapy

Although risedronate prevents bone loss in postmenopausal women, the agent does not appear to benefit premenopausal women being treated with chemotherapy for primary breast cancer, researchers report in an advance on-line issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Med Students Headlines)

Effects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patients

Abstract: This multicenter, open-label study evaluated the effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal women with osteoporosis in Brazil. Entry requirements included: osteoporosis of the spine/femoral neck diagnosed by a bone mineral density (BMD) T-score???2.5 or radiographic fragility fracture within the last year and no treatment with osteoporosis medication in the preceding 3mo. Patients were treated with once weekly risedronate of 35mg for 12wk. Patients also received 1000mg calcium carbonate and 400IU vitamin D. The main outcome was the effect on bone resorption, as assessed by the quantification of serum C-telopeptide of type I collagen (CTX). Of the 556 women screened, 480 women received ?1 dose of study drug (intent-to-treat...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Monthly risedronate (actonel) for postmenopausal osteoporosis.

Authors: PMID: 19104380 [PubMed - in process] (Source: Obstetrics and Gynecology)

Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study

Conclusion&nbsp;&nbsp;Compared to compliant women, noncompliant women incurred significantly higher physician care and hospital care costs. Due to lower drug costs, total direct health care costs were lower among noncompliant women. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0818-5Authors J. Blouin, University of Montreal Faculty of Pharmacy PO Box 6128 Centre-Ville Station Montreal Quebec Canada H3C 3J7A. Dragomir, University of Montreal Faculty of Pharmacy PO Box 6128 Centre-Ville Station Montreal Quebec Canada H3C 3J7M. Fredette, HEC Montreal Department of Management Sciences Montreal CanadaL.-G. Ste-Marie, University of Montreal Faculty of Medicine Montreal Quebec CanadaJ. C. Fernandes, University of Montreal Faculty of Medicine Montreal Quebe...

Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

Authors: Zikan V, Stepan JJ The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia. Forty women (age, 55-80 years) with postmenopausal osteoporosis (treated with ALN, RIS and RLX or untreated-control group) were given infusions of sodium ethylenediaminetetraacetic acid (EDTA; 10 mg/kg of body weight). Serum ionized calcium (iCa), plasma intact PTH and marker of bone resorption, serum beta C-terminal telopeptide of type I collagen (beta-CTX; beta CrossLaps) were followed for 180 min. In all women, decrease in serum iCa following the EDTA load resulted in an acute increase in serum PTH. Between 60 and 180 min,...

Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.

We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length ...

The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates

Conclusion: Improvements in treatment persistence and compliance may improve the impact of bisphosphonates in reducing the risk of fractures. Yearly administration may also improve the impact on fracture risk reduction, unless long-term persistence is substantially reduced. (Source: QJM)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

Conclusion: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the symptomatic management of OA. (Source: BMC Musculoskeletal Disorders)

Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence.

DISCUSSION: This review reinforces the irony that the least evidence is available for fragility fracture reduction in the group at greatest risk; the old old and those with non vertebral and hip fracture. Although there is good evidence for the benefit of the bisphosphonates (Alendronate and Risedronate), Teriparatide and Strontium Ranelate in vertebral fracture reduction, there are very limited data for non vertebral and hip fracture reduction. Strontium Ranelate is the only agent to date that has demonstrated a reduction in non vertebral and hip fracture events in this high risk elderly female population. Perhaps we need to adopt different strategies in managing older patients with osteoporosis as their fracture risks and treatment strategies may be quite different from younger populatio...

ACTONEL WITH CALCIUM (Risedronate Sodium And Calcium Carbonate) Kit [Procter And Gamble Pharmaceuticals, Inc.]

Updated Date: Dec 9, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bisphosphonates: What is the Latest Protocol?

I have read several articles and comments on Bisphosphonates, as it relates to dental implants, but this whole matter keeps developing and changing. What is the current protocol for managing dental implant patients taking Actonel? >>Read More and Comment (Source: Dental Implants Discussed by Experts)

Early Teriparatide Response May Hinge on Prior Bisphosphonate Therapy

In postmenopausal women with osteoporosis, prior treatment with risedronate does not impair early responsiveness to teriparatide to the same extent as prior treatment with alendronate, a study suggests. Reuters Health Information (Source: Medscape Diabetes Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Fluorescently Labeled Risedronate and Related Analogues: ??Magic Linker? Synthesis

Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). &lt;br/&gt; (Source: Bioconjugate Chemistry)

Differences in persistence among different weekly oral bisphosphonate medications

Conclusion&nbsp;&nbsp;This study provides further evidence of poor persistence to newly initiated oral weekly BP therapies, particularly for the patients started on generic alendronate. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0795-8Authors O. Sheehy, Centre Hospitalier de l??Université de Montréal (CHUM) Pharmacoepidemiology and Pharmacoeconomics Research Unit 3850 Saint-Urbain, Pavillon Masson Montreal QC H2W 1T7 CanadaC. M. Kindundu, Novartis Pharmaceuticals Canada Montreal QC CanadaM. Barbeau, Novartis Pharmaceuticals Canada Montreal QC CanadaJ. LeLorier, Centre Hospitalier de l??Université de Montréal (CHUM) Pharmacoepidemiology and Pharmacoeconomics Research Unit 3850 Saint-Urbain, Pavillon Masson Montreal QC H2W 1T7 Canada Jo...

Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis

In conclusion, BMD increase at the lumbar spine by bisphosphonate treatment was not related to any pretreatment parameters, including body size, body composition, and bone/mineral metabolism in postmenopausal Japanese women with primary osteoporosis, although FPG correlated partly to BMD through lean body mass. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-008-0005-yAuthors Hiroshi Kaji, Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine 7-5-2 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanItoko Hisa, Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine 7-5-2 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanYoshifumi Inou...

Update on Early Communication: Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D); Etidronate (Didronel); Ibandronate (Boniva); Pamidronate (Aredia); Risedronate (Actonel, Actonel W/Calcium); Tiludronate (Skelid); Zoledronic acid (Reclast, Zometa)

Early Communication about the FDA's review of safety data showed no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation (Source: FDA MedWatch)

Compatibility of risedronate sodium tablets with food thickeners.

CONCLUSION: Risedronate sodium tablets were compatible for 24 hours with five food thickeners. PMID: 18997142 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease

Abstract&nbsp;&nbsp;Bisphosphonates decrease bone resorption and reduce significantly the rate of skeletal complications in patients with metastatic bone disease. Bisphosphonates have also been shown to exhibit antitumor activity in vitro but in vivo results have been equivocal. In the present study, we investigated the effects of bisphosphonate treatment alone or in combination with the cytostatic docetaxel on the growth of breast cancer cells in bone. Tumor gowth was studied in an athymic nude mice model inoculated with MDA-231-B/luc+ breast cancer cells. Two days after the inoculation, mice were treated with risedronate, zolendronate or docetaxel alone or with a combination of risedronate and docetaxel. Bone destruction and tumor growth were evaluated radiographically, histologica...

Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo

In conclusion, our study shows that decreasing the bone mineral affinity of bisphosphonates is an effective therapeutic strategy to inhibit skeletal tumor growth in vivo. [Cancer Res 2008;68(21):8945&ndash;53] (Source: Cancer Research)

Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization

This study was undertaken to determine how PTH and risedronate alter bone quality following glucocorticoid excess.Five-month-old male Swiss-Webster mice were treated with the glucocorticoid prednisolone (5 mg/kg in a 60-day slow-release pellet) or placebo. From day 28 to day 56, 2 groups of glucocorticoid-treated animals received either PTH (5 [mu]g/kg) or risedronate (5 [mu]g/kg) 5 times per week. Bone quality and quantity were measured using x-ray tomography for the degree of bone mineralization, microfocal computed tomography for bone microarchitecture, compression testing for trabecular bone strength, and biochemistry and histomorphometry for bone turnover. In addition, real-time polymerase chain reaction (PCR) and immunohistochemistry were performed to monitor the expression of severa...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

Conclusions&nbsp;&nbsp;The absolute rate of clinical fractures among alendronate and risedronate users was similar both at 1&nbsp;year and beyond, suggesting comparable effectiveness between agents. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0772-2Authors J. R. Curtis, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAA. O. Westfall, University of Alabama at Birmingham Department of Biostatistics Birmingham AL USAH. Cheng, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAK. G. Saag, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAE. Delzell, University of Alabama a...

Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates

This article summarizes the most currently available data relative to nonvertebral and hip fracture risk reduction for the N-containing bisphosphonates alendronate, ibandronate, risedronate, and zoledronic acid, and presents results of an analysis of comparative efficacy of these compounds using the technique of adjusted indirect comparisons. Content Type Journal ArticleDOI 10.1007/s11914-008-0016-6Authors Marc C. Hochberg, University of Maryland School of Medicine 10 South Pine Street, MSTF 8-34 Baltimore MD 21201 USA Journal Current Osteoporosis ReportsOnline ISSN 1544-2241Print ISSN 1544-1873 Journal Volume Volume 6 Journal Issue Volume 6, Number 3 / September, 2008 (Source: Current Osteoporosis Reports)

Effect of risedronate in a minipig cartilage defect model with allograft

Cartilage/chondrocyte transplantation is frequently utilized in the repair of focal chondral defects. It has been proposed that failure of subchondral bone maintenance or restoration is a factor contributing to the failure of cartilage-forming transplants. Some studies reveal that the transplant is associated with subchondral bone resorption, often leading to deep pits beneath the presumptive cartilage repair site. Thus, the question is raised as to the utility of agents, such as bisphosphonates, to inhibit bone remodeling at the transplant site. In the present study we show that oral administration (three times weekly) of the bisphosphonate, risedronate, inhibited the subchondral bone loss deep to the cultured allogeneic graft tissue site in attempted repair of surgically created chondral...

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate

Conclusion&nbsp;&nbsp;High doses of bisphosphonates result in the accumulation of AGEs and a reduction in energy absorption of cortical bone. The increased accumulation of AGEs in these tissues may help explain altered bone matrix quality due to the administration of BPs in animal models. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0754-4Authors S. Y. Tang, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute Department of Biomedical Engineering Troy NY USAM. R. Allen, Indiana University-Purdue University Indianapolis Department of Anatomy and Cell Biology Indianapolis IN USAR. Phipps, Procter and Gamble Pharmaceuticals, Inc. Mason OH USAD. B. Burr, Indiana University-Purdue University Indianapolis Department of...

Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment

Conclusions&nbsp;&nbsp;The results suggested that long-term treatment with bisphosphonates necessitates careful follow-up of the patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00776-008-1265-zAuthors Kousuke Iba, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanJunichi Takada, Chitose City Hospital Orthopaedic Surgery Chitose JapanNaoko Hatakeyama, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanYasuhiro Ozasa, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanTakuro Wada, Sapporo Medical University School of Medicine D...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass

Conclusions&nbsp;&nbsp;HSA offers insight into the potential mechanisms of fracture risk reduction from pharmacologic intervention. In the current study, treatment with once-weekly bisphosphonates resulted in significant improvements in hip geometric parameters. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0762-4Authors S. L. Bonnick, Clinical Research Center of North Texas 2921 Country Club Road, Ste. 101 Denton TX 76210 USAT. J. Beck, Johns Hopkins University Baltimore MD USAF. Cosman, Helen Hayes Hospital Clinical Research Center West Haverstraw NY USAM. C. Hochberg, University of Maryland School of Medicine Baltimore MD USAH. Wang, Merck & Co., Inc. Merck Research Laboratories Rahway NJ USAA. E. de Papp, Merck & Co., Inc. Merck Research Laborato...

Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture

Conclusions: The vast majority of patients who experience a hip fracture do not take anti-osteoporotic therapy after the fracture. Furthermore, among patients who begin alendronate treatment after the fracture, the adherence to treatment decreases over time and remains suboptimal. (Source: JBJS [Am])

Low incidence of anti-osteoporosis treatment after hip fracture.

CONCLUSIONS: The vast majority of patients who experience a hip fracture do not take anti-osteoporotic therapy after the fracture. Furthermore, among patients who begin alendronate treatment after the fracture, the adherence to treatment decreases over time and remains suboptimal. PMID: 18829912 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)

Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective.

Authors: Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, Verschueren S, Milisen K Age is a major determinant of osteoporosis, but the elderly are rarely assessed and often remain untreated for this condition. Falls, co-morbidities and co-medications compound the risk of fracture in senile osteoporosis. The prevalence of osteoporosis is expected to increase with increasing life expectancy, and the associated fractures - particularly hip fractures - will lead to significant demands on health resources. Treatment of senile osteoporosis can include pharmacological and non-pharmacological intervention. Calcium and vitamin D dietary supplementation is a relatively low-cost way of reducing the risk of fracture. Pharmacological interventions with risedronate, zoledronic acid, or ...

Monthly Ibandronate as Effective as Weekly Risedronate or Alendronate

Monthly therapy is associated with fracture rates similar to weekly therapy in several patient types. Medscape Medical News (Source: Medscape Medical News Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Self-reported compliance with osteoporosis medication-Qualitative aspects and correlates.

CONCLUSION: Compliance with osteoporosis medication in Czech women is suboptimal, in particular the prevalence of co-medication with calcium/vitamin D should be higher. It is needed to implement strategies focused on the patient's beliefs about the disease and perceptions of outcome rather than those promoting the knowledge alone. PMID: 18774663 [PubMed - as supplied by publisher] (Source: Maturitas)

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study

Abstract&nbsp;&nbsp;The aim of this study was to assess the effect of treatment with risedronate 5&nbsp;mg daily relative to control in men with primary or secondary osteoporosis over 2&nbsp;years. Osteoporosis is a common condition in men that can have serious clinical consequences. In an earlier interim report, we found that 1&nbsp;year of risedronate therapy resulted in significant increases in bone mineral density (BMD) and a significant reduction in vertebral fractures compared to control in men with osteoporosis. We conducted an open-label, prospective, match-control trial on men with primary or secondary osteoporosis in a single center, outpatient setting. Men with primary or secondary osteoporosis, as defined by a baseline lumbar spine BMD T-score&nbsp;?&nbsp;??2.5 and a ba...

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

CONCLUSIONS: Osteoporosis treatment of high-risk women is cost-effective, with bisphosphonates providing the most benefit at lowest cost. For highest risk women, costs are offset by savings from fracture prevention. PMID: 18778176 [PubMed - in process] (Source: The American Journal of Managed Care)

Manhattan Research Announces Top 10 Product Sites Visited By Physicians

Diabetes treatment brand sites from Januvia, Actos, Byetta, and Avandia are among the top pharmaceutical product websites in terms of primary care physician visitation, according to a new from pharmaceutical and healthcare market research company Manhattan Research (www.manhattanresearch.com). Breaking into this year's top product site list are Actos, Actonel, Amitiza, and Aciphex, proving to be successful in increasing physician awareness online. (Source: IT / Internet / E-mail News From Medical News Today)

How effective is risedronate in preventing bone loss in patients on high-dose steroids?

Authors: Arabi A, Fuleihan GE Oral bisphosphonates have proven to be an effective strategy for the prevention and treatment of glucocorticoid-induced osteoporosis; however, information on the efficacy of these agents in patients receiving high-dose glucocorticoid therapy is scarce. In this Practice Point commentary, we discuss the 6-month, randomized, placebo-controlled study of Mok et al., which evaluated the efficacy of 5 mg oral risedronate daily for the prevention of bone loss at the spine and hip in patients receiving high-dose prednisolone therapy (&gt;0.5 mg/kg/day). Risedronate prevented bone loss at the spine and attenuated, but did not prevent, bone loss at the hip. We compare and contrast the findings of Mok et al. with previously published studies of bisphosphonate therapy ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Determinants of Persistence with Weekly Bisphosphonates in Patients with Osteoporosis.

CONCLUSION: Persistence to BP declined significantly over one year. Healthcare practitioners should take note of several factors when counselling patients taking BP for OP. PMID: 18709688 [PubMed - as supplied by publisher] (Source: J Rheumatol)

Actonel

Drug / Device: Actonel Defendant(s): Proctor & Gamble Pharmaceuticals Inc., Aventis Pharmaceuticals Inc. Full story on lexis.com (Source: LexisNexis&#174; Mealey's&#8482; Emerging Drugs & Devices Legal News)

Early Responsiveness of Women with Osteoporosis to Teriparatide Following Therapy with Alendronate or Risedronate.

Conclusion - This non-randomized but prospective study suggests there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure. (ClinicalTrials.gov number, NCT00130403). PMID: 18682511 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.

CONCLUSION: Clinicians prescribing long-term bisphosphonate therapy should be aware of, and monitor for, the potential development of excessive suppression, not only in bone resorption but also in bone formation. PMID: 18645694 [PubMed - in process] (Source: Climacteric)

A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.

Authors: Margiotta N, Capitelli F, Ostuni R, Natile G The paper describes the synthesis and characterization of a new platinum dinuclear complex (2) bearing a nitrogen-containing geminal bisphosphonate (NBP, 1), structurally related to the commercial drug risedronate. NBPs themselves have shown in quite a few cases to be endowed with anticancer activity, therefore the new platinum complex has two potential antitumor moieties (the NBP ligand and the platinum residue) and could have high affinity for bone tumors or metastases (due to the presence of NBP). The free bisphosphonate (1) has been crystallized by a sol-gel method and characterized by X-ray diffraction analysis. The platinum complex (2) has been found to have a dinuclear structure with the bisphosphonate bridging two platinum m...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

[Non-hormonal treatments of postmenopausal osteoporosis.]

Authors: Malaise O, Neuprez A, Reginster JY In the last decade, several medications have been registered and marketed in osteoporosis. They have demonstrated their antifracture efficacy. Subsequently, the clinical management of osteoporosis becomes more sophisticated and complex. Bisphosphonates (alendronate, risedronate, ibandronate, ibandronate and zoledronate) have demonstrated their efficacy on the axial and appendicular skeleton. On scientific grounds, it seems difficult to distinguish between them, in terms of efficacy and/or safety. A special interest should be focused on the optimisation of patients' adherence, which remains poor with the daily and weekly formulations. Raloxifene, a selective estrogen receptor modulator, has shown antifracture efficacy at the level of the lumba...

Once-yearly zoledronic acid more effective than daily risedronate

Glucocorticoid steroid treatment is essential therapy for many people with inflammatory conditions such as asthma and arthritis, but it often induces or worsens osteoporosis. Good news emerged from the 90th Annual Meeting of The Endocrine Society about an effective and simplified way to counteract this difficult, potentially disabling, side-effect of steroid treatment. A once-yearly infusion with zoledronic acid is significantly more effective that daily oral risedronate for preventing and treating glucocorticoid- induced osteoporosis, researchers reported at the meeting in San Francisco. (Source: Geriatrics Magazine)

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

The long-term efficacy of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease was evaluated. Three years of risedronate administration resulted in increasing BMD and reducing vertebral and nonvertebral fracture risk.Page: 730DOI: 10.1097/gme.0b013e318159f190Authors: Palomba, Stefano MD 1; Manguso, Francesco MD, PhD 2; Orio, Francesco Jr. MD, PhD 3; Russo, Tiziana MD 1; Oppedisano, Rosamaria MD 1; Sacchinelli, Angela MD 1; Falbo, Angela MD 1; Tolino, Achille MD 4; Zullo, Fulvio MD, PhD 1; Mastrantonio, Pasquale MD 5 (Source: Menopause)

NICE issues Final Appraisal Determination on secondary prevention of osteoporosis

NICE has issued a Final Appraisal Determination on the secondary prevention of osteoporosis in postmenopausal women, covering the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide. The guidance does not cover use for secondary prevention in women on long-term systemic corticosteroid treatment; this will be the subject of future guidance. The preliminary recommendations are as follows: ? Alendronate is recommended as a treatment option in this setting in women who are confirmed to have osteoporosis (T-score -2.5 SD or below); the preparation prescribed should be chosen on the basis of the lowest acquisition cost available. ? Risedronate and etidronate are recommended as alternative treatment options in women who are unable to comply with the...

NICE issues Final Appraisal Determination on primary prevention of osteoporosis

NICE has issued a Final Appraisal Determination on the primary prevention of osteoporosis in postmenopausal women, covering the use of alendronate, etidronate, risedronate, raloxifene and strontium ranelate. This guidance relates only to postmenopausal women who have osteoporosis defined by a T-score1 of -2.5 SD or below on DXA scanning. However, the diagnosis may be assumed in women aged 75 years or older if the clinician considers a DXA scan to be clinically inappropriate or unfeasible. The guidance does not cover use in women on long-term systemic corticosteroid treatment; this will be the subject of future guidance. The preliminary recommendations are as follows: ? Alendronate is recommended as a treatment option (preparation selected on basis of lowest acquisition cost) in this s...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Determination of the Microscopic Equilibrium Dissociation Constants for Risedronate and Its Analogues Reveals Two Distinct Roles for the Nitrogen Atom in Nitrogen-Containing Bisphosphonate Drugs

Andrea M. Hounslow, John Carran, Richard J. Brown, Dominik Rejman, G. Michael Blackburn, and Donald J. WattsWeb Release Date: Tue, 1 Jul 2008 00:00:00 EDT (Article) DOI: 10.1021/jm7015792 (Source: Journal of Medicinal Chemistry)

Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other?

Authors: Tysiewicz-Dudek M, Pietraszkiewicz F, Drozdzowska B Both Alzheimer's disease and osteoporosis occur mainly in persons aged over 60. Both diseases are often seen to co-occur in clinical practice, yet very few investigators have addressed this problem. They have demonstrated that several different clinical factors can lead to a higher incidence of osteoporosis in persons with Alzheimer's disease. Serum concentrations of vitamins D and K, calcium and PTH; the duration of sunlight exposure; dietary calcium intake; genetic factors as well as the effect of oestrogens on mineral bone density in patients with and without dementia have been studied. Furthermore, the effects of vitamin D and calcium preparations with or without bisphosphonates (risedronate) have also been assessed. The ...

Is there any difference in upper GI side effects with risedronate compared to alendronate?

The NLH Primary Care Q & A Service answered a very similar question to this in May 2007 and thus we will reproduce the answer at this point:Is the bisphosphonate alendronate any more likely to cause severe oesophageal reactions compared with other bisphosphonates such as risedronate? 8th May 2007The PRODIGY guideline on osteoporosis, based on NICE recommendations, states:? "Gastrointestinal adverse effects such as abdominal pain, dyspepsia, diarrhoea, or constipation are common. Severe oesophageal reactions (oesophagitis, oesophageal ulcers, strictures, erosions) are serious adverse effects but are uncommon. (Source: NLH Question Answering Service)

Bone Loss Prevented by Risedronate in Breast Cancer Survivors

Risedronate is effective in maintaining or improving bone mass in postmenopausal women who have had chemotherapy for breast cancer, researchers report in the June 1st issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Diabetes Headlines)

Bone drug works for breast cancer survivors

NEW YORK (Reuters Health) - Risedronate, better known by the brand name Actonel, is effective for maintaining or improving the bone strength of women who have had chemotherapy for breast cancer, researchers report. (Source: Reuters: Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide

This study describes our experience in using teriparatide for the treatment of SO in a sample of 141 elderly women of mean age 73.4±5.8 years, with a mean number of fractures of 3.0±0.85, with a spine deformity index (SDI) of 5.92±1.27 and a mean vertebral T-Score (L1??L4) of ??3.15±0.39, and a mean femoral T-Score of ??2.50±0.28. All these patients had been treated with antiresorptive drugs for at least 1 year: specifically 70 of them with Alendronate, 42 of them with Risedronate and 29 of them with Raloxifene. For 18 months, all these patients were injected subcutaneously with 20μg of teriparatide, with the daily addition of 1g of calcium and 880IU of vitamin D. The study was continued for 24 months, at the end of which the patients continued to take only calcium and vitamin D. ...

Vitamin D status and response to treatment in post-menopausal osteoporosis

Conclusions&nbsp;&nbsp;Optimal vitamin D repletion seems to be necessary to maximize the response to anti-resorbers in terms of both BMD changes and anti-fracture efficacy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0650-yAuthors S. Adami, Ospedale di Valeggio Rheumatology Unit 37067 Valeggio Verona ItalyS. Giannini, University of Padua Internal Medicine Padua ItalyG. Bianchi, Rheumatology Unit, ASL3 Genoa ItalyL. Sinigaglia, Ospedale G Pini Rheumatology Unit Milan ItalyO. Di Munno, University of Pisa Rheumatology Unit Pisa ItalyC. E. Fiore, University of Catania Internal Medicine Catania ItalyS. Minisola, University of Rome Internal Medicine Rome ItalyM. Rossini, Ospedale di Valeggio Rheumatology Unit 37067 Valeggio Verona Italy Journal Os...

Effects of Vitamin K2 and Risedronate on Bone Formation and Resorption, Osteocyte Lacunar System, and Porosity in the Cortical Bone of Glucocorticoid-Treated Rats

Abstract&nbsp;&nbsp;The purpose of the present study was to examine the effects of vitamin K2 and risedronate on bone formation and resorption, the osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid (GC)-treated rats. Forty-nine female Sprague-Dawley rats, 3 months of age, were randomized into five groups according to the following treatment schedule: age-matched control, GC administration, and GC administration with concomitant administration of vitamin K2, risedronate, or vitamin K2 + risedronate. At the end of the 8-week experiment, classical bone histomorphometric analysis was performed, and the osteocyte lacunar system and porosity were evaluated on the cortical bone of the tibial diaphysis. GC administration decreased percent cortical bone area and inc...

[Breast Cancer] Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Conclusion We conclude that in postmenopausal women with breast cancer with or without AI therapy, once-weekly oral risedronate was beneficial for spine and hip BMD, reduced bone turnover, and was well tolerated. (Source: Journal of Clinical Oncology)

Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis

We examined 144 male wistar rats: 48 shamoperated, 48 ORX, and 48 ORX-treated with a bisphosphonate (risedronate) 2 or 10 µg/kg/day, 5 days per week. Rats were sacrificed at 2, 4, 8, or 16 weeks after the beginning of the study. DXA was performed on a Hologic QDR 2000 on the whole body, whole tibia, and tibial metaphysis. Bone volumes (C.BV/C.TV, and BV/TV) were measured by histomorphometry on the proximal tibial. A significant correlation was obtained between weight measured by DXA and scale (r=0.993,P&lt;0.000001). However, DXA underestimated weight by 0.3%. This discrepancy was dependent on the rat??s weight. The weight bone length (WL) index was linearly correlated with BMD (r=0.86), BMC (r=0.96), and ash weight (r=0.97). Correlation with robusticity was lower than with the WL ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Actonel(Risedronate Sodium) Tablet, Film Coatedfor Oral Use [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: May 22, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis

Raja Bobba1, Jonathan D Adachi21Department of Medicine, St. Joseph&rsquo;s Healthcare - McMaster University, 2Department of Medicine, Alliance for Better Bone Health Chair in Rheumatology, St. Joseph&rsquo;s Healthcare, McMaster University, Hamilton, ON, CanadaAbstract: Osteoporosis in men is an increasingly recognized problem with associated fracture morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of therapy. Risedronate has demonstrated fracture efficacy in women and efficacy has been recently been investigated in men. In men, risedronate either maintains or increases bone mineral density. In placebo controlled trials it has been shown to be safe and effective in preventing fractures.Keywords: male osteoporosis, risedronate, bone mineral density...

Missed bisphosphonate dose raises fracture risk

Elderly women who take less than 80% of their prescribed doses of alendronate or risedronate have a 27% increased risk of nonvertebral fractures, say Canadian researchers. (Source: Pulse)

Has Risedronate been associated with any reports of atrial fibrillation?

We searched the NLH Musculoskeletal Specialist Library, the TRIP and Medline databases and the SPC for Actonel but found no studies reporting an association between risedronate and atrial fibrillation. In April 2008 we answered a question on alendronate and atrial fibrillation [1]. (Source: NLH Question Answering Service)

Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial

This study was performed to examine the additive effects of glucosamine or risedronate on the exercise therapy. In this study, 142 female patients with moderate OA of the knee, who had been recommended to undergo home exercise at the first visit to the hospital, were randomly given glucosamine hydrochloride, risedronate, or no additive. Although improvement after 18 months was observed in all groups using individual scales for evaluation of pain and function of the knee, no significant differences were observed between the groups regarding any of the scales, indicating no significant additive effect of glucosamine or risedronate. One reason for the lack of effect of glucosamine or risedronate on OA of the knee may be that the effect of these agents was occluded by the effect of ther...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women

British Journal of Clinical Pharmacology, Volume 0, Issue 0, Page ???, June 2003. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT ? Compliance with alendronate and risedronate is suboptimal. ? Few studies have specifically evaluated the impact of noncompliance with alendronate or risedronate on the incidence of osteoporotic fractures in ... (Source: British Journal of Clinical Pharmacology)

News From The Annals Of Internal Medicine, May 6, 2008

Study Finds Little Difference in Osteoporosis Drugs for Preventing FracturesA study of pharmacy records of 43,135 people who began to take osteoporosis drugs between 2000 and 2005 found 1,051 nonvertebral fractures within 12 months and no large differences in fracture risk between those who took risedronate, raloxifene, and alendronate (Article, p. 637). Those who took nasal calcitonin had more nonvertebral fractures than those who took alendronate. (Source: Bones / Orthopaedics News From Medical News Today)

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

CONCLUSION: Differences in fracture risk between risedronate or raloxifene and alendronate were small. Nasal calcitonin recipients may have a higher risk for nonvertebral fractures compared with alendronate recipients. Future studies that can better adjust for possible confounding may further clarify these relationships. PMID: 18458276 [PubMed - in process] (Source: Annals of Internal Medicine)

Relative effectiveness of drugs to prevent fractures in patients with osteoporosis

Alendronate, risedronate, and raloxifene seem to have similar efficacy in reducing the risk of non-vertebral fractures in people with osteoporosis, according to a large epidemiological study, however the risk reduction in nasal calcitonin users may possibly be somewhat less. A number of drugs have been shown to be effective in preventing osteoporotic fractures in clinical trials, however the data on their comparative effectiveness for fracture prevention are ambivalent. This population-based cohort study aimed to determine whether any significant difference between the main drugs in use could be shown using data from healthcare databases. The study populations consisted of enrolees in two US state-wide pharmaceutical benefit plans, providing medicines for low-income residents aged 65 and ...

Risedronate Sodium(Risedronate Sodium) Tablet, Film Coated [Teva Pharmaceuticals USA]

Updated Date: May 5, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA Approvals: Patanase, Actonel, Cimzia

The FDA has approved olopatadineHCl nasal spray (Patanase), a once-monthly formulation for risedronate sodium tablets (Actonel), and certolizumab pegol powder for solution (Cimzia). Medscape Medical News (Source: Medscape Internal Medicine Headlines)

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects.

Conclusions: In these healthy female subjects, esophageal transit was delayed when the tablets were given in the semisupine position. The branded risedronate tablet had a significantly faster transit time than the 2 generic formulations of alendronate tested. PMID: 18555931 [PubMed - in process] (Source: Clinical Therapeutics)

Actonel for osteoporosis cleared for use once per month

A new dosage form of once per month is now available for the osteoporosis drug Actonel. (Source: Drug Topics - Hot off the Press)

Once-Monthly Actonel Approved for Postmenopausal Osteoporosis

(Source: Physician's First Watch current issue)

Actonel for osteoporosis cleared for use once per month

A new dosage form of once per month is now available for the osteoporosis drug Actonel. (Source: Drug Topics - Drug Information)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

P&G gets nod for monthly Actonel

Federal regulators cleared the way for the distribution of a once-a-month form of Procter & Gamble Co.&#39;s Actonel osteoporosis medication, a drug that has been prescribed more than 55 million times. (PG) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis

CINCINNATI and BRIDGEWATER, N.J., April 24, 2008 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment and prevention... (Source: Drugs.com - New Drug Approvals)

FDA Approves New Once-a-Month Dose Of Actonel For Postmenopausal Osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. The FDA approval of the once-a-month dose is based on a study comparing Actonel 150 mg once monthly to Actonel 5 mg daily. (Source: Bones / Orthopaedics News From Medical News Today)

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. (Source: News-Medical News Feed)

Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.

In conclusion, prolonged treatment with risedronate improved arterial elasticity of small and large arteries, and decreased SVR. These beneficial vascular effects were not related to changes in cardiovascular risk factors and may be attributed to direct effects of risedronate on the vascular wall. PMID: 18515205 [PubMed - as supplied by publisher] (Source: Bone)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Reclast better than Actonel at increasing bone mass in GIO patients

Study shows once-yearly Reclast better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids -- Glucocorticoids, commonly known as steroids, widely used to treat inflammatory conditions but can increase the... (Source: Drugs.com - Clinical Trials)

Data presented at conference: once-yearly zoledronic acid versus daily risedronate in glucocorticoid-induced osteoporosis

BioSpace has reported on data from a study (n=833) comparing once-yearly zoledronic acid infusion to daily risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (GIO). The study results were presented at the European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO). The study was designed to demonstrate the non-inferiority of once-yearly zoledronic acid to daily risedronate in percentage change in lumbar spine BMD from baseline at 12 months. The press release does not contain detailed information on the study design and results which prevents full appraisal of the findings, but the following are noted: ? In patients who were being treated for GIO (n=545), those receiving the yearly infusion of zoledronic acid 5mg had larg...

Study Shows Once-Yearly Reclast Better Than Risedronate At Increasing Bone Mass In Patients With Osteoporosis Caused By Glucocorticoids

New data show that a once-yearly infusion of Reclast® (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids, commonly known as steroids3. These medications are widely used to treat inflammatory conditions but can cause bone loss and osteoporosis1. (Source: Health News from Medical News Today)

Osteoporosis - primary prevention: Appraisal consultation document issued by NICE for consultation

The National Institute for Health and Clinical Excellence (NICE) has published an appraisal consultation document (ACD ?? draft guidance) on the use of alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. The guidance recommends (direct from source): 1.1 Alendronate is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in the following groups: ? Women aged 70 years or older who have an independent clinical risk factor for fracture (see section 1.5) or an indicator of low BMD (see section 1.6) and who also have a T-score of -2.5 SD or below. In women aged 75 years or older who have two or more independent clinical risk factors for frac...

Osteoporosis - secondary prevention: Appraisal consultation document issued by NICE for consultation

The National Institute for Health and Clinical Excellence (NICE) has published an appraisal consultation document (ACD ?? draft guidance) on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. The guidance recommends (direct from source): 1.1 Alendronate is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who have a T-score of -2.5 SD or below. In women aged 75 years or older, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. When the decision has been made to initiate treatment with alendronate, the preparation pr...

Intravenous zoledronic acid for the treatment of osteoporosis

Abstract&nbsp;&nbsp;Osteoporosis is a preventable disease characterized by loss of bone mineral density, progression to diminished skeletal integrity, extensive bone fragility, and an increased risk of fracture. Morbidity and mortality from osteoporosis are significant, and the public health costs are substantial. Although safe and effective therapy is available, the disease remains underdiagnosed and undertreated. Oral bisphosphonates such as alendronate, risedronate, and ibandronate are the current first-line therapy; however, adherence to treatment is suboptimal, largely because the treatment regimen is difficult to follow. The bisphosphonate zoledronic acid (zoledronate), 5 mg, is administered as an annual 15-minute intravenous infusion for the treatment of postmenopausal osteopo...

Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization

Conclusion&nbsp;&nbsp;At 3&nbsp;years, women who were persistent and compliant with bisphosphonate therapy had lower total costs compared with non-persistent and non-compliant women, after controlling for relevant risk factors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0586-2Authors J. A. Sunyecz, Laurel Highlands Ob/Gyn, PC 1142 National Pike Road Hopwood PA 15445 USAL. Mucha, Outcomes Research and Econometrics Cambridge MA USAO. Baser, Thomson Healthcare Ann Arbor MI USAC. E. Barr, Roche Nutley NJ USAM. M. Amonkar, GlaxoSmithKline Collegeville PA USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study

According to the results of a Danish study published early online in the British Medical Journal (BMJ), there is no evidence to suggest that use of the bisphosphonates alendronate and etidronate is associated with an increased risk of atrial fibrillation (AF) or flutter. The authors note that an increased incidence of serious AF was observed in patients randomised to active medication in a trial of once-yearly zoledronic acid in the treatment of postmenopausal osteoporosis (OP) (NEJM 2007;356:1809-22; see link to NeLM report). This prompted re-analysis of earlier trials but the findings were inconsistent; overall data are therefore conflicting. Researchers therefore carried out this population-based cohort study to investigate the issue further, and to assess the association, if any, be...

The Variance of the Expressions of Extracellular Matrix Components and the Effects of the Anti-Osteoporotic Drugs on Mönckeberg's Arteriosclerosis.

We examined the effects of bisphosphonates, known as anti-osteoporotic drugs, in inorganic phosphate (Pi)-induced calcified bovine aortic smooth muscle cells (BASMCs) (in vitro arterial calcification model). Treatment with the bisphosphonate risedronate, significantly inhibited calcium deposition in the arterial calcification model. Risedronate also inhibited suppression of TE mRNA expression and the progression of osteopontin (OPN) and core binding factor-alpha1 (Cbfa1), an osteogenic transcription factor, by BASMCs calcification. Basically, bisphosphonates could inhibit phenotypic transition such as SMC to osteoblast-like cell. Inhibitory effects of bisphosphonates were also shown in female Sprague-Dawley rats with calcinosis induced by administration of an over-dose of vitamin D(2) (in ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Recalls and Safety Alerts: Severe Pain with Osteoporosis Drugs

FDA is alerting healthcare professionals that severe bone, joint, or muscle pain can occur in patients taking bisphosphonate drugs such as Fosamax (alendronate sodium), Actonel (risedronate sodium), Reclast (zoledronic acid) and Boniva (ibandronate s... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Global Osteoporosis Therapeutics Market to Reach US$11.1 Billion by 2010, According to New Report by Global Industry Analysts

Worldwide osteoporosis therapeutics market is projected to reach US$11.1 billion in sales by 2010. Aging population, continuing new product introductions, growing awareness of osteoporosis, and expansion of bone densitometry scanning are the prime growth drivers in the worldwide osteoporosis therapeutics market. However with the launch of newer treatments coupled with the patent expiry of major drugs including Fosamax, Actonel, and Boniva, growth in the market for osteoporosis therapeutics is expected to slow down by 2015. (PRWeb Feb 26, 2008) Read the full story at http://ww1.prweb.com/releases/osteoporosis/therapeutics/prweb723983.htm (Source: PRWeb: Medical Pharmaceuticals)

Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

Conclusions&nbsp;&nbsp;The incidence of ICR during treatment with antiresorptive agents among patients with severe postmenopausal osteoporosis in a routine setting is considerably higher than that observed in randomized clinical trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0566-6Authors S. Adami, University of Verona, Valeggio Sul Mincio Hospital (VR) Rheumatology Department 37067 Valeggio S/Mincio Verona ItalyG. Isaia, University of Turin Internal Medicine Department Turin ItalyG. Luisetto, University Hospital of Padova Endocrinology Department Padova ItalyS. Minisola, ??La Sapienza? University Clinical Sciences Department Rome ItalyL. Sinigaglia, Orthopedic Institute ??G.Pini? Milan ItalyS. Silvestri, Eli-Lilly Italia S.p.A. Florence...

Treatment of Paget's disease of bone: A survey of clinical practice in Australia.

Authors: Walsh JP, Attewell R, Stuckey BG, Hooper MJ, Wark JD, Fletcher S, Ferrari V, Eisman JA Consensus guidelines for the treatment of Paget's disease of bone have been published, but it is not known how closely these reflect clinical practice. We conducted a multi-centre, stratified, retrospective review of case notes of 531 subjects treated for Paget's disease of bone between 2000 and 2005 in 29 Australian centres. The subjects received 1072 courses of bisphosphonate treatment (pamidronate 363, alendronate 324, risedronate 208, tiludronate 103, zoledronic acid 69, and etidronate 5). The most recent treatment received was oral therapy in 57% of patients (alendronate 29%, risedronate 24%, and tiludronate 4%) and intravenous in 43% (pamidronate 33%, and zoledronic acid 10%). For oral...

Serum Osteoprotegerin and RANKL are not Specifically Altered in Women with Postmenopausal Osteoporosis Treated with Teriparatide or Risedronate: A Randomized, Controlled Trial

Horm Metab ResDOI: 10.1055/s-2008-1046787AbstractRisedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women. Seventy-four postmenopausal Caucasian women (age 64.1±1.0 years) were studied. Women with osteopenia served as controls (group 1, n=30). Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n=21) or teriparatide 20 &#956;g once daily (group 3, n=23) for six months. Blood samples for serum RANKL, OPG, N-terminal propeptide of type 1 collagen (P1NP), and C-terminal telopeptide of type 1 collagen (CTx) we...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate improves spinal BMD in patients on high-dose glucocorticoids

Risedronate improves spinal bone mineral density in people taking high doses of glucocorticoids, findings from a randomized, blinded, and placebo-controlled trial indicate. (Source: MedWire News - Bone Health)

Osteoclast Inhibitory Effects of Vitamin K2 Alone or in Combination with Etidronate or Risedronate in Patients with Rheumatoid Arthritis: 2-Year Results.

CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL. PMID: 18260178 [PubMed - as supplied by publisher] (Source: J Rheumatol)

The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis.

This study determined the prescribing patterns on the Health Services Executive's (HSE) Primary Care Reimbursement Services Scheme (HSE-PCRS) of medicines dispensed for the prophylaxis and treatment of osteoporosis in Ireland. The HSE - PCRS prescription databases were analysed for the years 2004/2005. Approximately 65% of patients (total 60,000) were dispensed either Alendronate (Fosamax once weekly) or Risedronate (Actonel once weekly). The majority of the patients (69.3%) were over 70 years. The study identified that the longer a patient was prescribed prednisolone the greater the likelihood of subsequently being prescribed a bisphosphonate. Approximately 50% of patients on long-term steroids did not receive prophylaxis for osteoporosis. There were low levels of co-prescribing (2.5%) wi...

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

Discussion&nbsp;&nbsp;There is new information about both properties. Mineral binding affinities differ among the clinically used BPs and may influence their differential distribution within bone, their biological potency, and their duration of action. The antiresorptive effects of the nitrogen-containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) appear to result from their inhibition of the enzyme farnesyl pyrophosphate synthase (FPPS) in osteoclasts. FPPS is a key enzyme in the mevalonate pathway, which generates isoprenoid lipids utilized for the post-translational modification of small GTP-binding proteins that are essential for osteoclast function. Effects on other cellular targets, such as osteocytes, may also be important. BPs share several common ...

Popular Osteoporosis Drugs Triple Risk Of Painful Bone Necrosis, Study Finds

A popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain. The research is the largest study of bone necrosis and bisphosphonates, a class of drugs used by millions of women worldwide to help prevent bone fractures due to osteoporosis. It is also the first study to explore the link between bone necrosis and specific brands of bisphosphonates, such as Actonel, Didrocal and Fosamax. (Source: ScienceDaily Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Phase III Data Published For Once Monthly Dose Of Risedronate To Treat Postmenopausal Osteoporosis

Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were published this month in the January issue of the peer- reviewed journal Bone. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily, increases in lumbar spine bone mineral density (BMD) at one year were similar for patients taking either the monthly or daily dosing regimens. (Source: Bones / Orthopaedics News From Medical News Today)

Use of Oral Bisphosphonates and the Risk of Aseptic Osteonecrosis: A Nested Case-Control Study.

CONCLUSION: In this cohort of elderly cardiovascular patients, an association was observed between oral bisphosphonate use and aseptic osteonecrosis. Further research into this putative association is required. PMID: 18203310 [PubMed - as supplied by publisher] (Source: J Rheumatol)

RCT: Efficacy and safety of risedronate once a month vs. once daily in the treatment of postmenopausal osteoporosis compared to once daily regimen

A study published in Bone has evaluated the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen for the treatment of postmenopausal osteoporosis. The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) involved women with postmenopausal osteoporosis who were randomised to receive either risedronate 5 mg daily (n = 642) or 150 mg once a month (followed by daily placebo) (n = 650) in a double-blind fashion for 2 years. Participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than -2.0 and at least one prevalent vertebral fracture. The primary efficacy endpoint was the mean percent change from baseline in lumbar spine bone mineral density after 1 year. Additional...

RCT: Efficacy and safety of risedronate once a month vs. once daily in the treatment of postmenopausal osteoporosis

A study published in Bone has evaluated the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen for the treatment of postmenopausal osteoporosis. The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) involved women with postmenopausal osteoporosis who were randomised to receive either risedronate 5 mg daily (n = 642) or 150 mg once a month (followed by daily placebo) (n = 650) in a double-blind fashion for 2 years. Participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than -2.0 and at least one prevalent vertebral fracture. The primary efficacy endpoint was the mean percent change from baseline in lumbar spine bone mineral density after 1 year. Additional...

Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis

BRIDGEWATER, N.J. and CINCINNATI, January 14, 2008 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis... (Source: Drugs.com - Clinical Trials)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)

Possibility of severe and sometimes incapacitating bone, joint, and/or muscle pain in patients taking bisphosphonates. (Source: FDA MedWatch)

Risedronate Safe and Effective in Preventing Bone Loss in High-Risk Postmenopausal Women on Anastrozole for the Prevention of Breast Cancer

Bone loss associated with anastrozole in postmenopausal women at high risk of breast cancer can be reversed with risedronate bisphosphonate therapy. (Source: Clinical Care Options Oncology - Breast Cancer)

The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

Abstract&nbsp;&nbsp;We constructed a mathematical model for assessing the cost-effectiveness of providing BMD (bone mineral density) scans to Japanese women aged 55 years and over and treating, with risedronate, those that are shown to be osteoporotic. Fracture rates, cost data, utility values, and the increased risks of fractures associated with T-score and vertebral fracture history were taken from published literature. We estimated the cost of fractures avoided due to risedronate treatment, allowing the net changes in cost, incorporating both intervention and fracture costs to be calculated. The QALYs (quality adjusted life years) gained through treatment were calculated enabling cost per QALY ratios to be presented. Further analyses were undertaken assuming treatment was reserved...

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra

Conclusions&nbsp;&nbsp;Bisphosphonate treatment significantly alters properties of bone collagen suggesting a contribution of the organic matrix to the anti-fracture efficacy of this drug class. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0533-7Authors M. R. Allen, Indiana University School of Medicine Department of Anatomy and Cell Biology, MS 5035 635 Barnhill Dr. Indianapolis IN 46202 USAE. Gineyts, INSERM Unit 403 and Université Claude Bernard Lyon1 Lyon FranceD. J. Leeming, Nordic Bioscience Diagnostics Herlev DenmarkD. B. Burr, Indiana University School of Medicine Department of Anatomy and Cell Biology, MS 5035 635 Barnhill Dr. Indianapolis IN 46202 USAP. D. Delmas, INSERM Unit 403 and Université Claude Bernard Lyon1 Lyon France Jou...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate induced transient ocular myasthenia

Raja V, Sandanshiv P, Neugebauer MJournal of Postgraduate Medicine 2007 53(4):274-275 (Source: Journal of Postgraduate Medicine)

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results

Conclusions&nbsp;&nbsp;Risedronate 75&nbsp;mg 2CDM was non-inferior in efficacy and did not show a difference in safety vs. 5&nbsp;mg daily after 12&nbsp;months, leading to a similar benefit. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0531-9Authors P. D. Delmas, University of Lyon and INSERM Research Unit 831 Lyon FranceC. L. Benhamou, INSERM U658 Orléans FranceZ. Man, Centro Tiempo Buenos Aires ArgentinaW. Tlustochowicz, Military Institut of Medicine Department of Internal Medicine and Rheumatology Warszawa PolandE. Matzkin, sanofi-aventis Bridgewater NJ USAR. Eusebio, Procter & Gamble Pharmaceuticals Mason OH USAJ. Zanchetta, Universidad del Salvador Instituto de Investigaciones Metabolicas Buenos Aires ArgentinaW. P. Olszynski, University of S...

Systematic review: Comparative efficacy of drugs to prevent fractures in osteoporosis

While there is good evidence to support the efficacy of various drugs for preventing bone fractures in people with osteoporosis, there are insufficient data to determine their comparative efficacy, according to a robust systematic review. The authors carried out this review for the US Agency for Healthcare Research and Quality (AHRQ), with the aim of clarifying the clinical benefits and harms associated with the different classes of drugs used for fracture prophylaxis in osteoporosis. Drugs evaluated were bisphosphonates, calcitonin, oestrogens, teriparatide, selective oestrogen receptor modulators (raloxifene and tamoxifen), testosterone, and vitamins (vitamin D) and minerals (calcium). A very comprehensive search strategy was used to locate systematic reviews and meta-analyses, and r...

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis.

CONCLUSION: Although good evidence suggests that many agents are effective in preventing osteoporotic fractures, data are insufficient to determine the relative efficacy or safety of these agents. PMID: 18087050 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)

Appeal panel asks NICE appraisal committee to review draft guidance on the primary and secondary prevention of osteoporosis

An Appeal Panel met in October 2007 to consider an appeal against the Final Appraisal Determination (FAD) documents published by NICE in June 2007 on the primary and secondary prevention of osteoporosis (see previous NeLM reports above). The appeals were upheld for both sets of guidance. For the draft guidance on primary prevention, the Appeal Panel upheld the appeal under Ground 1 (paragraphs 20, 35, and 63 of the appeal decision document), and made no findings in regard to aspects of Ground 2 (paragraph 81 of the appeal decision document) and Ground 3 (paragraph 116 of the appeal decision document). The Appeal Panel rejected the appeals on all other points. Appeals under Ground 1 relate to the Institute failing to act fairly and in accordance with its published procedures as set out i...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

SMC rejects risedronate sodium (Actonel) for osteoporosis in men

The Scottish Medicines Consortium (SMC) has announced that in the absence of a submission from the holder of the marketing authorisation for risedronate sodium (Actonel), the drug is not recommended for use within NHS Scotland for the treatment of osteoporosis in men at high risk of fractures. (Source: NeLM news - Musculoskeletal)

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial

Conclusions&nbsp;&nbsp;Risedronate improves spinal BMD in users of high-dose glucocorticoids. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0505-yAuthors C. C. Mok, Tuen Mun Hospital Department of Medicine and Nuclear Medicine Tuen Mun Hong KongK. H. Tong, Tuen Mun Hospital Department of Medicine and Nuclear Medicine Tuen Mun Hong KongC. H. To, Tuen Mun Hospital Department of Medicine and Nuclear Medicine Tuen Mun Hong KongY. P. Siu, Tuen Mun Hospital Department of Medicine and Nuclear Medicine Tuen Mun Hong KongK. M. Ma, Tuen Mun Hospital Department of Medicine and Nuclear Medicine Tuen Mun Hong Kong Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Contaminated Heart Valve Blamed For Infant's DeathActonel

NEWARK, N.J. - A contaminated tissue-based heart valve made by a company with a history of quality control problems caused the death of a 6-month-old infant, according to a complaint filed Nov. 8 in New Jersey federal court (Marie Markey, et al. v. Shelhigh, Inc., et al., No. 07-5403, D. N.J.). Drug/Device: Actonel bisphosphonate osteoporosis drugDefendant(s): Proctor & Gamble Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC Full story on lexis.com (Source: LexisNexis&#174; Mealey's&#8482; Emerging Drugs & Devices Legal News)

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Conclusions&nbsp;&nbsp;The REAL study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data taken from real-world clinical practice. The analysis supports the cost-effectiveness of risedronate compared to generic or brand alendronate and the use of risedronate for the treatment of osteoporotic Canadian women aged 65&nbsp;years or older with a BMD T-score ???2.5. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0504-zAuthors D. T. Grima, Cornerstone Research Group Inc. 6??4380 South Service Road Burlington ON L7L 5Y6 CanadaA. Papaioannou, McMaster University Department of Medicine Hamilton ON CanadaM. F. Thompson, Cornerstone Research Group Inc. 6??4380 South Service Road Burlington ON L7L 5Y6 CanadaM. K. ...

Once-Monthly Risedronate Effective Against Osteoporosis

In the randomized, double-blind, parallel-group MERIT-OP trial, once-monthly risedronate was as effective as daily dosing. Medscape Medical News (Source: Medscape Rheumatology Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker

Conclusions&nbsp;&nbsp;This exploratory analysis did not find a significant association between oral bisphosphonate use and increased risk of jaw surgery, a surrogate marker for osteonecrosis of the jaw. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0502-1Authors M. Pazianas, University of Pennsylvania School of Medicine 3615 Chestnut Street Philadelphia PA 19104 USAW. A. Blumentals, Roche Nutley NJ USAP. D. Miller, Colorado Center for Bone Research Lakewood CO USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.

CONCLUSION: CTX-II decreased with risedronate in patients with knee OA and levels reached after 6 months were associated with radiological progression at 24 months. Monitoring a marker of cartilage degradation 6 months after initiating treatment may be instructive in identifying patients with low progression. PMID: 17993283 [PubMed - as supplied by publisher] (Source: Osteoarthritis and Cartilage)

Synthesis and Biological Evaluation of -Halogenated Bisphosphonate and Phosphonocarboxylate Analogues of Risedronate

Mong S. Marma, Zhidao Xia, Charlotte Stewart, Fraser Coxon, James E. Dunford, Rudi Baron, Boris A. Kashemirov, Frank H. Ebetino, James T. Triffitt, R. Graham G. Russell, and Charles E. McKennaWeb Release Date: Fri, 2 Nov 2007 00:00:00 EDT (Article) DOI: 10.1021/jm0702884 (Source: Journal of Medicinal Chemistry)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

Conclusion&nbsp;&nbsp;Risedronate significantly reduced the risk of fragility fractures in postmenopausal women with osteopenia (femoral neck T-score between ??1 and ??2.5 SD) and no prevalent vertebral fractures. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0493-yAuthors E. S. Siris, Columbia University Medical Center Toni Stabile Osteoporosis Center 180 Fort Washington Avenue New York NY 10032 USAJ. A. Simon, George Washington University Washington DC USAI. P. Barton, Procter & Gamble Pharmaceuticals Cincinnati OH USAM. R. McClung, Oregon Osteoporosis Center Portland OR USAA. Grauer, Procter & Gamble Pharmaceuticals Cincinnati OH USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis Interna...

The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids

Glucocorticoids (GCs) alter bone strength such that patients receiving these medications have a high rate of fragility-related fractures. The purpose of this study was to assess whether concurrent treatment with GCs (prednisolone) and risedronate (an aminobisphosphonate) would prevent the reduction in bone strength induced by GCs, in a mouse model of GC-induced bone loss and in patients enrolled in a clinical study.We evaluated mice treated with prednisolone pellets alone, GCs plus risedronate, or placebo alone and iliac crest biopsy specimens obtained from patients who were treated with GCs plus placebo or GCs plus risedronate for 1 year. We measured the mass, architecture, and physical and material properties of bone (subject to therapeutic treatments) at nanoscale to macroscopic dimensi...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis ?? usefulness of alendronate and risedronate

Expert Opinion on Pharmacotherapy , Nov 2007, Vol. 8, No. 16, Pages 2743-2756. The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate. A search of the literature was conducted using ... (Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents)

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer

International Journal of Urology, Volume 0, Issue 0, Page ???, -Not available-. Aim:  Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third-generation oral bisphosphonate, on bone loss during androgen deprivation therapy was ... (Source: International Journal of Urology)

Fracture risk remains reduced one year after discontinuation of risedronate

Conclusions&nbsp;&nbsp;Despite the apparent resolution of effect on BMD and BTM, the risk reduction of new vertebral fractures remained in the year after treatment with risedronate was stopped. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0460-7Authors N. B. Watts, University of Cincinnati Bone Health and Osteoporosis Center 222 Piedmont Avenue, Suite 4300 Cincinnati OH 45219 USAA. Chines, Procter & Gamble Pharmaceuticals Cincinnati OH USAW. P. Olszynski, Midtown Medical Center Saskatoon SK CanadaC. D. McKeever, McKeever Orthopedic Clinic Houston TX USAM. R. McClung, Oregon Osteoporosis Center Portland OR USAX. Zhou, Procter & Gamble Pharmaceuticals Cincinnati OH USAA. Grauer, Procter & Gamble Pharmaceuticals Cincinnati OH USA Journal Osteopo...

First-Time Generic Approvals: Actonel, Biaxin Granules, Floxin

The FDA has approved first-time generic formulations for risedronate sodium 5-, 30-, and 35-mg tablets; clarithromycin for oral suspension 125 mg/5 mL and 250 mg/5 mL strengths; and ofloxacin otic drops 0.3% strength. Medscape Medical News (Source: Medscape PublicHealth Headlines)

Teva Announces Approval of Generic Actonel(R)

JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic vers... Biopharmaceuticals, FDA, GenericsTeva Pharmaceutical, Actonel, Risedronate, Procter and Gamble (Source: HSMN NewsFeed)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Teva gets generic approval for Procter's Actonel

Israel&#39;s Teva Pharmaceutical Industries Ltd. said Monday that the Food and Drug Administration approved its generic version of Procter & Gamble Co&#39;s Actonel to prevent and treat post-menopausal osteoporosis, according to various news reports. (TEVA) (PG) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

FDA approves Teva's osteoporosis generic

The Food and Drug Administration granted final approval Monday for Teva Pharmaceutical Industries Ltd.&#39;s application to market a generic version of Actonel. (PG) (TEVA) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Actonel halves risk of fracture in osteoporotic women

New data show that Actonel® 5mg (risedronate sodium tablets) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with established osteoporosis who have suffered a previous hip fracturei- a group of patients at high risk of a subsequent fracture. (Source: HealthcareRepublic Press Releases)

Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa)

Early communication of an ongoing safety review. (Source: FDA MedWatch)

Osteoporosis: non-hormonal treatment.

Authors: Rizzoli R Significant progress has been achieved in osteoporosis treatment, in terms of agents with novel mechanisms of action, of new schedules of administration, and of long-term treatment safety demonstration. Alendronate, ibandronate, intranasal calcitonin, parathyroid hormones, raloxifene, risedronate, hormone replacement therapy, strontium ranelate and zoledronate decrease the risk of vertebral fracture. Alendronate, risedronate, strontium ranelate and zoledronate reduce the risk of hip fracture in women with osteoporosis, hormone replacement therapy in postmenopausal women, and calcium and vitamin D in institutionalized patients. In two meta-analyses, the combination of calcium and vitamin D was able to reduce the risk of falling, and hip fracture risk was decreased (&g...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate More Than Counteracts Bone-Depleting Effects of Aromatase Inhibitors

There is a net gain in bone mineral density when a bisphosphonate is added to hormone therapy for breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Data Mount for Once-Monthly Bisphosphonate Treatment

Efficacy of risedronate is maintained with monthly rather than daily treatment. Medscape Medical News (Source: Medscape FamilyMedicine Headlines)

Preventing Bone Loss After Breast Cancer Treatment Using Osteoporosis Drug

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Susan Greenspan, M.D. [click link for full article] (Source: Bones / Orthopaedics News From Medical News Today)

Weekly Dose Of Osteoporosis Drug Prevents Bone Loss After Breast Cancer Treatment

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a new two-year study. Researchers evaluated 87 women enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. (Source: ScienceDaily Headlines)

New Phase III Data Presented For Once Monthly Dosing Regimen Of Risedronate To Treat Postmenopausal Osteoporosis

Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting. [click link for full article] (Source: Bones / Orthopaedics News From Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate prevents bone loss after breast cancer treatment

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. (Source: News-Medical News Feed)

Osteoporosis drug for breast cancer patients

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, as per a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center........ (Source: Medicineworld.org: New Article Alert)

NICE has arranged an appeal hearing against the final appraisal determination and guidance on osteoporosis - primary prevention and osteoporosis - secondary prevention including strontium ranelate

The Institute has arranged a hearing for three appeals received against the Final Appraisal Determination and Guidance on the clinical effectiveness and cost effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women AND Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. (Source: NICE | Nice Front Page (Welcome to NICE))

Risedronate Reduced Risk Of Fracture Among Osteoporotic Postmenopausal Women With History Of Hip Fracture

In a new analysis reported at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting, risedronate 5 mg decreased clinical fracture risk by 50% over three years relative to placebo in a group of postmenopausal women with osteoporosis who had suffered a previous hip fracture. This retrospective analysis of the risedronate HIP trial(1) evaluated the combined incidence of vertebral and nonvertebral clinical fractures among this high risk group of patients. [click link for full article] (Source: Bones / Orthopaedics News From Medical News Today)

Loss of treatment benefit due to low compliance with bisphosphonate therapy

Conclusions&nbsp;&nbsp;These results show a statistically significant association between level of compliance with bisphosphonates and level of fracture risk, emphasizing the importance of treatment compliance in obtaining maximal treatment benefit. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-007-0466-1Authors F. J. A. Penning-van Beest, PHARMO Institute P.O.Box 85222 3508 AE Utrecht The NetherlandsJ. A. Erkens, PHARMO Institute P.O.Box 85222 3508 AE Utrecht The NetherlandsM. Olson, Novartis Pharma AG Basel SwitzerlandR. M. C. Herings, PHARMO Institute P.O.Box 85222 3508 AE Utrecht The Netherlands Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bisphosphonates in Corticosteroid-Induced Osteoporosis

Abstract&nbsp;&nbsp;Corticosteroid osteoporosis is a common clinical problem with the risk of fracture, highest in postmenopausal women. The first choice for prevention is a potent oral bisphosphonate such as alendronate or risedronate. In patients intolerant of oral bisphosphonates, intravenous bisphosphonates should be used. Prophylactic therapy should be continued whilst patients continue significant doses of corticosteroid therapy. In patients receiving chronic low-dose corticosteroids where the BMD is substantially reduced, other therapies such as PTH should be considered, followed by a bisphosphonate. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12018-007-9000-4Authors Philip N. Sambrook, University of Sydney, Royal North Shore Hospital Institute of Bone a...

Hip fractures in users of first- vs. second-generation bisphosphonates

Conclusions&nbsp;&nbsp;The findings of this study suggest similar rates of hip fracture between the first- and second-generation bisphosphonates when used continuously among elderly females with a prior history of fracture. Content TypeJournal Article JournalOsteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Fracture prevention in postmenopausal women

New evidence; conclusions changed for: Raloxifene One systematic review and two RCTs added; categorisation changed from Beneficial to Trade-off between benefits and harms. New evidence; conclusion confirmed for: Calcium alone Two RCTs added; categorisation unchanged (Unlikely to be beneficial). Vitamin D alone One RCT added; categorisation unchanged (Unlikely to be beneficial). Alendronate One RCT added; categorisation unchanged (Beneficial). Risedronate One RCT added to harms; categorisation unchanged (Beneficial). Strontium ranelate One systematic review added; categorisation unchanged (Beneficial). Para...

Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.

Authors: Yamada S, Takagi H, Tsuchiya H, Nakajima T, Ochiai H, Ichimura A, Iwata H, Toriyama T Osteoporosis is a common adverse reaction induced by glucocorticoid treatment. Bisphosphonate, vitamin D(3) (VD(3)) or vitamin K(2) (VK(2)) is recommended as first or second choice of drug for treatment of glucocorticoid-induced osteoporosis. In the present study, the treatment effect of risedronate against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients was compared with that of alfacalcidol. Twelve patients were randomized to receive either risedronate (2.5 mg) or alfacalcidol (0.5 microg) daily for 48 weeks. Each patient also received 800 mg of calcium supplementation (800 mg/day) daily. Bone mineral density (BMD) and the biochemical markers of bone turnover were measu...

International Approvals: Actonel, Alvesco, Increlex

Canada has approved a new tablet strength and related regimen for risedronate sodium tablets (Actonel) and an expanded indication for inhaled ciclesonide (Alvesco); Europe has approved mecasermin [rDNA origin] 10-mg/mL injection (Increlex). Medscape Medical News (Source: Medscape PublicHealth Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs

Conclusions&nbsp;&nbsp;These data document that after adjusting for increased aBMD, vertebrae from animals treated with bisphosphonates have similar strength as those from untreated animals. Conversely, when adjusted for increased aBMD, alendronate treatment, but not risedronate treatment, significantly reduces the energy required for vertebral fracture, indicative of an alteration in bone quality. Content TypeJournal Article JournalOsteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate

Abstract&nbsp;&nbsp;The aim of our study was to examine compliance with a daily dose of 5??mg alendronate (ALN) and 2.5??mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stoppe...

A case of pachydermoperiostosis treated by oral administration of a bisphosphonate and arthroscopic synovectomy

Abstract&nbsp;&nbsp;Pachydermoperiostosis (PDP) is a rare hereditary disorder characterized by pachydermia, digital clubbing, and periosteal hypertrophy. Here, we report a case of PDP showing symptoms consistent with arthritis, which was treated by oral administration of risedronate sodium and arthroscopic synovectomy. Content TypeJournal Article JournalModern RheumatologyOnline ISSN 1439-7609Print ISSN 1439-7595 Journal VolumeVolume 17 Journal IssueVolume 17, Number 4 / August, 2007 (Source: Modern Rheumatology)

Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club

Abstract&nbsp;&nbsp;Cancer treatment-induced bone loss (CTIBL) is one of the most important side effects of adjuvant antineoplastic treatment in hormone-dependent neoplasms. Chemotherapy, GnRH analogs and tamoxifen can induce marked bone loss in premenopausal women with early breast cancer. Aromatase inhibitors (AIs) are replacing tamoxifen as the preferred treatment for postmenopausal women. As a class effect, steroidal (exemestane) and non-steroidal (anastrozole and letrozole) AIs increase bone turnover and cause bone loss (4%??5% over 2&nbsp;years). When compared to tamoxifen, the risk of getting a clinical fracture under AI treatment is increased by 35%??50%. In patients with prostate cancer, androgen deprivation therapy (ADT) increases bone turnover, reduces bone mass (4%??5%...

Once weekly risedronate (Actonel) approved in UK for treatment of osteoporosis in men

Risedronate (Actonel&#174; Once a Week) has received UK approval for a new indication of treatment of osteoporosis in men at high risk of fractures. (Source: NeLM news - Musculoskeletal)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics.

Conclusions: Considering that millions of patients have been prescribed bisphosphonates for the treatment of osteoporosis, the relative prevalence of ONJ in these patients was low. Age &gt;/=60 years, female sex, and previous invasive dental treatment were the most common characteristics of those who developed ONJ. However, it is not possible to draw further conclusions about the potential association between oral bisphosphonate use and ONJ in the identified studies because of incomplete reporting and the presence of confounding factors. PMID: 17919538 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

If a patient experiences GI side effects on alendronate, what are the alternative treatment choices? Can they switch to another bisphosphonate or strontium?

The CKS (formerly PRODIGY) guideline on osteoporosis reports that the first line treatment is "a bisphosphonate; alendronate, risedronate, cyclical etidronate, or monthly ibandronate (less preferred). " It later states:"Current or recent history of other upper gastrointestinal disorders: use risedronate or cyclical etidronate. (Source: NLH Question Answering Service)

Evidence that Treatment with Risedronate in Women with Postmenopausal Osteoporosis Affects Bone Mineralization and Bone Volume

Abstract&nbsp;&nbsp;Risedronate is used in osteoporosis treatment. Postmenopausal women enrolled in the Vertebral Efficacy with Risedronate Therapy trial received either risedronate (5 mg/day) or placebo for 3 years. Subjects received calcium and vitamin D supplementation if deficient at baseline. Lumbar spine bone mineral density (BMD) was measured at baseline and at 3 years. Quantitative back-scattered electron imaging (qBEI) was performed on paired iliac crest biopsies (risedronate, n = 18; placebo, n = 13) before and after treatment, and the mineral volume fraction in the trabecular bone was calculated. Combining dual-energy X-ray absorptiometric values with the mineral volume fraction for the same patients allowed us to calculate the relative change in trabecular bone volume with...

Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?

Authors: Black DM, Rosen CJ PMID: 17549088 [PubMed] (Source: Nature Clinical Practice. Rheumatology.)

NICE issues Final Appraisal Determination (FAD) on the use of alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporosis in postmenopausal women

The Final Appraisal Determination on the use of alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporosis in postmenopausal women has been issued by NICE. The guidance relates only to the initiation of therapy for the primary prevention of fragility fractures in postmenopausal women who have osteoporosis. The FAD recommends (direct from source): 1. Alendronate as a treatment option for the initiation of therapy for primary prevention of osteoporotic fragility fractures in: 2. ? Women aged 70 years or older who have one or more clinical factors suggestive of increased fracture risk or medical conditions suggestive of low BMD (see sections 1.3 and 1.4 of FAD) and a T-score of ??2.5 SD or below. In women aged 75 years or older who...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

NICE issues Final Appraisal Determination (FAD) on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

The National Institute of Health and Clinical Excellence had issued a Final Appraisal Determination (FAD) for consultation on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. The guidance relates only to the initiation of therapy for the secondary prevention of fragility fractures in postmenopausal women who have osteoporosis and have sustained a clinically apparent fragility fracture. The guidance recommends (direct from source): 1.1 Alendronate as a treatment option for the initiation of therapy for the secondary prevention of osteoporotic fragility fractures in post-menopausal women who have a T-score of ??2.5 SD or below. In women aged 75 years or...

Is risedronate associated with exacerbation of migraines in patients with a history of migraines?

We could find no evidence that risedronate is associated with exacerbations of migraine. The SPC for Actonel [1] makes no reference to migraine. (Source: NLH Question Answering Service)

[Extended reports] Assessment of non-vertebral fracture risk in postmenopausal women

Conclusions: The NV risk index is a convenient tool for selection of patients with osteoporosis with a high risk for NV fractures, and may help to choose from available treatments those with a proven efficacy for reduction of NV fracture risk. (Source: Annals of the Rheumatic Diseases)

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Authors: Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD Aromatase inhibitors have demonstrated their superiority to tamoxifen as adjuvant therapy for early breast cancer in postmenopausal women, but are associated with an increased risk of fractures. The aim of our study was to analyze bone loss, bone turnover and their determinants in postmenopausal women treated with anastrozole. We investigated bone loss and bone turnover markers (BTM) in a prospective open cohort study of 118 postmenopausal women treated with anastrozole for an early hormone-dependent breast cancer. Women without osteoporosis were not treated and compared with an age-matched control group of 114 healthy women. Osteoporotic patients (T-score&lt;/=-2.5 S.D.) received weekly risedronate. Bone miner...

FDA Approvals: Torisel, Neupro, Actonel

The FDA has approved temsirolimus injection (Torisel), a rotigotine transdermal system (Neupro), and a new dose regimen for risedronate sodium tablets (Actonel). (CME)Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Weekly risedronate in kidney transplant patients with osteopenia

Transplant International Volume 0, Issue 0, Page ???-???. (Source: Transplant International)

Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.

CONCLUSIONS: The exploration of new dosing schedules and formulations aims to identify the optimal bisphosphonate regimen for postmenopausal osteoporosis. To achieve this, careful consideration must be given to the choice of a scientifically valid study design that effectively, and ethically, meets the study objectives. Given the concerns regarding placebo-controlled antifracture studies, 2 alternative study designs should be considered, both using validated surrogate end points (bone mineral density and biochemical markers of bone turnover) as the principal mode of assessment. PMID: 17692726 [PubMed - in process] (Source: Clinical Therapeutics)

Actonel(Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: May 31, 2007 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease

Conclusions. Bisphosphonate might be beneficial for the prevention of steroid-induced bone loss in patients with glomerular diseases compared with vitamin D3. The combined therapy may be more effective, especially in patients treated with high-dose corticosteroids, including pulse therapy. A high urinary NTx level before receiving corticosteroids might be a predictive marker of the loss of BMD. (Source: Nephrology Dialysis Transplantation)

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)

Conclusions. Risedronate is effective in increasing BMD with or without aVD in CKD patients receiving long-term glucocorticoid therapy. Bone markers are of some use in predicting the response to anti-resorptive therapy. (Source: Nephrology Dialysis Transplantation)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Is the bisphosphonate alendronate any more likely to cause severe oesophageal reactions compared with other bisphosphonates such as risedronate?

Guidelines and studies examining adverse effects associated with bisphosphonates report on adverse gastrointestinal effects, there is relatively little discussion of severe oesophageal reactions. The PRODIGY guideline on osteoporosis, based on NICE recommendations, states:?&nbsp;"Gastrointestinal adverse effects such as abdominal pain, dyspepsia, diarrhoea, or constipation are common. (Source: NLH Question Answering Service)

If a patient prescribed risedronate 35mg weekly has CKD stage 3 or 4, is it safe to switch them to alendronic acid 70mg weekly?

GPNotebook's outlines the Renal Association's classification scheme for chronic kidney disease:"A more modern classification of chronic kidney disease (CKD) is based on estimated GFR, and recognises five stages of kidney disease, as follows: Stage 1: Normal GFR; GFR &gt;90 mL/min/1. 73 m2 with other evidence of chronic kidney damage Stage 2: Mild impairment; GFR 60-89 mL/min/1. (Source: NLH Question Answering Service)

FDA approves new Actonel dose

The U.S. Food and Drug Administration (FDA) approved a new dose for Actonel (risedronate sodium tablets) that will give patients the option of taking one Actonel 75 mg tablet on two consecutive days, for a total of two tablets monthly, to treat and prevent their postmenopausal osteoporosis. (Source: News-Medical News Feed)

The U.S. Food And Drug Administration Approves New Actonel Dose To Treat And Prevent Postmenopausal Osteoporosis

On April 16, 2007, the U.S. Food and Drug Administration (FDA) approved a new dose for Actonel(R) (risedronate sodium tablets) that will give patients the option of taking one Actonel 75 mg tablet on two consecutive days, for a total of two tablets monthly, to treat and prevent their postmenopausal osteoporosis. [click link for full article] (Source: Health News from Medical News Today)

FDA approves new dose of risedronate (Actonel) for treatment and prevention of postmenopausal osteoporosis

According to BioSpace, the US FDA has approved a new dose for Actonel&#174; (risedronate) to treat and prevent postmenopausal osteoporosis. The new dose of 75mg daily for two consecutive days each month (i.e. two tablets monthly) was approved based on the results of a clinical trial involving 1,299 postmenopausal women with osteoporosis (lumbar spine bone mineral density (LS BMD) T-score less than or equal to -2.5 OR a LS BMD T-score less than or equal -2.0 and at least one prevalent vertebral fracture). In this trial, increases in BMD measured at various sites in patients treated with risedronate 75mg at the above dose were found to be similar to those in patients treated with risedronate at a dose of 5mg daily, at both 6 and 12 months. Side effects were also similar between the two dosin...

Call for greater use of comparative effectiveness studies to help advance disease management

The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal. Patients taking the osteoporosis treatment risedronate (Actonel, risedronate sodium) were almost half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment, according to the REAL (RisedronatE, ALendronate) study. (Source: EurekAlert! - Medicine and Health)

Osteoporosis Treatment For Preventing First Fracture, Australia

Some osteoporosis medications have been recommended for reimbursement on the PBS for use in the prevention of osteoporotic fractures in older Australians. Osteoporosis medication risedronate (trade names Actonel and Actonel Combi) has this week been recommended for reimbursement on the Pharmaceutical Benefits Scheme (PBS) for the prevention of osteoporotic fractures for patients aged 70 years or over with a low bone density (T-score of -3.0 or less). [click link for full article] (Source: Bones / Orthopaedics News From Medical News Today)

Bisphosphonate efficacy and clinical trials for postmenopausal osteoporosis: Similarities and differences.

Authors: Boonen S In clinical trials, the bisphosphonates risedronate and alendronate have each been shown to reduce the risk of vertebral and nonvertebral fractures as early as 6 months (risedronate) and 12 months (alendronate). In contrast to risedronate and alendronate, ibandronate only reduces the risk of vertebral fractures, with no evidence for its efficacy in hip and nonvertebral fracture reduction. The antifracture efficacy of different bisphosphonates must rely on fracture data since bone mineral density measurements and changes in bone turnover markers appear to have no strict linear correlation with fracture risk reductions. The antifracture efficacy of different bisphosphonates ideally should be compared via head-to-head comparisons in fracture endpoint trials. PMID: 17...

Drug Helps Prevent Hip Fractures In Parkinson Disease

A drug used to strengthen bone has been found to help reduce the high incidence of hip fractures among people with Parkinson disease, according to a study published in the March 20, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology. The two-year study involved 242 elderly men with Parkinson disease in Tokyo, Japan. Half of the group received the drug risedronate and vitamin D2. The remaining men received placebo and vitamin D2. [click link for full article] (Source: Parkinson's Disease News From Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bone drug may benefit immobile Parkinson's patients

NEW YORK (Reuters Health) - Immobilization and lack of sunlight exposure cause accelerated bone loss in people with Parkinson's disease, increasing their risk of hip fracture. But taking the bone-building drug Actonel with vitamin D seems to curb the risk of fractures in elderly men with Parkinson's disease, even though they continue to have frequent falls. (Source: Reuters: Health)

Drug slows Parkinson's-related bone loss

The drug risedronate seems to slow osteoporosis in Parkinson's disease patients, thus reducing hip fractures, say Japanese researchers. (Source: United Press International - Health Business)

Risedronate Cuts Hip Fracture Risk in Parkinson's Disease

Combination treatment with the bisphosphonate risedronate and vitamin D2 reduces the risk of hip fractures in individuals with Parkinson disease ? a leading cause of morbidity in this patient group.Medscape Medical NewsCaroline Cassels (Source: Medscape Medical News Headlines)

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease

Conclusion: Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures. (Source: Neurology)

EDITOR'S CORRESPONDENCE: Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials

(Source: Archives of Internal Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

EDITOR'S CORRESPONDENCE: Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials--Reply

(Source: Archives of Internal Medicine)

NICE issues Appraisal Consultation Document on secondary prevention osteoporosis

NICE has issued an Appraisal Consultation Document on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. This guidance assumes that women who receive treatment have an adequate calcium intake and are vitamin D replete. Supplementation should be considered if there is doubt about adequate intake. The following preliminary recommendations have been made: ? Alendronate is recommended for the initiation of therapy for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who have a T-score of -2.5 SD or below confirmed by DXA scanning. For women aged 75 years or older, a DXA scan may not be required if the responsible clinic...

NICE issues Appraisal Consultation Document on primary prevention osteoporosis

NICE has issued an Appraisal Consultation Document on the use of alendronate, etidronate, risedronate, raloxifene, and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women i.e. in women who have osteoporosis, but who have not sustained a clinically apparent fragility fracture. This guidance assumes that women who receive treatment have an adequate calcium intake and are vitamin D replete. Supplementation should be considered if there is doubt about adequate intake. The following preliminary recommendations have been made: ? Alendronate is recommended for the initiation of primary prevention of osteoporotic fragility fractures in women aged 70 years or older, who have one or more clinical risk factors suggestive of low BMD and a T-sco...

Osteochemonecrosis of jaws and bisphosphonates.

Authors: Khosa AD, Nayyar MS, Beirne JC Osteochemonecrosis of the jaws is a well described side effect of bisphosphonate therapy. Bisphosphonates are non metabolised analogues of pyrophosphate that are capable of localizing to bone, slowing both rate of growth and rate of dissolution therefore reducing the rate of bone turnover. Although the exact mechanism is not clear but it has been established that bisphosphonates target osteoclast, inhibiting their function in several ways: There are two types of bisphosphonates. The first are oral preparations of bisphosphonates, which include Alendronate and Risedronate. They are indicated for the treatment of osteoporosis. They are considered as lower risk of osteochemonecrosis. The second are administered intravenously. Pamindronate is a first...

Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate

In conclusion, alendronate decreases bone resorption markers more obviously and rapidly than risedronate, especially in high risk for fracture, but not significantly according to the guidelines of the Japan Osteoporosis Society. Content TypeJournal Article JournalJournal of Bone and Mineral MetabolismOnline ISSN 1435-5604Print ISSN 0914-8779 Journal VolumeVolume 25 Journal IssueVolume 25, Number 2 / March, 2007 (Source: Journal of Bone and Mineral Metabolism)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women

Abstract??We evaluated adherence with raloxifene therapy compared with daily bisphosphonate in Asian postmenopausal women at increased risk of osteoporotic fractures. In this 12-month observational study conducted in Asia (Hong Kong, Malaysia, Pakistan, Philippines, Singapore, Taiwan), 984 postmenopausal women (aged 55 years or older) were treated with raloxifene 60?mg/day (n= 707; 72%) or daily bisphosphonate (alendronate 10?mg/day;n= 206; 21%, or risedronate 5?mg/day;n= 71; 7%) during their normal course of care. Patients were assessed at baseline, 6, and 12 months. Baseline characteristics (including age, race, education, menopausal status, and baseline fractures) were comparable between the raloxifene and bisphosphonate groups. More women on raloxifene completed the study compared with...

Our picks of the week's stories from the National electronic Library for Medicines news service, Feb 5-9

NICE appraisal consultation document recommends against use of cetuximab for locally advanced head and neck cancer Meta-analysis: intensive statin treatment of limited benefit Cochrane review: Effects of low-dose glucocorticoids on radiological progression in rheumatoid arthritis Updated US guidelines on HRT published Tramadol associated with withdrawal and risk of dependency Aprotinin use during CABG associated with worse long-term outcome? Fracture risk with intermittent high-dose oral glucocorticoid therapy FDA approves orlistat (Xenical) for over-the-counter use Canadian Health Technology Assessment: Point-of-care anticoagulation monitoring devices Risedronate for prevention of bone loss in breast cancer patients Latest figures on usage of Electronic Prescription Service by ...

Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty

Conclusion??These outcomes suggested that risedronate might reduce the periprosthetic bone resorption after cementless THA. Content TypeJournal Article JournalOsteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Risedronate for prevention of bone loss in breast cancer patients

A small 1-year randomised, double-blind, placebo-controlled trial has examined whether once-weekly oral risedronate 35mg is efficacious and safe in preventing bone loss associated with chemotherapy in breast cancer patients. The Risedronate??s Effect on Bone Loss in Breast Cancer (ReBBeCa) study was conducted in 87 postmenopausal women with breast cancer treated with chemotherapeutic agents with or without the concomitant use of tamoxifen or aromatase inhibitors. The primary outcomes were the 12-month changes in spine and hip bone mineral density (BMD). Secondary outcomes included changes in markers of bone resorption and formation. After 12 months, BMD increased by 1.2% at the spine and 1.3% at the hip in women on risedronate vs. decreases in the placebo group of 0.9% at the spine and ...

Risedronate prevents bone loss in breast cancer survivors

NEW YORK (Reuters Health), Feb 7 - Once-weekly treatment with risedronate prevents bone loss in breast cancer survivors who underwent chemotherapy, according to the results of a new study, suggesting that early bisphosphonate treatment be considered for these patients. (Source: AuntMinnie.com Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.

CONCLUSIONS: Oxidative stress plays an important role in the pathogenesis of PMO. Studied drugs had ultimate effects on reducing lipid peroxidation. Raloxifene also had potent effects in the enhancement of antioxidant defense system. PMID: 17227729 [PubMed - in process] (Source: Archives of Medical Research)

Osteoporosis: strategies for prevention and management.

Authors: Keen R Osteoporosis is a serious public health issue, affecting up to 1 in 2 women and 1 in 5 men over the age of 50 years. The common osteoporotic fractures occur at the spine, wrist and hip. For the patient affected by osteoporosis, these fractures are associated with significant morbidity and, in the case of hip and spine fractures, an excess mortality. The treatment of osteoporotic fractures is also associated with a significant healthcare cost for society. Currently, measurement of bone mineral density using dual energy X-ray absorptiometry is the gold standard for the diagnosis of osteoporosis. In the future, however, assessment of fracture risk will be based on algorithms incorporating clinical risk factors and bone density measurements, where appropriate. The goal of t...

A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients

Conclusion. This preliminary study showed that patients with marked cartilage loss (JSN&ge;0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA. (Source: Rheumatology)

The diagnosis and treatment of male osteoporosis: Defining, assessing, and preventing skeletal fragility in men.

Authors: Boonen S, Kaufman JM, Goemaere S, Bouillon R, Vanderschueren D Male osteoporosis is associated with a significant burden in terms of morbidity, mortality, and economic cost. Despite recent advances in the understanding of the male osteoporotic syndrome, the evaluation and treatment of men suffering from osteoporosis remains a clinical challenge. In men with osteoporosis, it remains particularly critical to exclude underlying pathological causes as these are much more likely to be present than in women. There is increasing evidence that the approaches developed to diagnose and treat the disorder in women may be equally useful in men. The available evidence suggests that the anti-fracture efficacy of treatment with alendronate, risedronate, or teriparatide is similar in both sex...

[The effect of risedronate treatment on bone turnover markers in patients with hip fracture]

CONCLUSION: Risedronate treatment was found effective in decreasing bone resorption and thus in reducing the risk for refractures in patients with hip fractures due to minor trauma. PMID: 17483649 [PubMed - indexed for MEDLINE] (Source: Acta Orthopaedica et Traumatologica Turcica)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Fracture prevention in postmenopausal women

New evidence; conclusions changed for Calcium alone. New evidence; previous conclusions confirmed for Alendronate, Parathyroid hormone, Raloxifene, Risedronate, Strontium ranelate, Etidronate, Ibandronate, and Vitamin D analogues (alfacalcidol or calcitriol). (Source: Clinical Evidence)

Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.

CONCLUSIONS: (1) Low doses of risedronate or alendronate suppressed osteocyte apoptosis induced by fatigue loading of the ulna in rats. (2) There was no difference between the effects of risedronate or alendronate on osteocyte apoptosis at these doses. PMID: 17240209 [PubMed - as supplied by publisher] (Source: Bone)

PERSPECTIVE: Osteonecrosis of the Jaw -- Do Bisphosphonates Pose a Risk?

Nitrogen-containing bisphosphonates are used widely for the management of metastatic cancer in bone (intravenous zoledronic acid or pamidronate), for the prevention and treatment of osteoporosis (oral alendronate, risedronate, and ibandronate ... (Source: New England Journal of Medicine)

How long does a patient living in a Nursing Home have to take a bisphosphonate for, for it to be effective?

We found relatively little on this topic. &nbsp; One paper we found, published this year, compared daily versus weekly alendronate [1], this reported:"The evaluation of the changes in BMD in all regions revealed a significant increase in BMD in both groups compared to baseline values except for spine (L2-L4) in alendronate group at 6th and 12th month and femoral neck in risedronate group at 6th month. (Source: NLH Question Answering Service)

Fastest Osteoporosis Drug: Actonel

Title: Fastest Osteoporosis Drug: ActonelCategory: Health NewsCreated: 11/28/2006Last Editorial Review: 11/28/2006 (Source: MedicineNet Womens Health General)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Our picks of the week's stories from the National electronic Library for Medicines news service, Nov 20-24

Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample Study suggesting an increase in cardiovascular risk with naproxen published PSNC advice - Private prescriptions for controlled drugs Comment: varenicline for smoking cessation Oral anticoagulation therapy management by telephone vs attendance at anticoagaulation clinics CHD risk assessment tools for primary prevention give variable results (of uncertain worth) Composite endpoints in clinical trials - interpret with care Byetta (exenatide) approved for treatment of type 2 diabetes in Europe RCT: Self management for men with lower urinary tract symptoms Bivalirudin for patients with acute coronary syndromes Observational study compari...

Millions With Arthritis May Benefit From Bone Loss Drug

People taking a widely used medication to strengthen fragile, aging bones may also be protecting their joints, according to a recent study led by Johns Hopkins rheumatologist Clifton Bingham, M.D.Researchers began to wonder if risedronate might be used to treat osteoarthritis after noticing that the drug, and other compounds in the same class of drugs, not only slowed joint damage in animals, but also reduced cartilage-irritating bone lesions in humans. [click link for full article] (Source: Arthritis News From Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

New Study Shows Actonel Almost Halves The Risk Of Hip Fractures Compared To Alendronate

Data published from a retrospective study of over 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel® (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. These results were published in the peer-reviewed journal Osteoporosis International. [click link for full article] (Source: Women's Health / OBGYN News From Medical News Today)

Comparative therapeutic use of Risedronate and Calcarea phosphorica - allopathy versus homeopathy - in bone repair in castrated rats.

Authors: Werkman C, Segnini Senra G, Rocha RF, Brandão AA Osteoporosis, a disease characterized by progressive bone loss, has been the target of several studies in the past few years. It results in a much higher risk for fractures and might cause slower bone lesion healing. The aim of this work was to study the effects of Risedronate (allopathic medicine) and Calcarea phosphorica 6CH (homeopathic medicine) on the repair of bone lesions in male rats with osteoporosis induced by castration. Eighty-four three-month-old rats were used divided into four groups of twenty-one animals each. Three groups where castrated and one group was submitted to Sham surgery. One month later, cortical lesions were made in all animals' tibiae and, after one day, the different experimental treatments began ...

Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates

AbstractCorticosteroids are widely used as anti-inflammatory and immunosuppressive agents to treat a variety of chronic conditions. Long-term (&gt;1 year) corticosteroid use can lead to bone loss, and therefore, osteopenia or osteoporosis. Corticosteroid-induced osteoporosis (CIO) leads to increased bone fragility and subsequently fractures, which, in turn, lead to a loss of physical, emotional and social health for the patient and increased costs for healthcare providers. A wealth of data exists demonstrating the efficacy of the oral bisphosphonates, etidronate, alendronate and risedronate in increasing bone mineral density in patients with CIO or preventing bone loss in patients commencing corticosteroid therapy. Data regarding fracture prevention are less clear, as statistically signif...

Observational study comparing risedronate with alendronate published

A large observational study comparing risedronate with alendronate for the prevention of fractures in osteoporosis suggests that risedronate is more effective: the design and duration of the study, however, mean that this result should be treated with caution. The (manufacturer sponsored) study was a retrospective observational study that looked at fracture rates during the first year of therapy in patients taking risedronate and alendronate. It used healthcare utilisation data from a number of US health plans to determine fracture incidence over the first year of treatment with one or other of the drugs. Patients included in the analysis were women aged 65 and over who started taking either of the drugs once weekly from July 2002, with at least three months data after initiation and wit...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

New study shows Actonel almost halves the risk of hip fractures compared to alendronate

Data published today from a retrospective study of over 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. These results were published today in the peer-reviewed journal Osteoporosis International. (Source: EurekAlert! - Medicine and Health)

Actonel halves the risk of hip fractures compared to alendronate

Postmenopausal women taking Actonel were half as likely to sustain a hip fracture in the first year of treatment. (Source: Orthopedics News - Doctors Lounge)

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study

Conclusion Patients receiving risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than patients receiving alendronate. Content TypeJournal Article JournalOsteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

CADTH systematic review: Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

This systematic review conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH) assessed the clinical effectiveness of etidronate, alendronate, and risedronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women receiving these treatments compared with untreated women, over a follow-up period of at least one year. The review notes that for etidronate, most trials enrolled a small number of participants and were not necessarily designed to measure fractures; available evidence for alendronate and risedronate is more robust. Of note: ? Etidronate, used at 400 mg/d demonstrated a main benefit in the secondary prevention of vertebral fractures. No statistically significant reductions in vertebral fractures were observed when it was...

CADTH clinical and economic analysis: Teriparatide and bisphosphonates for treatment of osteoporosis in women

This report from the Canadian Agency for Drugs and Technologies in Health (CADTH) assesses the clinical and cost effectiveness of teriparatide compared to the bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. The clinical analysis compare teriparatide to bisphosphonates or placebo, and the economic analysis compared teriparatide to bisphosphonates or no drug therapy. The clinical assessment noted the following: ? Compared with placebo, teriparatide 20 mcg/d confers a significant reduction in the risk of vertebral and non-vertebral fractures as secondary prevention. ? Teriparatide 40 mcg/d and alendronate 10 mg/d are not significantly different in the secondary prevention of non-vertebral fractures. ? Teriparatide 20 mcg/d, ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study

Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee OA Structural Arthritis (KOSTAR) study, which is the largest study to date investigating a potential structure-modifying OA drug, tested the efficacy of risedronate in providing symptom relief and slowing disease progression in patients with knee OA.The study group comprised 2,483 patients with medial compartment knee OA and 2-4 mm of joint space width (JSW), as determined using fluoroscopically positioned, semiflexed-view radiography. Patients were enrolled in 2 parallel 2-year studies in North America and the European Union. These studies evaluated the efficacy of risedronate at dosages of 5 mg/day, 15 mg/day, 35 mg/week (in Europe), and 50...

Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy

In this study, we examine whether these adverse structural effects are reversible and whether treatment with bisphosphonate is protective by in vivo serial micro-magnetic resonance (µ-MR) imaging and spectroscopy. Rabbits (n = 16) were divided into four groups, a control group (n = 4) and three groups (n = 4 each) receiving GC in the form of dexamethasone (0.45&#8201;mg/kg/day). In one of the GC groups dexamethasone exposure was discontinued after 2 weeks, the other two groups were maintained on dexamethasone, with one receiving risedronate (5&#8201;µg/kg twice per week) from the beginning of treatment, the other one receiving risedronate after 2 weeks. Animals were imaged at baseline and at 2, 4, and 8 weeks. Trabecular bone volume fraction (trabecular bone volume/tissue volume, TB...

Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?

Abstract  Over the past 12 years bisphosphonates have become a mainstay of treatment for postmenopausal osteoporosis. As a class, bisphosphonates significantly suppress bone turnover and increase BMD at the lumbar spine and other site through their direct inhibitory effects on osteoclasts. Alendronate and risedronate reduce the incidence of clinical vertebral and non-vertebral fractures. Etidronate and both oral and intravenous ibandronate reduce the incidence of clinical vertebral fractures, but data from primary analyses for reduction in non-vertebral fractures are currently less robust. Intravenous administration of zoledronate is under late-stage investigation for use in postmenopausal osteoporosis. Combinations of alendronate with estrogen or raloxifene provide a greater reduction ...

[Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment]

Authors: Di Munno O, Delle Sedie A Glucocorticoids (GC) are diffusely used to treat a wide variety of inflammatory and autoimmune disorders, including rheumatic diseases. GC-induced osteoporosis (GIO) is the most common and serious side-effect for patients receiving GC. Loss of bone mineral density (BMD) is greatest in the first few months of GC use; fracture (Fx) risk is significantly increased at the spine and hip on doses even as low as 2.5 mg of prednisolone daily; Fx risk increases rapidly from the onset of therapy and, for a given BMD, is higher in GIO than in postmenopausal OP. General measures to reduce bone loss include use of the lowest effective dose; consideration of alternative routes of administration; adequate calcium and vitamin D supplementation. Today, results from la...

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.

CONCLUSIONS: In all 3 countries, postmenopausal women prescribed a weekly regimen of bisphosphonates had significantly greater rates of compliance than women prescribed a daily regimen, and they persisted longer with treatment. However, compliance and persistence rates were suboptimal for both regimens. PMID: 17157124 [PubMed - indexed for MEDLINE] (Source: Clinical Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

NICE issues Appraisal Consultation Document on secondary prevention of osteoporotic fragility fractures

NICE has issued preliminary guidance on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who have sustained a clinically apparent osteoporotic fracture. The closing date for comments is 20 October 2006. This guidance covers the treatment of postmenopausal women who have normal levels of calcium and vitamin D however, if there is doubt about this, calcium and/or vitamin D supplementation should be considered. This guidance does not cover the treatment of women with other medical conditions associated with low bone mineral density or who are on long-term systemic corticosteroids. The following preliminary recommendations have been made: ? Alendronate is recommend...

NICE Appraisal Consultation Document on primary prevention of osteoporotic fragility fractures suggests restriction of drug treatments to women aged 75 years and older

NICE has issued preliminary guidance on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the primary prevention of osteoporotic fragility fractures in postmenopausal women who have not sustained a clinically apparent osteoporotic fracture. The closing date for comments is 20 October 2006. This guidance covers the treatment of postmenopausal women who have normal levels of calcium and vitamin D however, if there is doubt about this, calcium and/or vitamin D supplementation should be considered. This guidance does not cover the treatment of women with other medical conditions associated with low bone mineral density or who are on long-term systemic corticosteroids. The following preliminary recommendations have been made: ? Alendronate is recomme...

Bisphosphonate Side Effects: Cause For Growing Concern

They may be among the most-prescribed drugs in America, but bisphosphonates such as Fosamax, Actonel, Boniva and Zometa are also facing growing concerns about side effects including osteonecrosis of the jaw (ONJ), a rare syndrome in which jaw bone tissue dies. These bisphosphonate side effects directly contradict the drugs&#039; intent, which is to strengthen bones and prevent bone loss in women and men with osteoporosis. (PRWEB Sep 27, 2006) Trackback URL: http://www.prweb.com/chachingpr.php/UGlnZy1IYWxmLVNpbmctU3VtbS1JbnNlLVplcm8= (Source: PRWeb: Medical Pharmaceuticals)

Higher Persistency Rates Seen With FOSAMAX® Once Weekly Therapies Compared To Other Weekly And Monthly Oral Bisphosphonates

Higher persistency rates were seen among osteoporosis patients taking FOSAMAX® Once Weekly (alendronate) therapies than were seen among patients taking ibandronate once monthly or once weekly risedronate therapies, according to results from two new outcomes studies conducted by Merck & Co., Inc. that compared persistency rates of weekly versus monthly oral bisphosophate dosing frequency. [click link for full article] (Source: Endocrinology News From Medical News Today)

Women With Osteoporosis More Likely To Stay On Once-Monthly Oral Bonviva® Than On A Once-Weekly Treatment Regimen

Women taking highly effective once-monthly oral Bonviva® (ibandronic acid) for postmenopausal osteoporosis were more likely to stay on treatment during the first six months relative to those on a weekly bisphosphonate (alendronate or risedronate) according to findings presented today at the 28th Annual Meeting of the American Society for Bone Mineral Research (ASBMR)1. [click link for full article] (Source: Women's Health / OBGYN News From Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Fosamax Injury Cases Sent To New York MDL, But Not Actonel Cases

WASHINGTON, D.C. - Federal Fosamax injury cases will be litigated in a Manhattan court, but cases involving another bisphosphonate, Actonel, will not, the Judicial Panel on Multidistrict Litigation (JPMDL) decided Aug. 16 (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, JPMDL; See 6/22/06, Page 17). Full story on lexis.com (Source: LexisNexis&#174; Mealey's&#8482; Emerging Drugs & Devices Legal News)

FDA warns of Canadian counterfeit drugs

Consumers should not purchase medications from Web sites that have prescription orders filled by Mediplan Prescription Plus Pharmacy or Mediplan Global Health in Manitoba, warned the FDA. Apparently the sites are selling counterfeit drugs to U.S. consumers that include versions of Lipitor, Actonel, Nexium, Hyzaar, Ezetrol (sold as Zetia in the U.S.), Crestor, Celebrex, Arimidex, Propecia, and Diovan. (Source: Drug Topics - Hot off the Press)

Efficacy and tolerability of once-weekly administration of 17.5??mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen

In conclusion, once-weekly oral dosing with 17.5??mg risedronate was well tolerated in Japanese osteoporotic patients, and showed equivalent efficacy to once-daily oral dosing with 2.5??mg risedronate. This once-weekly regimen is expected to provide a more convenient therapeutic option as an alternative to daily dosing and to enhance patient compliance in long-term therapy for osteoporosis. Content TypeJournal Article JournalJournal of Bone and Mineral MetabolismOnline ISSN 1435-5604Print ISSN 0914-8779 Journal VolumeVolume 24 Journal IssueVolume 24, Number 5 / September, 2006 (Source: Journal of Bone and Mineral Metabolism)

Guidelines for diagnosis and management of Paget's disease of bone in Japan

Abstract  We here propose guidelines for the diagnosis and management of Paget's disease of bone (PDB) in Japan. These guidelines provide basic information on the epidemiology, pathophysiology, clinical signs and symptoms, diagnosis, indications for treatment, and available therapy, including orthopedic surgery. PDB is a chronic disorder characterized by focal abnormalities of bone turnover. The characteristic feature of PDB is excessive osteoclastic bone resorption coupled to increased and disorganized bone formation. The most common symptom of PDB is pain in involved bones. The most serious complication of PDB is malignant bone or soft-tissue tumor. PDB is uncommon in Japan; our survey in 2003 found 169 patients with PDB. The prevalence of PDB in Japan is 0.15/100??000; in patie...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Osteoporosis Treatment Now Approved In Europe And US For Men

The US Food and Drug Administration (FDA) this week approved Actonel&reg 35mg (risedronate sodium tablets) for 'treatment to increase bone mass in men with osteoporosis'. This follows the positive outcome in July 2006 of the European application for the additional indication of 'treatment of osteoporosis in men at high risk of fracture'. [click link for full article] (Source: Health News from Medical News Today)

FDA Approvals: Remicade and Actonel

The FDA has approved an expanded indication for infliximab injection (Remicade) and a new indication for risedronate (Actonel). (CME,CE)Medscape Medical NewsLaurie Barclay,Yael Waknine (Source: Medscape Dermatology Headlines)

Male sufferers now have access to osteoporosis drug Actonel

The U.S. Food and Drug Administration (FDA) has given it's approval for the drug Actonel (risedronate sodium) to be used to treat osteoporosis in men. (Source: News-Medical News Feed)

The U.S. Food And Drug Administration Approves Actonel For Broader Use In Men With Osteoporosis

On August 11,2006, the U.S. Food and Drug Administration (FDA) approved Actonel(R)(risedronate sodium tablets) 35 mg for treatment to increase bone mass inmen with osteoporosis. FDA approval of this new indication for Actonelopens the door for more men with osteoporosis to benefit from Actoneltreatment. Actonel 5 mg was approved in 2000 for use in men and women toprevent and treat certain forms of steroid-induced osteoporosis. [click link for full article] (Source: Bones / Orthopaedics News From Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Actonel (risedronate) approved in the US for use in men with osteoporosis

According to BioSpace, the FDA has approved Actonel&#174; (risedronate sodium) 35mg (once weekly tablet) for an additional indication ?? as treatment to increase bone mass in men with osteoporosis. This preparation is currently licensed in the UK for the treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures; and for the treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. This additional approval of Actonel is based on a two-year, placebo-controlled, double-blind multi-centre clinical trial involving 284 male patients with osteoporosis. In the trial, patients treated with once-a-week Actonel 35 mg experienced statistically significant improvements in lumbar spine bone mineral density and in bone turnover markers at all ...

P&G's Actonel OK'd for male osteoporosis

The U.S. Food and Drug Administration late last week approved Procter & Gamble's osteoporosis drug Actonel for a new use in men. (Source: United Press International - Health Business)

When a patient who is on long term steroidal therapy is prescribed a bisphosphonate, should calcium and vitamin D be also prescribed?

PRODIGY has a guideline on osteoporosis prevention [1], which includes the scenario 'Prevention and treatment of steroid-induced osteoporosis'. &nbsp; This states:"What drug treatment is recommended? First-line: a bisphosphonate (alendronate, risedronate, or cyclical etidronate). (Source: NLH Question Answering Service)

Recalls and Safety Alerts: Severe Bone and Muscle Pain with Bisphosphonates

A recent FDA article describes severe pain associated with two bisphosphonate drugs: Fosamax (alendronate sodium) and Actonel (risedronate sodium). The article, which was published in the Archives of Internal Medicine, describes over a hundred r... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

Conclusion: Although not enough evidence is available to prove a causal link, it seems that under specific circumstances local defenses can become overwhelmed resulting in ONJ. (Source: Annals of Oncology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ArthritisCentral News and Views #40 -- 12/29/05

Special Series of Podcasts on the Diagnosis and Treatment of Osteoporosis: Part III--The Use of Bisphosphonate Medication for the Treatment of Osteoporosis Dr. Rutstein interviews Dr. Raj Marwah, a rheumatologist and Clinical Professor at the Department of Internal Medicine at Texas Tech Health Sciences in El Paso. Topics include: What are bisphosphonates and how do they work? Are there advantages of one bisphosphonate over another? (Fosamax vs. Actonel vs. Boniva) What special instructions should the patient follow in taking these medications to ensure maximum absorption of the drug with the fewest side effects? What adverse side effects are seen with use of bisphosphonates? (Source: ArthritisCentral News and Views)

ArthritisCentral News and Views #3 -- 03/28/05

ArthritisCentral News and Views #3 (11 MB) The significance and implications of the FDA's approval of a new once a month treatment for osteoporosis called Boniva is discussed Background information on the current bisphosphonates Fosamax and Actonel is provided. Do you really need to switch? What about new patients recently diagnosed with osteoporosis? The issue of prolotherapy in osteoarthritis of the knee--a response to a subscriber's question. The dilemna of unproven forms of treatment and a warning about not spending your "hard-earned" money on them. Before you get too "desperate," Dr. Rutstein wants you to make sure that you have exhausted all approved and beneficial treatments. (Source: ArthritisCentral News and Views)

ArthritisCentral News and Views #8 -- 05/04/05

ArthritisCentral News and Views #8 (11 MB) A discussion of the inter-relationship of rheumatoid arthritis and heart disease, highlighting the role of inflammation. Dr. Rutstein offers you advice on how to decrease your risk of cardio-vascular disease. Evaluating whether Echinacea works based on a review of the medical literature. Is it worth the expense? A report on Fosamax and Actonel and associated bone pain, and what to do about it. Bone damage to the jaw with the use of bisphosphonate osteoporosis medications, especially with intravenous treatments. What are some of the symptoms to alert you to this problem? Survival benefits of anti-malarial drugs in systemic lupus erythematosus (SLE). Should all lupus patients be on this treatment? The risky but exciting ...

ArthritisCentral News and Views #42 -- 04/27/06

The Role of Calcium and Vitamin D in Postmenopausal Women A report from the Women's Health Initiative has evaluated whether supplemental calcium and vitamin D provide any significant benefit in osteoporosis treatment. The study investigated whether the supplements provided any significant protection against future bone fractures. The study has a number of design flaws, which are pointed out. These include the fact that the control group was allowed to take calcium and vitamin D on their own along with hormonal therapy, bisphosphonates, and miacalcin. Scientists question whether the vitamin D dose of 400 I.U.s per day used in this study is really sufficient for women. Compliance in taking the calcium carbonate and vitamin D prescribed in this study was associated with a decreased rate of hi...

Fosamax / Actonel Plaintiffs Seek Own MDL July 27

WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation (JPMDL) will hear arguments on July 27 on the creation of a multidistrict litigation for claims involving Fosamax and Actonel brand bisphosphonates (In Re: Fosamax and Actonel Products Liability Litigation, MDL Docket No. 1789, JPMDL; See 5/4/06, Page 26). Full story on lexis.com (Source: LexisNexis&#174; Mealey's&#8482; Emerging Drugs & Devices Legal News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice

Clinical and Experimental Pharmacology and Physiology Volume 33, Issue 7, Page 601-606, Jul 2006 (Source: Clinical and Experimental Pharmacology and Physiology)

International Approvals: Herceptin, Actonel Plus Calcium, Testim

The EU has approved a new indication for trastuzumab infusion (Herceptin); Canada has approved copackaged 35-mg risedronate sodium and 1250-mg calcium carbonate tablets (Actonel Plus Calcium) and topical testosterone gel 1% (Testim 1%).Medscape Medical NewsYael Waknine (Source: Medscape Medical News Headlines)

Trial shows men benefit from osteoporosis drug

Risedronate, an osteoporosis drug produced by Procter & Gamble Pharmaceuticals and Sanofi-Aventis U.S., proved effective for men with the disease in a Phase III trial, the two companies said Monday. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Is there any information on use of risedronate for Paget's disease beyond 2 months?

The Midlands Therapeutics Review and Advisory Committee recently published a review on this subject [1]. We recommend you read the document as it covers all aspects of prescribing and the relevant evidence (see reference section for URL). (Source: NLH Question Answering Service)

Aredia / Zometa MDL Created, But Fosamax, Actonel Cases Left Out

WASHINGTON, D.C. - A federal judicial panel on April 18 created a multidistrict litigation for the bisphosphonate drugs Aredia and Zometa made by Novartis Pharmaceuticals Corp. but excluded same-class drugs Fosamax and Actonel, made by Merck & Co. Inc. and Sanofi-Aventis, respectively (In Re: Aredia and Zometa Products Liability Litigation, MDL Docket No. 1760, JPMDL; See 2/16/06, Page 17). Full story on lexis.com (Source: LexisNexis&#174; Mealey's&#8482; Emerging Drugs & Devices Legal News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Between-Meal Risedronate Does Not Alter Bone Turnover in Nursing Home Residents

Journal of the American Geriatrics Society Volume 54, Issue 5, Page 790-795, May 2006 (Source: Journal of the American Geriatrics Society)

Role of vitamin K2 in the treatment of postmenopausal osteoporosis.

Authors: Iwamoto J, Takeda T, Sato Y Vitamin K2, raloxifene, and bisphosphonates, such as etidronate, alendronate, and risedronate, are widely used in the treatment of postmenopausal osteoporosis in Japan. A meta-analysis study has demonstrated the efficacy of anti-resorptive agents: raloxifene and etidronate have been shown to reduce the incidence of vertebral fractures, and alendronate and risedronate have been shown to reduce the incidence of both vertebral and hip fractures. Furthermore, a report of the World Health Organization (WHO) has provided evidence from a randomized controlled trial suggesting that vitamin K2, which may stimulate bone formation via gamma-carboxylation of osteocalcin and/or steroid and xenobiotic receptors (SXRs), reduces the incidence of vertebral fractures...

Would You Like to Record Your Side Effects for later use? It is Free and Easy. >> Start Today

Spread the word: Share, Email, Print



How Effective was Risedronate for You? Share Your Positive and Negative Experiences.

blog comments powered by Disqus
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.


Thank you for visiting Patientsville.com.